<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Chin Med</journal-id><journal-id journal-id-type="iso-abbrev">Chin Med</journal-id><journal-id journal-id-type="pmc-domain-id">463</journal-id><journal-id journal-id-type="pmc-domain">chimed</journal-id><journal-title-group><journal-title>Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">1749-8546</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11931805</article-id><article-id pub-id-type="pmcid-ver">PMC11931805.1</article-id><article-id pub-id-type="pmcaid">11931805</article-id><article-id pub-id-type="pmcaiid">11931805</article-id><article-id pub-id-type="pmid">40122800</article-id><article-id pub-id-type="doi">10.1186/s13020-025-01075-4</article-id><article-id pub-id-type="publisher-id">1075</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>A new paradigm for drug discovery in the treatment of complex diseases: drug discovery and optimization</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Yuan</surname><given-names initials="Y">Yu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Yu</surname><given-names initials="L">Lulu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Bi</surname><given-names initials="C">Chenghao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="L">Liping</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Su</surname><given-names initials="B">Buda</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nie</surname><given-names initials="J">Jiaxuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Dou</surname><given-names initials="Z">Zhiying</given-names></name><address><email>zhiyingdou@163.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Yang</surname><given-names initials="S">Shenshen</given-names></name><address><email>shine2099@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0455-0969</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="Y">Yubo</given-names></name><address><email>yaowufenxi001@sina.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05dfcz246</institution-id><institution-id institution-id-type="GRID">grid.410648.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 1816 6218</institution-id><institution>State Key Laboratory of Component-Based Chinese Medicine, </institution><institution>Tianjin University of Traditional Chinese Medicine, </institution></institution-wrap>Tianjin, 301617 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01mtxmr84</institution-id><institution-id institution-id-type="GRID">grid.410612.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0604 6392</institution-id><institution>Collaborative Innovation Center of Mongolian Medicine, </institution><institution>Inner Mongolia Medical University, </institution></institution-wrap>Hohhot, 010110 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/012tb2g32</institution-id><institution-id institution-id-type="GRID">grid.33763.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1761 2484</institution-id><institution>School of Traditional Chinese Medicine, </institution><institution>Tianjin University of Chinese Medicine, </institution></institution-wrap>Tianjin, 301617 China </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue-id pub-id-type="pmc-issue-id">478385</issue-id><elocation-id>40</elocation-id><history><date date-type="received"><day>8</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>10</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>24</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-25 10:25:45.437"><day>25</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13020_2025_Article_1075.pdf"/><abstract id="Abs1"><p id="Par1">In the past, the drug research and development has predominantly followed a "single target, single disease" model. However, clinical data show that single-target drugs are difficult to interfere with the complete disease network, are prone to develop drug resistance and low safety in clinical use. The proposal of multi-target drug therapy (also known as "cocktail therapy") provides a new approach for drug discovery, which can affect the disease and reduce adverse reactions by regulating multiple targets. Natural products are an important source for multi-target innovative drug development, and more than half of approved small molecule drugs are related to natural products. However, there are many challenges in the development process of natural products, such as active drug screening, target identification and preclinical dosage optimization. Therefore, how to develop multi-target drugs with good drug resistance from natural products has always been a challenge. This article summarizes the applications and shortcomings of related technologies such as natural product bioactivity screening, clarify the mode of action of the drug (direct/indirect target), and preclinical dose optimization. Moreover, in response to the challenges faced by natural products in the development process and the trend of interdisciplinary and multi-technology integration, and a multi-target drug development strategy of "active substances&#160;&#8212;&#160;drug action mode&#160;&#8212;&#160;drug optimization" is proposed to solve the key challenges in the development of natural products from multiple dimensions and levels.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Natural products</kwd><kwd>Drug repurposing</kwd><kwd>Drug discovery</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82141209</award-id><award-id>82474217</award-id><principal-award-recipient><name name-style="western"><surname>Yang</surname><given-names>Shenshen</given-names></name><name name-style="western"><surname>Li</surname><given-names>Yubo</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>the foundation of New 20 University Policies of Jinan</institution></funding-source><award-id>202333018</award-id><principal-award-recipient><name name-style="western"><surname>Li</surname><given-names>Yubo</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; International Society for Chinese Medicine and BioMed Central Ltd. 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par26">From 2014 to 2023, the US Food and Drug Administration (FDA) approved 456 new drugs [<xref ref-type="bibr" rid="CR1">1</xref>]. Among them, problems such as high research and development costs, long research cycles, and clinical safety and efficacy have become obstacles to drug research and development. The traditional drug research and development mode usually follows the method of "one drug, one target", which plays a unique therapeutic advantage in the clinic and brings huge clinical benefits [<xref ref-type="bibr" rid="CR2">2</xref>&#8211;<xref ref-type="bibr" rid="CR4">4</xref>]. It is undeniable that there are some problems in the treatment of single-target drugs, such as insufficient therapeutic effect, adverse side effects (off-target effects, etc.) and increased incidence of drug resistance [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. The main reason is that when a single target drug interferes with the target or inhibits the downstream pathway, the body produces self-resistance, activates the bypass biological pathway, the mutation of the therapeutic target and the activation/interaction of its upstream and downstream effectors [<xref ref-type="bibr" rid="CR7">7</xref>&#8211;<xref ref-type="bibr" rid="CR9">9</xref>]. In addition, off-target effects also limit the therapeutic effect of single-target drugs, which can also bring corresponding toxicity when bringing the expected efficacy [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. A variety of complex molecular networks participate in the mechanism of many common diseases, especially when dealing with complex diseases, single target drugs are difficult to achieve the expected efficacy [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par27">The complexity of disease is mainly caused by the joint action of genetic, physiological, environmental and behavioral factors, involving a variety of potential targets and pathways, and including a variety of pathophysiological states in this complex network [<xref ref-type="bibr" rid="CR13">13</xref>]. Cardiovascular disease, cancer, alzheimer's disease, diabetes, kidney disease and infectious diseases (lower respiratory tract infection, malaria, tuberculosis, HIV/AIDS) and other complex diseases are the main causes of death in the world [<xref ref-type="bibr" rid="CR14">14</xref>]. These diseases involve highly complex etiologies, leading to intricate pathogenesis, and drugs targeting single targets or single pathogenic pathways are not easy to achieve good therapeutic effects. In addition, the occurrence and development of disease is a dynamic process of development and transformation, and the complexity is also reflected in the complexity of clinical symptoms and prevention means [<xref ref-type="bibr" rid="CR15">15</xref>]. For example, the sudden disease COVID-19 affects not only the respiratory tract but also the gastrointestinal tract, nervous or cardiovascular system (cough, fever, diarrhea, etc.) [<xref ref-type="bibr" rid="CR16">16</xref>]. As a result, traditional single target drugs make it difficult to treat multiple symptoms at the same time [<xref ref-type="bibr" rid="CR17">17</xref>]. In addition, the prevalence of complications during disease progression is on the rise, that is, the presence of one disease usually leads to the occurrence of one or more other diseases, which also increases the complexity and difficulty of diagnosis and treatment [<xref ref-type="bibr" rid="CR18">18</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref>]. This shows that "single-target, high affinity and high selectivity" may not be enough for effective treatment in clinical practice, especially in the face of complex multifactorial diseases, single-target drugs often have poor efficacy or high toxicity.</p><p id="Par28">The proposal of "designed multiple ligands" in 2004 provided a new idea for drug design and discovery, that is, multi-target drugs simultaneously regulate multiple targets and multiple links in the disease network system, affect the overall balance of the body, and then improve the efficacy and safety (reduce toxicity and drug resistance) [<xref ref-type="bibr" rid="CR21">21</xref>]. Compared with single-target drugs, multi-target drugs have the characteristics of "multi-target, low affinity and low selectivity", which overcome the limitations of single-target drugs from the perspective of total effect and provide positive clinical effects [<xref ref-type="bibr" rid="CR22">22</xref>]. At present, there are three different treatment methods in the field of multi-target therapy, which are multi-drug combination therapy, fixed-dose drug combination therapy and multi-target drug therapy. The first two multi-target therapies are drug combinations, which can improve the efficacy or reduce the individual dose, reduce side effects and drug resistance through the interaction between multiple drugs (synergy, addition, antagonism), so as to improve the clinical effect [<xref ref-type="bibr" rid="CR23">23</xref>]. According to historical data, since the first combination drug was approved by the FDA in 1943, drug combinations have become more and more common. In the past decade, FDA has approved more than 80 kinds of combination drugs [<xref ref-type="bibr" rid="CR24">24</xref>]. It is worth noting that natural products are natural multi-target drugs, which have the characteristics of structural diversity, high multi-target activity and low toxicity, and become an important source of one drug multi-target drugs [<xref ref-type="bibr" rid="CR25">25</xref>]. Medicinal plants provide a large number of natural products, and a variety of drugs have been found and applied in clinics, such as morphine, paclitaxel, resveratrol, etc. Therefore, the development of drugs from natural products derived from medicinal plants has become a hot research direction of multi-target drugs, and the combination of drugs simultaneously includes a variety of therapeutic methods in the field of multi-target therapy (a variety of multi-target drug combinations).</p><p id="Par29">However, it has always been a difficult problem to develop multi-target drugs with good drug resistance from natural products. The key problems existing in the current natural product research and development strategy are: (1) the material basis of efficacy is unknown; (2) the activity research is not deep enough, and the mechanism of action is not clear; (3) ignoring the formulation of the clinical optimal dose [<xref ref-type="bibr" rid="CR26">26</xref>&#8211;<xref ref-type="bibr" rid="CR28">28</xref>]. The great progress of modern disciplines has spawned a variety of biological and chemical methods to solve the above problems. Potential natural products were initially screened from natural products based on their own activities or toxic side effects, therapeutic factors, and therapeutic targets [<xref ref-type="bibr" rid="CR29">29</xref>]. Key technologies such as network pharmacology, integrative omics, CRISPR gene editing, and direct targets were used to clarify the target proteins and mechanism of action of natural products [<xref ref-type="bibr" rid="CR30">30</xref>]. In addition, dose prediction is performed at many stages of drug discovery and development to achieve drug design [<xref ref-type="bibr" rid="CR31">31</xref>]. Therefore, the interdisciplinary and technological integration provide new technologies and strategies for the research and development of natural products. However, how to highly integrate interdisciplinary methods has been an obstacle in natural product drug discovery. The purpose of this review is to summarize the strategies and technologies established in the development of natural products from medicinal plants, and propose a multidisciplinary natural product research and development system to solve the key problems in the development of natural products, so as to achieve the goal of "identify components, recognize mechanism and explicit doses".</p></sec><sec id="Sec2"><title>Natural product discovery technology</title><p id="Par30">Traditionally, drug development takes over a decade and billions of dollars, with less than 1% of compounds entering clinical trials. However, the safety, dosage, and toxicity characteristics of drugs in drug repurposing strategies are known, greatly improving the efficiency of the drug discovery process [<xref ref-type="bibr" rid="CR32">32</xref>]. The most representative drugs are aspirin and sildenafil [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].&#160;Therefore, drug repurposing provides new ideas and methods for the treatment of complex diseases, such as artemisinin (<italic toggle="yes">Artemisia annua</italic>) [<xref ref-type="bibr" rid="CR35">35</xref>], As2O3 (<italic toggle="yes">Arsenic</italic>) [<xref ref-type="bibr" rid="CR36">36</xref>], bicyclol (<italic toggle="yes">Schisandra chinensis (Turcz.) Baill.</italic>) [<xref ref-type="bibr" rid="CR37">37</xref>], ephedrine (<italic toggle="yes">Ephedrae herba</italic>) [<xref ref-type="bibr" rid="CR38">38</xref>], etc. The screening of traditional drug repurposing is often based on clinical experience and observation. With the development of research technology, methods such as phenotype screening (high-throughput screening (HTS) and high-content screening (HCS)), disease target and chemical structure screening (computer-aided drug design (CADD)), and machine learning (ML) have been proposed and applied, effectively improving the possibility of drug repurposing.</p><sec id="Sec3"><title>High-throughput screening and high-content screening</title><p id="Par31">The use of de-risk compounds in treating diseases through "drug repurposing" can rapidly develop drugs that can be applied to clinical treatment [<xref ref-type="bibr" rid="CR39">39</xref>]. HTS technology, based on molecular or cellular level experimental methods, has gradually become a powerful tool for accelerating drug combination therapy research due to its characteristics of trace, fast, sensitive, and efficient. Currently, the commonly used HTS systems are divided into biochemical and cell screening systems [<xref ref-type="bibr" rid="CR40">40</xref>]. Among them, the biochemical screening system is mainly based on fluorescence or absorbance to detect the binding of purified target proteins to drugs or the impact of enzyme activity (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a, b); Cell screening systems typically detect the ability of drug-induced cell phenotypes without knowing the target (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>c, d). Currently, a large number of studies have utilized this method to the screening of natural products and/or multi-target drugs (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>High throughput screening strategy for drugs. <bold>a</bold> and <bold>b</bold> belongs to the biochemical level entity screening methods. <bold>c</bold> and <bold>d</bold> belongs to the cell level entity screening methods. <bold>e</bold> and <bold>f</bold> belongs to the virtual screening methods. PH: Pondus Hydrogenii; CAT: Chloramphenicol Acetyltransferase;&#160;GFP: Green fluorescent protein; QSAR: Quantitative Structure&#8211;Activity Relationships</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="13020_2025_1075_Fig1_HTML.jpg"/></fig><table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Application examples of high throughput screening techniques</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Method</th><th align="left" colspan="1" rowspan="1">Drug library</th><th align="left" colspan="1" rowspan="1">Total drugs</th><th align="left" colspan="1" rowspan="1">Screening quantity</th><th align="left" colspan="1" rowspan="1">Screening drugs</th><th align="left" colspan="1" rowspan="1">Disease</th><th align="left" colspan="1" rowspan="1">Refs.</th></tr></thead><tbody><tr><td align="left" rowspan="13" colspan="1">HTS</td><td align="left" colspan="1" rowspan="1">Compound library</td><td align="left" colspan="1" rowspan="1">430,376</td><td align="left" colspan="1" rowspan="1">378</td><td align="left" colspan="1" rowspan="1">RU-0415529</td><td align="left" colspan="1" rowspan="1">SARS-COV-2</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR157">157</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Small Molecule Libraries</td><td align="left" colspan="1" rowspan="1">3100</td><td align="left" colspan="1" rowspan="1">74</td><td align="left" colspan="1" rowspan="1">(S)-amlodipine besylate</td><td align="left" colspan="1" rowspan="1">Craniopharyngioma</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR158">158</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Marine compound library</td><td align="left" colspan="1" rowspan="1">200</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Naamidine J</td><td align="left" colspan="1" rowspan="1">Hepatitis B</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR159">159</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">The HTS customized library</td><td align="left" colspan="1" rowspan="1">2097</td><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">Panobinostat</td><td align="left" colspan="1" rowspan="1">Pituitary neuroendocrine tumors</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR160">160</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">lead-like compound library</td><td align="left" colspan="1" rowspan="1">1280</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">LMK 235, PI 828, Pyroxamide et al</td><td align="left" colspan="1" rowspan="1">Medulloblastoma</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR161">161</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Compound library</td><td align="left" colspan="1" rowspan="1">3.8 million</td><td align="left" colspan="1" rowspan="1">392</td><td align="left" colspan="1" rowspan="1">BAY-593</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR162">162</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">FDA library</td><td align="left" colspan="1" rowspan="1">2625</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Baicalin</td><td align="left" colspan="1" rowspan="1">Acute ischemic stroke</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR163">163</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Compound library</td><td align="left" colspan="1" rowspan="1">137,585</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">Morpholine series and Sulfonylamine series</td><td align="left" colspan="1" rowspan="1">Tuberculosis</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR164">164</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">purchased from Selleck</td><td align="left" colspan="1" rowspan="1">227</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Cepharanthine</td><td align="left" colspan="1" rowspan="1">Japanese encephalitis</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR165">165</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">FDA-approved drugs</td><td align="left" colspan="1" rowspan="1">1622</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Albendazole</td><td align="left" colspan="1" rowspan="1">Tumor</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR166">166</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">herb extracts</td><td align="left" colspan="1" rowspan="1">578</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">Ginsenoside F2</td><td align="left" colspan="1" rowspan="1">Hepatocellular carcinoma</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR167">167</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Spectrum Collection library</td><td align="left" colspan="1" rowspan="1">2400</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Phenylmercuric acetate&#12289;Captan&#12289;Chloranil et al</td><td align="left" colspan="1" rowspan="1">Schizophrenia</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR168">168</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Non-cancer drug</td><td align="left" colspan="1" rowspan="1">4518</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">Disulfiran&#12289;Tepoxalin et al</td><td align="left" colspan="1" rowspan="1">Cancer</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR169">169</xref>]</td></tr></tbody></table></table-wrap></p><p id="Par32">HCS technology was gradually developed after the rise of HTS technology, also known as cellomics, which is a cell phenotype screening technology combining automatic fluorescence microscopy with automatic image analysis [<xref ref-type="bibr" rid="CR41">41</xref>]. The experimental process includes 5 parts: cell culture, sample preparation and exposure, image acquisition, image analysis and data mining. On the premise of maintaining the integrity of cell structure and function, HCS realizes the simultaneous detection of multiple targets and parameters (cell morphology and intracellular parameters) of natural products by analyzing the cell image in the porous plate [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Compared with HTS, the results obtained by HCS are diversified, and have been applied to the identification of therapeutic compounds for various human diseases, including: cell signaling pathways, oncology, neurobiology, in vitro toxicology, target verification and other fields of life sciences [<xref ref-type="bibr" rid="CR44">44</xref>&#8211;<xref ref-type="bibr" rid="CR46">46</xref>]. Therefore, HCS can better cope with the complexity of drug research, and more and more studies apply HCS technology to the screening of drug screening (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Application examples of high content screening techniques</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Method</th><th align="left" colspan="1" rowspan="1">Target</th><th align="left" colspan="1" rowspan="1">Drug library/Drug</th><th align="left" colspan="1" rowspan="1">Total drugs</th><th align="left" colspan="1" rowspan="1">Screening quantity</th><th align="left" colspan="1" rowspan="1">Screening drugs</th><th align="left" colspan="1" rowspan="1">Disease</th><th align="left" colspan="1" rowspan="1">Refs.</th></tr></thead><tbody><tr><td align="left" rowspan="16" colspan="1">HCS</td><td align="left" colspan="1" rowspan="1">Nitroreductase and the red fluorescent protein mCherry</td><td align="left" colspan="1" rowspan="1">Drug/compound library</td><td align="left" colspan="1" rowspan="1">138</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Belinostat</td><td align="left" colspan="1" rowspan="1">Focal segmental glomerular sclerosis</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR170">170</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Epithelial mesenchymal transition</td><td align="left" colspan="1" rowspan="1">MedChemExpress (MCE) compound library</td><td align="left" colspan="1" rowspan="1">306</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Camptothecin, dimethyl curcumin, artesunate et al</td><td align="left" colspan="1" rowspan="1">Fibrotic diseases and cancer</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR171">171</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Transcriptional repressor Snail</td><td align="left" colspan="1" rowspan="1">Crude extract from the leaves of X. vielana</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">24</td><td align="left" colspan="1" rowspan="1">Compound 12</td><td align="left" colspan="1" rowspan="1">Osteosarcoma</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR172">172</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Schistosoma mansoni thioredoxin glutathione reductase (SmTGR)</td><td align="left" colspan="1" rowspan="1">Compound library</td><td align="left" colspan="1" rowspan="1">29</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">2-[2-(3-methyl-4-nitro-5-isoxazolyl)vinyl]pyridine and 2-(benzylsulfonyl)&#8722;1,3-benzothiazole</td><td align="left" colspan="1" rowspan="1">Schistosomiasis</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR173">173</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">&#945;-SMA,&#160;E-cadherin</td><td align="left" colspan="1" rowspan="1">Chinese herbal medicine Tong-Mai-Yang-Xin-Wan (TMYX)</td><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Glycyrrhizic acid, glyasperin A, and licorisoflavan A</td><td align="left" colspan="1" rowspan="1">Chronic kidney disease</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR174">174</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DNA, F-actin, and microtubules</td><td align="left" colspan="1" rowspan="1">FDA-approved drugs</td><td align="left" colspan="1" rowspan="1">55</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Combination vinblastine/ispinesib</td><td align="left" colspan="1" rowspan="1">Triple-negative breast cancer</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR175">175</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">B7-H3</td><td align="left" colspan="1" rowspan="1">FDA-approved drugs</td><td align="left" colspan="1" rowspan="1">1114</td><td align="left" colspan="1" rowspan="1">55</td><td align="left" colspan="1" rowspan="1">Ingenol-3-angelate</td><td align="left" colspan="1" rowspan="1">Osteosarcoma</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR176">176</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">123 protein targets</td><td align="left" colspan="1" rowspan="1">Target-selective inhibitor library</td><td align="left" colspan="1" rowspan="1">600</td><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Osteosarcoma</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR177">177</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Green fluorescent protein</td><td align="left" colspan="1" rowspan="1">targeted anti-cancer therapy drug library</td><td align="left" colspan="1" rowspan="1">99</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">Imatinib</td><td align="left" colspan="1" rowspan="1">Triple-negative breast cancer</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR178">178</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Cardiac function</td><td align="left" colspan="1" rowspan="1">medicinal herbs-derived natural compounds library</td><td align="left" colspan="1" rowspan="1">347</td><td align="left" colspan="1" rowspan="1">23</td><td align="left" colspan="1" rowspan="1">Cyanidin chloride</td><td align="left" colspan="1" rowspan="1">Cardiomyopathy</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR179">179</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Col-12</td><td align="left" colspan="1" rowspan="1">Self-built library</td><td align="left" colspan="1" rowspan="1">614</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Danshensu, lawsone, and sanguinarine</td><td align="left" colspan="1" rowspan="1">Collagen-related diseases</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR180">180</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Intestinal neutrophil accumulation and ROS level</td><td align="left" colspan="1" rowspan="1">Peach Blossom Decoction, Pulsatilla Decoction, and Gegen Qinlian Decoction</td><td align="left" colspan="1" rowspan="1">74</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Palmatine, daidzin, oroxyloside et al</td><td align="left" colspan="1" rowspan="1">Inflammatory bowel diseases</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR181">181</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Sirt3</td><td align="left" colspan="1" rowspan="1">Tongmaiyangxin pills</td><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">licoisoflavone A</td><td align="left" colspan="1" rowspan="1">Cardiac hypertrophy</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR182">182</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Macrophage</td><td align="left" colspan="1" rowspan="1">Xuanfeibaidu Formula</td><td align="left" colspan="1" rowspan="1">104</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Polydatin, isoliquiritin, acteoside et al</td><td align="left" colspan="1" rowspan="1">COVID-19</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR183">183</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">&#945;-SMA</td><td align="left" colspan="1" rowspan="1">A standard TCM compound library</td><td align="left" colspan="1" rowspan="1">344</td><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">Ligustrazine, glycyrrhizic acid, astragaloside iv et al</td><td align="left" colspan="1" rowspan="1">Chronic kidney disease</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR184">184</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">YFP-CL1</td><td align="left" colspan="1" rowspan="1">Self-established TCM library</td><td align="left" colspan="1" rowspan="1">89</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Salvianolic acid A, salvianolic acid B, and ellagic acid</td><td align="left" colspan="1" rowspan="1">Alzheimer's disease</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR185">185</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Computer-aided drug design</title><p id="Par33">The occurrence of diseases is often related to multiple targets. Natural products can simultaneously regulate variety disease processes to achieve optimal therapeutic effects. Computer aided drug design (CADD) is a commonly used method for developing multi-target drugs, mainly divided into structure-based drug design (SBDD) (molecular docking, molecular dynamics, and virtual screening) and ligand-based drug design (LBDD) (pharmacophore model and quantitative structure&#8211;activity relationship model) [<xref ref-type="bibr" rid="CR47">47</xref>].</p><sec id="Sec5"><title>Structure-based drug screening</title><p id="Par34">SBDD is an important tool for discovering potent small molecule drugs, mainly based on the 3D structure of biomolecules or macromolecular ligand complexes for drug design, including molecular docking, pharmacophore models, and molecular dynamics simulations [<xref ref-type="bibr" rid="CR48">48</xref>].&#160;Virtual screening is a method of SBDD, which can be divided into receptor-based virtual screening (RBVS) and ligand-based virtual screening (LBVS) based on the presence or absence of receptor structures [<xref ref-type="bibr" rid="CR49">49</xref>]. Among them, RBVS, also known as structure based virtual screening (SBVS), rapidly and effectively searches and discovers bioactive molecules in a large virtual compound library based on protein crystal structure or homology modeling [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Taking the development of COVID-19 therapeutic drugs as an example, the active ingredients are docked with viral surface proteins (spike glycoprotein, ACE2, etc.) and host targets (Mpro, RdRp, etc.) to screen virus-targeted drugs (to prevent the virus from binding to host cells) and host-targeted drugs (to prevent the virus from replicating in host cells) [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. The active ingredients screened after molecular docking should be further calculated (such as molecular dynamics simulation) to increase the reliability of docking [<xref ref-type="bibr" rid="CR54">54</xref>]. In addition, SBDD is also applied to drug development for complex diseases, involving software and case studies as shown in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>.
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Structure-based and ligand-based drug repurposing methods</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Method</th><th align="left" rowspan="2" colspan="1">Main Software</th><th align="left" rowspan="2" colspan="1">Introduce</th><th align="left" colspan="3" rowspan="1">Example</th></tr><tr><th align="left" colspan="1" rowspan="1">Protein Crystal</th><th align="left" colspan="1" rowspan="1">Medicine</th><th align="left" colspan="1" rowspan="1">Refs</th></tr></thead><tbody><tr><td align="left" rowspan="14" colspan="1">Molecular Docking</td><td align="left" colspan="1" rowspan="1">AutoDock(AutoDock 4, AutoDock Vina and PyRx)</td><td align="left" colspan="1" rowspan="1">Free for academic use. AutoDock applies a semi-flexible docking method with Protein flexibility to evaluate the docking results based on the binding free energy. Docking algorithm takes genetic algorithm, simulated annealing, etc. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://autodock.scripps.edu/">https://autodock.scripps.edu/</ext-link>)</td><td align="left" colspan="1" rowspan="1">M<sup>pro</sup> (PDB:6LU7), PL<sup>pro</sup> (PDB:4OVZ), RdRp(PDB:6NUS),S-protein (PDB: 6VSB)</td><td align="left" colspan="1" rowspan="1">Luteolin</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR186">186</xref>&#8211;<xref ref-type="bibr" rid="CR188">188</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DOCK</td><td align="left" colspan="1" rowspan="1">Free for academic use. Dock applies a semi flexible docking method to reassemble the rigid fragments of small molecules based on the geometric properties of the receptor surface for conformational search, has Protein flexibility. Dock uses a force field to score the docking results. The docking algorithm uses shape fitting, lowest energy binding. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dock.compbio.ucsf.edu/">https://dock.compbio.ucsf.edu/</ext-link>)</td><td align="left" colspan="1" rowspan="1">M<sup>pro</sup> (PDB:6LU7)</td><td align="left" colspan="1" rowspan="1">Andrographolide</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR189">189</xref>, <xref ref-type="bibr" rid="CR190">190</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">SwissDock</td><td align="left" rowspan="2" colspan="1">Free for academic use. SwissDock is a web server based on the protein ligand docking program EADock DSS. SwissDock uses a force field to score the docking results (Full fitness score and binding affinity values). Docking algorithm uses stochastic, local search and combination of broad and local search of the conformational space. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.swissdock.ch">http://www.swissdock.ch</ext-link>.)</td><td align="left" colspan="1" rowspan="1">Nsp15(6VWW)</td><td align="left" colspan="1" rowspan="1">Sarsasapogenin, ursonic acid, ajmalicine, silymarin, novobiocin and aranotin</td><td align="left" rowspan="2" colspan="1">[<xref ref-type="bibr" rid="CR191">191</xref>&#8211;<xref ref-type="bibr" rid="CR193">193</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">M<sup>pro</sup>(6Y84)</td><td align="left" colspan="1" rowspan="1">Curcumin, demethoxycurcumin, EGCG, EGC, hesperidin et al</td></tr><tr><td align="left" colspan="1" rowspan="1">Fred</td><td align="left" colspan="1" rowspan="1">Free for academic use. FRED operates in traditional docking mode and mixed mode, which uses the structure of binding ligand and protein structure to screen molecules. It&#8217;s Docking algorithm is Exhaustive search algorithm. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.eyesopen.com/oedocking">https://www.eyesopen.com/oedocking</ext-link><underline>)</underline></td><td align="left" colspan="1" rowspan="1">SARS-CoV-2 S-ACE2 complex (7DF4)</td><td align="left" colspan="1" rowspan="1">HCC1,4,11</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR194">194</xref>, <xref ref-type="bibr" rid="CR195">195</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">SLIDE</td><td align="left" colspan="1" rowspan="1">Free for academic use. SLIDE can accurately calculate the flexible docking of receptors, and search and calculate all the alternative conformations of receptor ligand complexes. According to the theoretical model of uniform field, the docking score is made. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.schrodinger.com/">https://www.schrodinger.com/</ext-link>)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR196">196</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">eHiTS</td><td align="left" colspan="1" rowspan="1">Free for academic use. eHiTS breaks the ligand into rigid segments, connects flexible chains, and independently and systematically docks each rigid segment to every possible position in the cavity. Score the docking results according to empirical and knowledge. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://bip.weizmann.ac.il/toolbox/structure/ehits.htm">https://bip.weizmann.ac.il/toolbox/structure/ehits.htm</ext-link>)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR197">197</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CDOCKER</td><td align="left" colspan="1" rowspan="1">Commercial. Based on molecular dynamics, the algorithm of annealing (semi-flexible docking) is simulated by using CHARMm force field. Score the docking results according to Force-field. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.3ds.com/products/biovia/discovery-studio">https://www.3ds.com/products/biovia/discovery-studio</ext-link>)</td><td align="left" colspan="1" rowspan="1">M<sup>pro</sup> (PDB:6LU7)</td><td align="left" colspan="1" rowspan="1">Viomycin, 5,3&#8242;,4&#8242;-trihydroxyflavone, scutellarein, and shikonin</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR198">198</xref>&#8211;<xref ref-type="bibr" rid="CR200">200</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">MOE</td><td align="left" rowspan="2" colspan="1">Commercial. MOE is a comprehensive application environment and technology development platform, which supports the design of small molecular drugs and biopharmaceuticals through Conformational analysis. Has Protein flexibility. Score the docking results according to the Empirical and Force-field. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.chemcomp.com/en/Products.htm">https://www.chemcomp.com/en/Products.htm</ext-link>)</td><td align="left" colspan="1" rowspan="1">S-protein (PDB: 6VSB)</td><td align="left" colspan="1" rowspan="1">Ginsenoside Ra2, ginsenoside Rb1, glycyrrhizic acid, berberine chloride et al</td><td align="left" rowspan="2" colspan="1">[<xref ref-type="bibr" rid="CR201">201</xref>&#8211;<xref ref-type="bibr" rid="CR203">203</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>M<sup>pro</sup> (PDB:6LU7)</p><p>S-protein (PDB:6ZCZ)</p></td><td align="left" colspan="1" rowspan="1">Salvianolic acid B</td></tr><tr><td align="left" colspan="1" rowspan="1">FlexX</td><td align="left" colspan="1" rowspan="1">Commercial. FlexX uses fragment growth method to consider the flexible and fast automatic docking procedure of ligand conformation, and takes free energy as the basis to evaluate docking results.Docking algorithm uses incremental and construction. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://flexx.readthedocs.io/en/stable/">https://flexx.readthedocs.io/en/stable/</ext-link>)</td><td align="left" colspan="1" rowspan="1">M<sup>pro</sup> (PDB:6LU7)</td><td align="left" colspan="1" rowspan="1">Mitoxantrone, leucovorin, birinapant and dynasore</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR204">204</xref>, <xref ref-type="bibr" rid="CR205">205</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">GOLD</td><td align="left" colspan="1" rowspan="1">Commercial. GOLD uses genetic algorithm for docking, and the ligand is completely flexible and the protein is partially flexible when docking. With Protein flexibility. GOLD scores the docking results according to Force-field. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ccdc.cam.ac.uk/discover/blog/gold-the-all-in-one-molecular-docking-package/">https://www.ccdc.cam.ac.uk/discover/blog/gold-the-all-in-one-molecular-docking-package/</ext-link>)</td><td align="left" colspan="1" rowspan="1">M<sup>pro</sup>; 3CL<sup>pro</sup>; PL<sup>pro</sup></td><td align="left" colspan="1" rowspan="1">Flavonoids extracted; phenylethanoid glycosides</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR206">206</xref>&#8211;<xref ref-type="bibr" rid="CR208">208</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Surflex</td><td align="left" colspan="1" rowspan="1">Commercial. Surflex is a fully automatic and flexible molecular docking algorithm, which combines the scoring function of Hammerhead docking system with search engine (molecular similarity based on surface) and scores the docking results with Empirical. With protein flexibility. The docking algorithm uses incremental and xonstruction. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.biopharmics.com/products.html">http://www.biopharmics.com/products.html</ext-link>)</td><td align="left" colspan="1" rowspan="1">3CL<sup>pro</sup> (PDB: 6LU7)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR209">209</xref>, <xref ref-type="bibr" rid="CR210">210</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">GLIDE</td><td align="left" colspan="1" rowspan="1">Commercial. GLIDE is a complete systematic search for the conformation, orientation and location space of docking ligands. Based ligand docking with energetics, Combine the conformational analysis (ChemScore function) results of the docking. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.schrodinger.com/platform/products/glide/">https://www.schrodinger.com/platform/products/glide/</ext-link>)</td><td align="left" colspan="1" rowspan="1">M<sup>pro</sup></td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR211">211</xref>, <xref ref-type="bibr" rid="CR212">212</xref>]</td></tr><tr><td align="left" rowspan="10" colspan="1">Molecular Dynamics</td><td align="left" colspan="1" rowspan="1">GROMACS</td><td align="left" colspan="1" rowspan="1">GROMACS is suitable for biological macromolecules, supporting various common classical force fields and several less visible force fields. In addition, the software has rich built-in analysis tools and adopts a multi-level parallel approach to allocate computing tasks. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gromacs.org/">https://www.gromacs.org/</ext-link>)</td><td align="left" colspan="1" rowspan="1">M<sup>pro</sup></td><td align="left" colspan="1" rowspan="1">Peonidin 3-O-glucoside, kaempferol 3-O-&#946;-rutinoside, 4-(3,4-Dihydroxyphenyl)&#8722;7-methoxy-5-[(6-O-&#946;-D-xylopyranosyl-&#946;-D-glucopyranosyl)oxy]&#8722;2H-1-benzopyran-2-one, quercetin-3-D-xyloside, and quercetin 3-O-&#945;-L-arabinopyranoside</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR213">213</xref>, <xref ref-type="bibr" rid="CR214">214</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">AMBER</td><td align="left" colspan="1" rowspan="1">AMBER is a tool set composed of multiple components, which supports different molecular types such as protein, DNA, RNA, carbohydrate and fat, as well as a general force field GAFF and multiple water molecular models for small organic molecules. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ambermd.org/tutorials/">https://ambermd.org/tutorials/</ext-link>)</td><td align="left" colspan="1" rowspan="1">S-protein</td><td align="left" colspan="1" rowspan="1">Withanolide D and withaferin A</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR215">215</xref>, <xref ref-type="bibr" rid="CR216">216</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CHARMM</td><td align="left" colspan="1" rowspan="1">CHARMM is a universal and flexible molecular simulation software that provides strong support for water molecule models, membrane models and implicit solvent models (such as polarization force fields). (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://academiccharmm.org/">https://academiccharmm.org/</ext-link>)</td><td align="left" colspan="1" rowspan="1">M<sup>pro</sup></td><td align="left" colspan="1" rowspan="1">Hinokiflavone, myricetin and artemisinin</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR217">217</xref>, <xref ref-type="bibr" rid="CR218">218</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Desmond</td><td align="left" colspan="1" rowspan="1">Desmond can efficiently simulate biological systems, using algorithms and numerical techniques to simulate display solvent/membrane systems. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.schrodinger.com/platform/products/desmond/">https://www.schrodinger.com/platform/products/desmond/</ext-link>)</td><td align="left" colspan="1" rowspan="1">M<sup>pro</sup></td><td align="left" colspan="1" rowspan="1">Laurolitsine</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR219">219</xref>, <xref ref-type="bibr" rid="CR220">220</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">LAMMPS</td><td align="left" colspan="1" rowspan="1">LAMMPS is a large-scale atomic/molecular massively parallel simulator, which can be used to simulate systems of atoms, polymer molecules, biomolecules, metals and particles. And supports a variety of coarsening models. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://lammps.sandia.gov/">http://lammps.sandia.gov/</ext-link>)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR221">221</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">ESPResSo</td><td align="left" colspan="1" rowspan="1">Espresso specifically for coarse graining model. The simulation system includes polymers, liquid crystals, colloids, polyelectrolytes, ferrofluids and biological systems. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://espressomd.org">http://espressomd.org</ext-link>)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">NAMD</td><td align="left" colspan="1" rowspan="1">nAMD is a kind of dynamic simulation software for biological macromolecules (proteins, lipids, carbohydrates, nucleic acids), which is extensible. And supports an implicit solvent model based on Generalized Born model. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ks.uiuc.edu/Research/namd/">http://www.ks.uiuc.edu/Research/namd/</ext-link>)</td><td align="left" colspan="1" rowspan="1">M<sup>pro</sup></td><td align="left" colspan="1" rowspan="1">Curcumin derived polyphenols</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR222">222</xref>, <xref ref-type="bibr" rid="CR223">223</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DL_POLY</td><td align="left" colspan="1" rowspan="1">At present, DL_POLY has two versions which are DL_POLY _ Classic and DL_POLY_4. It can simulate macromolecules, polymers, ionic systems and solutions by molecular dynamics. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.scd.stfc.ac.uk/Pages/DL_POLY.aspx">https://www.scd.stfc.ac.uk/Pages/DL_POLY.aspx</ext-link>)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR224">224</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CP2K</td><td align="left" colspan="1" rowspan="1">CP2K is a molecular dynamics simulation software based on the first principle, which is widely used to simulate solids, liquids, molecules, periods, materials, crystals and biological systems. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cp2k.org/">http://www.cp2k.org/</ext-link>)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR225">225</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CPMD</td><td align="left" colspan="1" rowspan="1">CPMD is a powerful ab initio scientific simulation software, which is widely used in the research of material physics, chemistry and macromolecular biology. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cpmd.org/">http://www.cpmd.org/</ext-link>)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR226">226</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec6"><title>Ligand-based drug screening</title><p id="Par35">LBDD is another widely used method in CADD, which can be used when protein crystals (such as membrane proteins) are unknown (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>f). The screening of LBDD is mainly achieved by evaluating the molecular similarity between the submitted molecules and the disease-related biologically active molecular library [<xref ref-type="bibr" rid="CR55">55</xref>]. The pharmacophore model clarifies the space and pharmacodynamic characteristics required for the interaction between drug molecules (ligands) and specific biological target receptors, which has been widely used in the research and development of natural products. Similarly, taking COVID-19 drug development as an example, collect the structure and efficacy characteristics of small molecule anti COVID-19 drugs with precise therapeutic effects as the training set. The structure and efficacy characteristics of small molecule anti-COVID-19 drugs with definite efficacy were collected as the training set. Then the multi-dimensional pharmacophore algorithm (HipHop, LigandScout, etc.) was used to establish the pharmacophore [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. The component has multi-target activity if a compound can match multiple pharmacophores [<xref ref-type="bibr" rid="CR57">57</xref>].</p></sec><sec id="Sec7"><title>Others</title><p id="Par36">With the rapid development of artificial intelligence (AI) technology, new research tools have been provided for the field of drug repurposing, which not only shortens the R&amp;D cycle but also provides new options for some rare or intractable diseases [<xref ref-type="bibr" rid="CR58">58</xref>]. Large-scale studies have confirmed that sildenafil protects brain cells and may become a new treatment for alzheimer's disease [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Currently, AI drug repurposing includes data mining and analysis, machine learning, and computational simulation. The TxGNN model proposed by Marinka Zitnik's team uses graph neural networks and metric learning modules to achieve drug repurposing in clinical centers [<xref ref-type="bibr" rid="CR32">32</xref>]. Secondly, the quantitative structure&#8211;activity relationship based on AI technology applies AI technologies such as deep learning and machine learning to the study of the relationship between drug molecular structure and biological activity, accelerating the development of combination drugs [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. In addition to the above methods, fragment-based virtual screening (FBVS) technology can discover molecules with higher binding efficiency through fewer fragment compounds, and has become a hot topic in drug research [<xref ref-type="bibr" rid="CR63">63</xref>].</p><p id="Par37">With the advent of the era of big data, the integration of computer simulation technology and in vitro research can quickly and accurately screen multi-target drugs and combined drugs from the natural product library [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>].&#160;Whether it is a single-target drug or a multi-target drug, the process of drug research and development includes two stages: the discovery and optimization of the lead. The biggest challenge after obtaining a lead compound is to optimize the pharmacodynamics (PD) and pharmacokinetics (PK) of the drug while considering the rationality of target combination, activity balance, and target selectivity. If the activity difference of natural products to each target is too large, it is difficult to set the dosage, leading to adverse reactions or difficult to achieve the desired effect. Therefore, identifying the interaction between drugs and targets is an important research field of drug discovery.</p></sec></sec></sec><sec id="Sec8"><title>The mode of action of natural products</title><p id="Par38">Clarification of mode of action (MOA) helps to promote drug development based on ensuring drug safety. For example, the main molecular target of the antimalarial drug quinine has yet to be identified, resulting in an unknown MOA of recognized biologically active molecules that cannot reduce its toxic response [<xref ref-type="bibr" rid="CR66">66</xref>]. In addition, MOA provides a basis for drug combination methods, such as the significant improvement of tumor tissue destruction in all cancers through the use of multiple monoclonal antibody combinations [<xref ref-type="bibr" rid="CR67">67</xref>]; the combination of antiepileptic drugs with different MOAs has greater effectiveness and can reduce the risk of hospitalization and emergency treatment [<xref ref-type="bibr" rid="CR68">68</xref>]. However, the main MOA of natural products based on phenotypic screening is unknown. Drugs based on target screening rarely bind to direct targets alone, and indirect targets need to be explored to help improve the efficacy/selectivity of compounds [<xref ref-type="bibr" rid="CR69">69</xref>]. Here we summarize the identification methods for direct/indirect drug targets.</p><sec id="Sec9"><title>Direct target discovery strategy</title><p id="Par39">The direct target is the key to understanding the active substance MOA in natural products. The interaction between the &#8220;internal exposure dose&#8221; of small molecules of natural products entering the target organ and the direct target is the basis of their direct pharmacodynamic effects [<xref ref-type="bibr" rid="CR70">70</xref>]. For example, the oncoprotein PML-RAR is the direct drug target of As2O3 in the treatment of acute promyelocytic leukemia [<xref ref-type="bibr" rid="CR71">71</xref>]. The "target fishing" strategy is a highly operational direct target identification technique (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>), which mainly uses the principle of changing the stability of drugs after binding with target proteins to identify the possible targets of natural products, specifically divided into labeling, non-labeling and other methods (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>) [<xref ref-type="bibr" rid="CR72">72</xref>]. These technologies can quickly capture target proteins that may have specific interactions with drug-active substances.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Direct targets fishing. TCM: Traditional Chinese Medicine; LC&#8211;MS/MS: Liquid Chromatography-Tandem Mass Spectrometry; UV: Ultraviolet</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="13020_2025_1075_Fig2_HTML.jpg"/></fig><table-wrap id="Tab4" position="float" orientation="portrait"><label>Table&#160;4</label><caption><p>Identification methods of drug direct/indirect target</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Technology</th><th align="left" colspan="1" rowspan="1">Principle</th><th align="left" colspan="1" rowspan="1">Application Characteristics</th><th align="left" colspan="1" rowspan="1">Limitation</th><th align="left" colspan="1" rowspan="1">Application</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="6" colspan="1">Labeling Method</td><td align="left" colspan="1" rowspan="1">Immobilized probe</td><td align="left" colspan="1" rowspan="1">Conventional bioactive small molecules are affixed to biocompatible inert resins, which are then used to isolate target proteins from the entire proteome</td><td align="left" colspan="1" rowspan="1">The synthesis is simple, and all adsorbed protein can be analyzed indiscriminately</td><td align="left" colspan="1" rowspan="1">The length of the connecting chain and the structural modification of small molecules can affect the binding force between the affinity probe and the target protein</td><td align="left" colspan="1" rowspan="1">Trapoxin and histone deacetylase (HDAC) specific binding</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR227">227</xref>&#8211;<xref ref-type="bibr" rid="CR229">229</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Activity-Based Protein Profiling (ABPP)</td><td align="left" colspan="1" rowspan="1">Probes are synthesized by retaining the pharmacological activity of their parent molecule and subsequently incubated with live cells, lysates or tissue homogenates, and protein targets are identified using proteomic methods after binding to the target protein</td><td align="left" colspan="1" rowspan="1">Directly applied to living cells, it reflects the real drug-target interaction under cell physiological conditions</td><td align="left" colspan="1" rowspan="1">Prone to false positive results</td><td align="left" colspan="1" rowspan="1">Parthenolide modifies focal adhesion kinase 1 (FAK1)</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR227">227</xref>, <xref ref-type="bibr" rid="CR229">229</xref>,<xref ref-type="bibr" rid="CR230">230</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Photoaffinity probe (PAL)</td><td align="left" colspan="1" rowspan="1">Chemical probes are prepared by doping photoreactive groups to covalently cross-link to adjacent amino acid residues under UV irradiation. Click chemistry-based enrichment captures labeled proteins for proteomic analysis</td><td align="left" colspan="1" rowspan="1">It has small volume and high efficiency</td><td align="left" colspan="1" rowspan="1">Binding of some non-specific proteins, affecting the accuracy of the results</td><td align="left" colspan="1" rowspan="1">Tropomyosin as a novel target of betulinic acid</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR227">227</xref>, <xref ref-type="bibr" rid="CR231">231</xref>, <xref ref-type="bibr" rid="CR232">232</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Click&#160;chemistry</td><td align="left" colspan="1" rowspan="1">Based on the synthesis of carbon-heteroatom bonds (C-X-C), small molecule probes are obtained by introducing orthogonal reactive groups (alkynes, alkenes, etc.) into the structure of natural products. Subsequently, the probes are bound to proteins in situ using click chemistry in cells. Finally, azide-modified reporter groups (biotin or fluorescent) are attached to the probe-target protein complexes using click reactions. And then the targets are detected, enriched and identified (SDS-PAGE)</td><td align="left" colspan="1" rowspan="1">Can be carried out in living cells; It has rapid and specific chemical coupling under aqueous conditions; It has little or no effect on the structure and pharmacological activity of small molecules</td><td align="left" colspan="1" rowspan="1">Some natural product active ingredients do not bind well to their targets; azide is toxic</td><td align="left" colspan="1" rowspan="1">Artemisinin could successfully pull-down plasmepsinl (PM I), plasmepsin II (PM II), merozoite surface protein 1 (MSP1) and actin</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR227">227</xref>, <xref ref-type="bibr" rid="CR233">233</xref>&#8211;<xref ref-type="bibr" rid="CR235">235</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Small-molecule affinity chromatography</td><td align="left" colspan="1" rowspan="1">Using the affinity between small molecules and proteins, the small molecules are made into solid-phase adsorbent and subsequently adsorbed on the protein with affinity in the protein mixture, and finally, a suitable eluent is selected to elute the bound proteins</td><td align="left" colspan="1" rowspan="1">High affinity and specificity, suitable for complex organic systems with extremely low target product concentrations</td><td align="left" colspan="1" rowspan="1">It is difficult to identify proteins that have an affinity for this spatial structure</td><td align="left" colspan="1" rowspan="1">Isochlorogenic acid A and luteolin-7-O-glucuronide have a stronger affinity with vascular endothelial growth factor receptor 2 (VEGFR2)</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR236">236</xref>&#8211;<xref ref-type="bibr" rid="CR239">239</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Phage Display Technology</td><td align="left" colspan="1" rowspan="1">Build a phage library and incubate with the target molecule, then remove unbound and non-specific phages, and use buffer to elute and separate the target bound phages. Finally, the eluted phages are infected and amplified in the bacteria</td><td align="left" colspan="1" rowspan="1">Simple, efficient, and low-cost</td><td align="left" colspan="1" rowspan="1">Three to five rounds of biological selection are required to separate specific and high affinity peptide binders</td><td align="left" colspan="1" rowspan="1">Bcl-2 was identified as paclitaxel binding protein</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR240">240</xref>&#8211;<xref ref-type="bibr" rid="CR242">242</xref>]</td></tr><tr><td align="left" rowspan="5" colspan="1">Label-Free</td><td align="left" colspan="1" rowspan="1">Drug affinity responsive target stability (DARTS)</td><td align="left" colspan="1" rowspan="1">After the drug is combined with the corresponding protein, it will make the structure of the target protein relatively stable, and the activity of the same enzymatic hydrolysis reaction will change, making it less susceptible to protease decomposition</td><td align="left" colspan="1" rowspan="1">Small molecules needn&#8217;t structural modification, have strong specificity, and can directly use original small molecule compounds or even inconspicuous compound drugs as research objects, making the operation convenient</td><td align="left" colspan="1" rowspan="1">Identifying targets with low protein abundance has limitations</td><td align="left" colspan="1" rowspan="1">Aconitine could well bind to cytosolic phospholipase A2 (cPLA2)</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR236">236</xref>,<xref ref-type="bibr" rid="CR239">239</xref>,<xref ref-type="bibr" rid="CR243">243</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Cellular thermal shift assay (CETSA)</td><td align="left" colspan="1" rowspan="1">Incubate small molecules with cell and tissue homogenate, then undergo thermal denaturation, using the principle of target proteins becoming structurally stable after binding to drug molecules, and finally verify using protein immunoblotting</td><td align="left" colspan="1" rowspan="1">High selectivity</td><td align="left" colspan="1" rowspan="1">High drug concentrations, commonly used for target identification, are still to be determined for larger and more complex soluble proteins and membrane proteins to be determined</td><td align="left" colspan="1" rowspan="1">Direct binding of Herbacetin and serum/glucocorticoid regulated kinase 1 (SGK1)</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR236">236</xref>,<xref ref-type="bibr" rid="CR244">244</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Stability of proteins from rates of oxidation (SPROX)</td><td align="left" colspan="1" rowspan="1">The denaturation dependence of methionine side chain oxidation in proteins mediated by hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) is used to measure the folding free energy of proteins and the Kd value of protein ligand complexes, similar to the DARTS technique</td><td align="left" colspan="1" rowspan="1">Enables detection of direct and indirect effects of protein-ligand binding in complex biological mixtures</td><td align="left" colspan="1" rowspan="1">The rate of oxidation is susceptible to amino acid residues. Protein concentration is affected by chemical denaturants, resulting in a weak oxidation reaction that is not easily detectable</td><td align="left" colspan="1" rowspan="1">28 proteins were identified to interact with manassantin A</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR236">236</xref>, <xref ref-type="bibr" rid="CR244">244</xref>&#8211;<xref ref-type="bibr" rid="CR246">246</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Thermal proteomic profiling (TPP)</td><td align="left" colspan="1" rowspan="1">A technique that combines the CETSA method with quantitative proteomics techniques. Using the principle that high temperature can denature proteins, cells are heated before and after administration. Subsequently, the denaturation curve was obtained through quantitative analysis of soluble proteins</td><td align="left" colspan="1" rowspan="1">Identify direct targets of action indiscriminately from intact cells or tissues. And can calculate the melting temperature (Tm) of the target protein</td><td align="left" colspan="1" rowspan="1">Only detect the interaction between small molecules and soluble proteins</td><td align="left" colspan="1" rowspan="1">Nucleolar protein 14 (Nop14) is a specific target of vioprolide A</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR247">247</xref>,<xref ref-type="bibr" rid="CR248">248</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Limited proteolysis mass spectrometry (LiP-MS)</td><td align="left" colspan="1" rowspan="1">LiP-MS uses the principle of limited hydrolysis to identify protein targets of small molecule drugs. After binding to the target protein, the small molecule drug will stabilize the rotein structure at the overall or local level, which greatly reduces the possibility of peptides on the protein surface being exposed and cleaved by proteases</td><td align="left" colspan="1" rowspan="1">No need to design synthetic molecular probes, use drug molecules to directly conduct binding experiments in vitro to obtain direct binding targets and their binding sites</td><td align="left" colspan="1" rowspan="1">Low abundance proteins are difficult to detect; When small molecule binding causes changes in protein structure, it is difficult to accurately locate the precise region of drug binding</td><td align="left" colspan="1" rowspan="1">The deubiquitinase UCHL3 is a direct target of farrerol</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR249">249</xref>, <xref ref-type="bibr" rid="CR250">250</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Other</td><td align="left" colspan="1" rowspan="1">Proteolysis-targeting chimeras (PROTAC)</td><td align="left" colspan="1" rowspan="1">Also known as &#8220;Targeted Degradomics&#8221;. Use the ubiquitin-protease system to develop drugs for target proteins and find drug targets from degraded differential proteins</td><td align="left" colspan="1" rowspan="1">Inducing the degradation of target proteins does not require strong affinity, which is beneficial for discovering targets with weaker affinity</td><td align="left" colspan="1" rowspan="1">Off-target effects; fewer PROTAC molecules targeting &#8220;undruggable&#8221; proteins</td><td align="left" colspan="1" rowspan="1">MAFF protein is a potential target of lathyrol</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR251">251</xref>, <xref ref-type="bibr" rid="CR252">252</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec10"><title>Indirect target discovery strategy</title><p id="Par40">More and more studies have proved that there are complex and comprehensive dialogue mechanisms between various organs. In many pathological cases, the communication between organs has changed, and the regulation of multiple organ crosstalk is the internal system regulation strategy for the treatment of disease or injury [<xref ref-type="bibr" rid="CR73">73</xref>]. Dual-directional or multidirectional communication connections such as kidney-brain axis [<xref ref-type="bibr" rid="CR74">74</xref>], lung-gut axis [<xref ref-type="bibr" rid="CR75">75</xref>], gut-brain axis [<xref ref-type="bibr" rid="CR76">76</xref>] have also been proposed in drug treatment of complex diseases or chronic diseases. Several studies have proposed that natural products regulate the physiological metabolic process through intermediary substances (such as endogenous metabolites, exosomes, intestinal flora, etc.) in the treatment of complex or chronic diseases, thus playing an indirect therapeutic role in the disease [<xref ref-type="bibr" rid="CR77">77</xref>]. In addition, the development of indirect targets helps to avoid the technical challenges of undruggable targets and reduce the toxic side effects of drugs [<xref ref-type="bibr" rid="CR78">78</xref>]. Therefore, disease-related networks, protein&#8211;protein interaction networks, and other biological network models can be constructed through systems biology methods. By analyzing the network topology and interactions between nodes, indirect targets can be identified.</p><sec id="Sec11"><title>Systems biology</title><p id="Par41">The basic information flow in the biological system is from DNA to RNA, then to protein and finally to metabolites (genome-transcriptome-proteome-metabolome). These technologies can quickly and comprehensively grasp the pathogenesis of the disease [<xref ref-type="bibr" rid="CR79">79</xref>]. In recent years, research on patent drug targets has turned to molecular approaches for identifying new targets based on the cellular mechanisms underlying disease phenotypes [<xref ref-type="bibr" rid="CR80">80</xref>]. In addition to characterizing and understanding the disease, "omics" technology can also determine how drugs act at the molecular level [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR81">81</xref>].</p><p id="Par42">Genomic drug targets are the discovery of disease-related pathogenic genes and new drug targets through genomic technology, providing strategies for clinical disease prevention, diagnosis and treatment [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. Since the late 1970s, mRNA has been experimentally used as a potential therapeutic target, and the discovery pathways include whole genome sequencing, gene chips or RNA sequencing, genomics, etc., to identify genetic variant sites or differentially expressed genes associated with diseases. As we all know, the same gene is associated with many different indications, and the development of therapeutic drugs targeting this gene may be applicable to the diseases associated with this gene [<xref ref-type="bibr" rid="CR84">84</xref>]. For example, 5&#945; reductase inhibitors are used not only for prostate hyperplasia but also for hair loss [<xref ref-type="bibr" rid="CR85">85</xref>]. In addition, genomics can also evaluate the effectiveness and specificity between compound targets [<xref ref-type="bibr" rid="CR86">86</xref>]. By disrupting protein expression when binding to mRNA and affecting disease progression [<xref ref-type="bibr" rid="CR87">87</xref>]. Anderson DE et al. through functional screening of the bat genome found that carolacton, an inhibitor of the novel host protein MTHFD1, potently blocked replication of several RNA viruses, including SARS-CoV-2 [<xref ref-type="bibr" rid="CR88">88</xref>].</p><p id="Par43">Transcriptome is a high-throughput characterization of RNA. Previous studies have proved that drug repositioning based on transcriptomic gene expression and target identification is an effective method to find disease-candidate drugs [<xref ref-type="bibr" rid="CR89">89</xref>]. Jia Z et al. use transcriptomics to find the key MOA of COVID-19, including endocytosis, the lysosome and neutrophil degranulation, and repositioned two antiviral drugs, saquinavir and ribavirin [<xref ref-type="bibr" rid="CR90">90</xref>]. In recent years, the new genome editing technology CRISPR-Cas9 and RNAi technology have provided powerful tools for target discovery and identification research. For example, DrugTargetSeqR technology combines high-throughput sequencing, computational mutation discovery, and CRISPR-Cas9 to identify drug targets [<xref ref-type="bibr" rid="CR91">91</xref>]. And successfully revealed the mechanism of action of ispinesib and YM155 and the mechanism of drug resistance.</p><p id="Par44">In addition to the direct target identification strategy of chemical proteomics, proteomics also provides unique insights into disease biology beyond the genome and transcriptome. Using proteomics techniques to evaluate protein expression profiles in health and disease or drug treatment samples, identifying targets closely related to disease occurrence, development, and treatment [<xref ref-type="bibr" rid="CR92">92</xref>]. For example, the splicing, glycolysis and nucleotide synthesis pathways are important pathways of SARS-COV-2 replication and potential therapeutic targets, and pladienolide B, 2-DG, ribavirin and nms-873 can be used as potential therapeutic options for the COVID-19 [<xref ref-type="bibr" rid="CR93">93</xref>]. To more accurately quantify proteins, the combination of mass spectrometry with stable isotope labeling methods (<sup>13</sup>C, <sup>15</sup>N, <sup>14</sup>N, <sup>2</sup>H) strategy or unlabeled methods [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR95">95</xref>]. For example, Zhang et al. [<xref ref-type="bibr" rid="CR96">96</xref>] found that Gamabufotalin may be a new inhibitor of Hsp90 at the cellular level by using a stable isotope labeling method, thus playing an anti-cancer role. In addition, protein post-translational modifications (phosphorylation, glycosylation, acetylation, etc.) can affect the function and activity of proteins, and therapeutic drugs can be developed targeting modified enzymes, modified proteins and sites [<xref ref-type="bibr" rid="CR97">97</xref>].</p><p id="Par45">Metabolomics, as a newly developed technology in recent years, most studies small molecule substances with molecular weights within 1500&#160;Da in cells, tissues, or biological fluids, revealing changes in the metabolic characterization of the organism [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]. As an indirect or auxiliary target discovery technology, metabolomics directly reflects the organism&#8217;s function by interfering with metabolic enzymes to cause the accumulation or consumption of metabolites [<xref ref-type="bibr" rid="CR100">100</xref>]. The discovery of regulatory targets for natural products can also draw on metabolic flow analysis and functional metabolomics developed based on metabolomics technology. Studies have shown that metabolic disorders in patients with COVID-19 are associated with the severity, and intervention of arginine, tryptophan or purine metabolism can significantly improve the excessive inflammatory response [<xref ref-type="bibr" rid="CR101">101</xref>]. Therefore, in the MOA study of natural products, metabolomics systematically quantifies the flow distribution of metabolic networks in cells or tissues, and reveals important metabolic enzymes that cause changes in metabolic flow [<xref ref-type="bibr" rid="CR102">102</xref>]. For example, metformin exerts anti-liver cancer effects by blocking glycolytic flux through the HIF-1&#945;/PFKFB3/PFK1 regulatory axis [<xref ref-type="bibr" rid="CR103">103</xref>].</p></sec><sec id="Sec12"><title>Network pharmacology</title><p id="Par46">The molecular mechanism of complex diseases is caused by abnormal intracellular regulatory networks involving interactions between multiple genes and multifunctional proteins. The "one drug, one gene, one disease" model currently hinders the innovation of complex disease treatment drugs [<xref ref-type="bibr" rid="CR104">104</xref>]. Network pharmacology is defined as &#8220;integrating systems biology, bioinformatics, network science and other disciplines, from the perspective of system level and biological network as a whole, to analyze the molecular association between drugs and treatment objects, reveal the systematic pharmacological mechanism of drugs, to guide new drug research and development and clinical diagnosis and treatment&#8221; [<xref ref-type="bibr" rid="CR105">105</xref>]. As a multi-component complex system, natural products enter the more complex human life system and network pharmacology provides a research strategy of "multi-component-multi-gene-multi-target-complex disease" to elucidate the complex interaction mode between complex components and multiple effects of natural products [<xref ref-type="bibr" rid="CR106">106</xref>&#8211;<xref ref-type="bibr" rid="CR108">108</xref>].</p><p id="Par47">The drug development process is a long process, mainly involving four stages: drug research and development, preclinical research, clinical trials and new drug applications, approval for marketing and post-marketing monitoring. The real target validation (disease and drug targets) in drug research and development and the balance of drug exposure/selectivity in disease-targeted tissues and healthy tissues in preclinical research are easy to be ignore, resulting in a high failure rate of clinical drug development [<xref ref-type="bibr" rid="CR109">109</xref>]. Among them, the identification of natural product MOA is helpful in identifying candidate drugs, and further optimizing the efficacy and specificity of its inhibitory molecular targets, so as to achieve better efficacy and reduce the off-target effect. The final characterization of natural products with clear MOA is a crucial step in determining preclinical candidate drugs. Generally speaking, the final characterization includes high-dose pharmacology, PK/PD study, dose linearity and repeated administration PK of drugs, which provide the necessary data for optimizing the first-in-human dose (FIH) of drugs [<xref ref-type="bibr" rid="CR110">110</xref>]. Methods commonly used for extrapolation from animals to humans fall into two main categories [<xref ref-type="bibr" rid="CR111">111</xref>]: 1) the minimum expected biological effect dose (MABEL) and no observed effect level (NOAEL), which are based on the body's treatment, tolerance characteristics, and/or pharmacological properties of drugs; 2) A quantitative pharmacology model based on mechanistic principles.</p></sec></sec></sec><sec id="Sec13"><title>Safe medication dosing optimization</title><sec id="Sec14"><title>Traditional dose optimization strategy</title><p id="Par48">There are complex interactions between drugs in the process of combined drug development, and it is difficult to find the optimal dose of clinical combined drugs by using traditional design methods. Among them, predicting the maximum recommended starting order (MRSD) has become a key node in transitioning from non-clinical to clinical drug development [<xref ref-type="bibr" rid="CR107">107</xref>]. The traditional dose evaluation method is recommended by the FDA and European Medicines Agency (EMA), which has the NOAEL and MABEL [<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR112">112</xref>]. NOAEL is a commonly used estimation method to determine the FIH dose of the human body in the first clinical trial. Although the factor of safety was introduced, the differences in the characteristics of PK and PD that may exist between species and the binding characteristics of drugs and receptors were ignored, resulting in a significant deviation in the effective human dose [<xref ref-type="bibr" rid="CR111">111</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. In addition, this method is based on the minimum toxicity risk rather than pharmacological activity. In some cases, it cannot accurately predict the FIH dose of drugs with strong pharmacological activity and low toxicity [<xref ref-type="bibr" rid="CR114">114</xref>].</p><p id="Par49">Since TGN1412 and BIA10-2474 events, the MABEL method for estimating MRSD by fitting PK/PD data has been put forward and continuously optimized, taking into account pharmacological dose/concentration&#8211;response curve and receptor occupancy (agonist&#8201;&#8804;&#8201;10%, Antagonist&#8201;&#8804;&#8201;90%) [<xref ref-type="bibr" rid="CR108">108</xref>]. The MABEL evaluation method dramatically reduces the risk of clinical subjects and the estimated MRSD has good tolerance. However, potential PK differences between species were overlooked and a large amount of mechanistic data was required. And for drugs with adverse reactions originating from excessive pharmacological effects, the initial dose estimation may be too high [<xref ref-type="bibr" rid="CR111">111</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]. There are many differences in clinical trial design related to the physical and chemical properties, biological activity, decomposition rate, absorption, distribution, metabolism and excretion (ADME) of small-molecule drugs and large-molecule drugs. This results in different methods of inter-species scaling for these two types of classification. However, as a commonly used method of interspecific scaling, the allometric scaling method is unsuitable for drugs with insufficient overall accuracy, narrow applicability, specific species binding/distribution, or liver metabolism dependence [<xref ref-type="bibr" rid="CR116">116</xref>].</p></sec><sec id="Sec15"><title>Dose optimization strategy based on quantitative pharmacology model</title><p id="Par50">With the development of emerging technologies such as big biological data, computer technology, and machine learning, FDA has proposed new drug research and development and scientific evaluation based on quantitative pharmacology. This makes it possible to apply model simulation technology to study complex biological processes [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]. The traditional PK/PD model is mainly used to improve the administration plan and individualized treatment of approved drugs, but this semi-mechanism PK/PD model cannot predict the drug exposure level, nor can it further predict the drug effect in different situations (between other drugs or biomarker) [<xref ref-type="bibr" rid="CR119">119</xref>]. Therefore, FDA proposed a model physiologically based pharmacokinetic (PBPK) based on physiological, biochemical, and anatomical parameters, which simulates the ADME process of drugs in the body by connecting various tissues and organs with blood circulation as the center [<xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR121">121</xref>] (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Compared with the traditional dose optimization model, PBPK not only considers the physical and chemical properties of the compound itself but also introduces physiological parameters of the body, emphasizes the different basis for describing the reaction rate constant of drug transport in and out of the room, and establishes the relationship between drug exposure and effect in target tissue [<xref ref-type="bibr" rid="CR122">122</xref>,<xref ref-type="bibr" rid="CR123">123</xref>]. At the same time, coupled with PD, a physiological-based pharmacokinetic/pharmacodynamic model (PBPK-PD) is constructed to characterize the systemic level of drug ADME and tissue-level drug effects, more accurately predicting the time course of drug effects. The optimal dosage regimen can be expected in various complex situations, such as combination therapy and disease complications [<xref ref-type="bibr" rid="CR124">124</xref>]. In addition to interspecific extrapolation, PBPK provides a practical framework for in vitro in vivo extrapolation (IVIVE) [<xref ref-type="bibr" rid="CR125">125</xref>]. For example, by integrating the in vitro data of Vero cells infected by SARS-CoV-2, the PBPK model was used to simulate the concentration of hydroxychloroquine in lung fluid under different administration schemes to explore the most effective strategy [<xref ref-type="bibr" rid="CR126">126</xref>]. At present, PBPK has been widely used in various stages of clinical drug development, such as drug regimen adjustment for special populations [<xref ref-type="bibr" rid="CR127">127</xref>], risk assessment [<xref ref-type="bibr" rid="CR128">128</xref>], toxicity assessment [<xref ref-type="bibr" rid="CR129">129</xref>], drug interaction research [<xref ref-type="bibr" rid="CR130">130</xref>] and drug-disease interaction prediction [<xref ref-type="bibr" rid="CR131">131</xref>].<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Establish physiologically based pharmacokinetic model for cross-species extrapolation of drug dose. SP: species-specific physiology like blood flow rates or organ volumes; EX: tissue-specific gene expression of enzymes and transporters; KP: kinetic parameters in active processes; FU: fraction unbound quantifying binding to plasma proteins</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="13020_2025_1075_Fig3_HTML.jpg"/></fig></p><p id="Par51">In addition, due to race, age, gender, genetic background and many other factors, human response to drug exposure is different. Therefore, the impact of population-level variability in the dose-response relationship should be considered in the development of drug combinations [<xref ref-type="bibr" rid="CR132">132</xref>]. As a parameter-based modeling method (bottom-up), PBPK can also be combined with population pharmacokinetics (Pop-PK) for drug dose selection [<xref ref-type="bibr" rid="CR133">133</xref>]. Different from the classical PK, Pop-PK is a data-driven computational model that uses a "top-down" method to reflect inter-individual and intra-individual variability, identify the factors that cause pharmacokinetic variations (age, gender, race, body weight, etc.), and can be used to simulate drug concentrations in large sparse sample individuals [<xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR135">135</xref>]. The two are combined in a complementary manner, linking exposure to clinical outcomes and addressing individual differences in the target population. A case in point is, Pop-PBPK, established by Offman E et al. [<xref ref-type="bibr" rid="CR136">136</xref>], who confirmed that individual differences in lymphatic circulation influence the human blood volume and renal clearance rate of subcutaneous injection of polyethylene glycol peptide. In addition, the Pop-PBPK model can also provide safe and effective dosage plans for different life stages or special populations (elderly, children, pregnant women, patients with impaired kidney and liver function, etc.) [<xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]. For example, physiological changes during pregnancy will change the drug exposure dose. Increasing the oseltamivir dose after three months of pregnancy is recommended by combining Pop-PK with the PBPK model [<xref ref-type="bibr" rid="CR139">139</xref>]. Race difference is also one of the focuses of current drug development. The PBPK model combined with the Pop-PK model provides a solution to this problem. For instance, Feng S et al. [<xref ref-type="bibr" rid="CR140">140</xref>] use the PBPK model to predict the PK racial sensitivity and initial dose of bitopertin. In contrast, Pop-PK was used to confirm racial differences and provide a basis for dose adjustment.</p><p id="Par52">Therefore, in the study of combined administration of natural products, the PBPK model can be used to conduct multi factor correlation analysis on multiple components, tissue parameters and pharmacokinetics/efficacy at the same time [<xref ref-type="bibr" rid="CR141">141</xref>]. Law FCP et al. [<xref ref-type="bibr" rid="CR142">142</xref>]construct a PBPK model for tea polyphenol mixtures to predict the total concentration of tea catechin mixtures in human plasma after taking green tea or Polyphenon E (PE). In addition, the PBPK model can also be applied to the study of drug interaction in natural products. For example, according to the PBPK model, it is proved that silybin-raloxifene can be used together, and the mechanism of action is to inhibit the intestinal glucuronic acid reaction <sup><xref ref-type="bibr" rid="CR143">143</xref></sup>. Therefore, in the process of optimizing the dosage of natural products, the PBPK-PD model has the following advantages compared to the traditional PK/PD model: firstly, considering human ADME, dose optimization is directly carried out from the drug concentration of the target cells or organs in the human body; secondly, integration the PK results of multiple-components to reflect the comprehensive effects of various components and targets in natural products; thirdly, it compensates for the biases caused by clinical small sample trials and patient physiology; fourthly, it can overcome species differences and to some extent replace animal experiments and bioequivalence experiments, accelerating calculation speed and reducing research costs.</p></sec></sec><sec id="Sec16"><title>Multidisciplinary research framework for the treatment of natural products of COVID-19</title><p id="Par53">Since the beginning of the COVID-19 pandemic, preclinical/clinical studies of hundreds of potential drugs have been carried out, but only a few small-molecule antiviral drugs (such as remdesivir) and 11 kinds of monoclonal antibodies have been approved for clinical use to treat COVID-19. Natural products play a vital role in the prevention and treatment of this epidemic situation. Internationally recognized innovative drugs should have novel structures, new targets, mechanisms therapeutic uses and so on. This leads to the slow development process and high consumption of innovative drugs, and drug repurposing has gradually become a hot spot for common and rare diseases in treatment [<xref ref-type="bibr" rid="CR144">144</xref>]. For instance, drugs such as chloroquine and remdesivir show good antiviral activity. Finding drugs or combinations to treat COVID-19 at different pathological stages from natural products provides a new perspective for developing COVID-19 drugs. However, there are 2 key problems in natural products and synergetic mechanism: first, the active substances lack drug action mode research, which cannot improve the success rate of drug development; Second, the current ADME research on natural products lacks multi-component integration and "in vitro in vivo" correlation model, which cannot provide data for the optimization of combination drugs, leading to the weak risk control ability of clinical trials.</p><p id="Par54">But the aforementioned single technology can only solve some of the problems. HTS, HCS and CADD provide the initial chemical basis for the development of natural products. However, the screening results differ significantly from the overall structure of the biological system and cannot reflect the comprehensive pharmacological effects of the drug, and CADD is highly dependent on the quantity and quality of available data and the predictive/discriminative ability to underlying algorithms. Therefore, the combination of HTS and CADD has the advantages of rapid screening and optimization of drugs, improving the efficiency and accuracy of drug design, and speeding up the drug development process. However, the natural products identified as candidates for disease treatment are multi-target drugs that affect multiple systems in organisms (direct binding and indirect regulation). Omics technology can mine robust data and identify disease/natural product targets and mechanisms of action. However, the results of using only one method to identify natural product targets are susceptible to factors such as selectivity, specificity and biochemical or physiological correlation [<xref ref-type="bibr" rid="CR100">100</xref>]. Therefore, according to the structural characteristics of candidate natural products, integrating multi omics methods to fully mine data significantly improves the ability to decipher complex drug target associations [<xref ref-type="bibr" rid="CR145">145</xref>]. In addition, effective human dose prediction is a key factor in drug development, and traditional dose optimization methods cannot represent drug exposure in target organs or tissues. At the same time, the FDA issued draft guidelines to encourage the pharmaceutical industry to consider underrepresented races and populations (elderly,&#160;children, pregnant women, lactating women, and patients with comorbidities) in the early stages of drug development [<xref ref-type="bibr" rid="CR146">146</xref>]. Model-informed drug development (MIDD) is a quantitative model based on preclinical and clinical data that helps to enhance clinical trial design/efficacy and ultimately achieve optimal dosing in individual patients, including underrepresented populations [<xref ref-type="bibr" rid="CR147">147</xref>]. Among them, PBPK, as a component of MIDD, can simulate drug interactions and evaluate organ/tissue exposure based on the clinical situation of the initial study and outside the population, providing the best dose for individuals [<xref ref-type="bibr" rid="CR148">148</xref>].</p><p id="Par55">With the development of technology, interdisciplinary research strategies and technical means have been proposed for the research and development of innovative drugs. Therefore, we offer to use new drug discovery technologies such as MOA and PBPK to conduct research on COVID-19 natural products from the perspective of &#8220;distinguishing substances, identifying patterns, and determining dosages&#8221; (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). First, the antiviral activity of the existing natural products library extracts was tested in vitro with the help of HTS technology and CADD technology, and more professional keynote screening methods can be adopted, namely physiological screening [<xref ref-type="bibr" rid="CR149">149</xref>]. Then, on the basis of clarifying the pharmacodynamics of active natural products, with the help of metabolomics, chemical synthesis and mass spectrometry detection technology, target discovery of active ingredients (direct and indirect targets) in complex organisms was carried out to clarify the MOA of natural products. Further classifying the &#8220;candidate natural products&#8221; with different MOAs, according to the pharmacological weight and dose-response relationship of different &#8220;candidate natural products&#8221;, provides the basis for the formulation of the optimization scheme of combined drugs. PBPK model can build a &#8220;in vitro-in vivo&#8221; bridge of candidate natural products, and the in vitro dose ratio can be inferred from the in vivo dose of target organs. Specifically, the pharmacokinetics and tissue distribution of combined natural products and different monomers in vivo can be studied through in vivo experiments to obtain the parameters required for PBPK modeling (PK, tissue distribution, excretion data, etc.). The animal PBPK model of natural products (monomers) was constructed by using the "top-down" strategy, and the PBPK model of combined natural products was further constructed by integrating and analyzing the PBPK model parameter values of different natural products. The optimal ratio of combined natural products was determined by PBPK model, and the modeling parameters were replaced with human-specific values to achieve different dose extrapolation and species extrapolation.<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Development of natural products for the treatment of COVID-19 based on MOA and PBPK</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="13020_2025_1075_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec17"><title>Conclusion and future perspective</title><p id="Par56">Drug research and development is at the core of the pharmaceutical industry, aiming to find safe and effective therapeutic drugs. Single-target drugs can accurately target a single target of a disease, thereby blocking the biological activity of the target. Compared with multi-target drugs, they have advantages such as clear mechanism of action, relatively smooth development process, and predictable safety. In recent years, studies have shown that single-target drugs have potential side effects in the treatment of complex/chronic diseases (such as tumors, depression, diabetes, etc.), such as narrow application range, easy to develop drug resistance, insufficient efficacy and poor safety. With the development of medical technology and further research on disease pathogenesis, it is found that multi-target drug therapy can make up for the limitations of single-target drug therapy for complex/chronic diseases. A large number of natural products have been proven to have obvious clinical therapeutic advantages. The compatibility optimization of candidate natural products with clear activity can greatly improve the accessibility of new drug discovery, such as the combination of arsenic tetrasulfide, indirubin and tanshinone IIA in the treatment of leukemia [<xref ref-type="bibr" rid="CR150">150</xref>]; The combined extract of polyphenols in tea (veregen&#8482;) has become the first botanical drug approved by FDA [<xref ref-type="bibr" rid="CR151">151</xref>]. As the starting point for the development of natural product therapies, these studies focus on multi-target drug development based on multi-component combinations, which not only promotes the discovery of innovative drugs, but also improves the feasibility of developing multi-target drugs based on natural products.</p><p id="Par57">In recent years, natural product research has increasingly shown the characteristics and advantages of multidisciplinary cross-integration, mainly focusing on the discovery and isolation of natural products, structural modification and synthesis of natural products, and the mechanism of action and efficacy evaluation of natural products [<xref ref-type="bibr" rid="CR152">152</xref>]. However, drug discovery is a systematic process, and multi-target drug development faces huge challenges and problems. Mainly reflected in the following 4 aspects: First, disease-related biological networks are complex, and which combination of targets can produce the best therapeutic effect has become a major problem; secondly, the synthesis and design success rate of multi-pharmacophore molecules is low.; thirdly, whether multi-target drugs specifically bind to the expected target also affects the optimization of pharmacokinetics and pharmacodynamics; finally, multi-target drugs are highly heterogeneous in clinical research and have complex trial designs (it is necessary to consider multiple factors such as dose optimization and efficacy), and safety is difficult to monitor. Based on the existing problems in current multi-target drug research, this article proposes a research strategy that combines advanced technologies for drug discovery such as phenotypic screening, MOA and PBPK. Provide strategies for the research of multi-target drugs derived from natural products from 2 aspects: the determination of real targets and the balance of multi-target activities, the impact of target synergy on dose, and the balance between clinical dose/efficacy/toxicity. This strategy uses HCS platforms to concentrate resources on in-depth research and optimization of potential multi-target natural products, or uses computer-assisted multi-target drug design to optimize the affinity and stability of multi-target drugs. Subsequently, on the basis of clarifying the in vivo drug efficacy, direct target and indirect target mining technologies are integrated to comprehensively explore the complex mechanisms of diseases and drugs, improve the efficiency and accuracy of target identification, and eliminate off-target effects. These strategies ignore the balance of drug exposure/selectivity between disease-targeted tissues and healthy tissues. For example, the exposure/selectivity of remdesivir, an antiviral drug for COVID-19, at a dose of 100&#160;mg in the lung may be too low, while the concentration in the kidney may be too high. Therefore, the optimal dose is high drug exposure (low dose) in diseased tissues and the minimum drug exposure (high dose) in healthy tissues [<xref ref-type="bibr" rid="CR109">109</xref>]. Therefore, by establishing a PBPK model to balance the efficacy and safety of multi-target drugs, the optimal dosage of multi-target drugs can be accurately adjusted based on the in vivo pharmacokinetic parameters and efficacy of natural products.</p><p id="Par58">Although this article proposes a development strategy for natural product multi-target drugs, it is not sufficient to solve all the problems. First of all, the genetic, functional or compositional heterogeneity of healthy and diseased tissues has also brought significant challenges to drug discovery and development [<xref ref-type="bibr" rid="CR153">153</xref>]. Single-cell omics or whole-genome sequencing provides a new direction for patient stratification and personalized treatment. For example, Deng G et al. [<xref ref-type="bibr" rid="CR154">154</xref>] used a research strategy that combines single-cell multi-omics with target confirmation to find that cycloastragenol (Astragalus membranaceus) can directly target and downregulate tissue cathepsin B, enhancing anti-tumor immunity. In addition, Tang C et al. [<xref ref-type="bibr" rid="CR155">155</xref>] proposed comboSC, which stratifies individual patient samples through single-cell RNA sequencing to identify synergistic drug/small molecule combinations or small molecules that can be paired with immune checkpoint inhibitors. In addition, although the PBPK model balances the efficacy and safety of multi-target drugs to a certain extent. However, the reference values established by the PBPK model require a large number of experimental measurements, and some species' parameters are difficult to obtain. Meanwhile, the introduction of the 3R principle (i.e., replacement, reduction, and refinement) and the species differences between animals and humans have led to greater drug sensitivity. On this basis, a research model combining the PBPK model and organ chips was proposed [<xref ref-type="bibr" rid="CR156">156</xref>]. Organ chips can obtain some data that are impossible or difficult to obtain in traditional experiments, further improving the accuracy and efficiency of PBPK simulation results. Therefore, innovative research technologies should be combined in drug development strategies to effectively promote the transformation of new drugs from concept to clinic.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>FDA</term><def><p id="Par2">US Food and Drug Administration</p></def></def-item><def-item><term>HTS</term><def><p id="Par3">High throughput screening</p></def></def-item><def-item><term>HCS</term><def><p id="Par4">High&#160;content screening</p></def></def-item><def-item><term>CADD</term><def><p id="Par5">Computer-aided drug design</p></def></def-item><def-item><term>QSAR</term><def><p id="Par6">Quantitative structure&#8211;activity relationship</p></def></def-item><def-item><term>AI</term><def><p id="Par7">Artificial intelligence</p></def></def-item><def-item><term>VS</term><def><p id="Par8">Virtual screening</p></def></def-item><def-item><term>SBDD</term><def><p id="Par9">Structure-based drug design</p></def></def-item><def-item><term>LBDD</term><def><p id="Par10">Ligand-based drug design</p></def></def-item><def-item><term>PD</term><def><p id="Par11">Pharmacodynamics</p></def></def-item><def-item><term>PK</term><def><p id="Par12">Pharmacokinetics</p></def></def-item><def-item><term>MOA</term><def><p id="Par13">Mode of action</p></def></def-item><def-item><term>MABEL</term><def><p id="Par14">Minimum expected biological effect dose</p></def></def-item><def-item><term>NOAEL</term><def><p id="Par15">No observed effect level</p></def></def-item><def-item><term>MRSD</term><def><p id="Par16">Maximum recommended starting order</p></def></def-item><def-item><term>EMA</term><def><p id="Par17">European Medicines Agency</p></def></def-item><def-item><term>ADME</term><def><p id="Par18">Absorption, distribution, metabolism and excretion</p></def></def-item><def-item><term>PBPK</term><def><p id="Par19">Physiologically based pharmacokinetic</p></def></def-item><def-item><term>PBPK-PD</term><def><p id="Par20">Physiological-based pharmacokinetic/pharmacodynamic model</p></def></def-item><def-item><term>IVIVE</term><def><p id="Par21">In vitro in vivo extrapolation</p></def></def-item><def-item><term>PopPK</term><def><p id="Par22">Population pharmacokinetics</p></def></def-item><def-item><term>PE</term><def><p id="Par23">Polyphenon E</p></def></def-item><def-item><term>MIDD</term><def><p id="Par24">Model informed drug development</p></def></def-item><def-item><term>STORM</term><def><p id="Par25">Spatial Temporal Operative Real Metabolomics</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Yu Yuan, Lulu Yu and Chenghao Bi have contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Thanks to all participants of the cohort for their contributions to this study.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization: Yu Yuan, Yubo Li. Writing-original draft: Yu Yuan, Lulu Yu, Liping Huang. Investigation: Buda Su, Chenghao Bi, Jiaxuan Nie. Visualization: Zhiying Dou, Chenghao Bi. Supervision: Zhiying Dou, Shenshen Yang, Yubo Li. Writing-review &amp; editing: Shenshen Yang, Yubo Li.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the National Natural Science Foundation of China (82141209 and 82474217), and the foundation of New 20 University Policies of Jinan (NO 202333018).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>This manuscript has no associated data.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par59">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par60">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par61">The authors declare that there are no conflicts of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Advancing Health Through Innovation: New Drug Therapy Approvals 2023. the Food and Drug Administration Web. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023">https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023</ext-link></mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keam</surname><given-names>SJ</given-names></name></person-group><article-title>Trastuzumab deruxtecan: first approval</article-title><source>Drugs</source><year>2020</year><volume>80</volume><issue>5</issue><fpage>501</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1007/s40265-020-01281-4</pub-id><pub-id pub-id-type="pmid">32144719</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Keam SJ. Trastuzumab deruxtecan: first approval. Drugs. 2020;80(5):501&#8211;8. 10.1007/s40265-020-01281-4.<pub-id pub-id-type="pmid">32144719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-020-01281-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>P</given-names></name><name name-style="western"><surname>Cross</surname><given-names>D</given-names></name><name name-style="western"><surname>J&#228;nne</surname><given-names>PA</given-names></name></person-group><article-title>Kinase drug discovery 20 years after imatinib: progress and future directions</article-title><source>Nat Rev Drug Discov</source><year>2021</year><volume>20</volume><issue>7</issue><fpage>551</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00195-4</pub-id><pub-id pub-id-type="pmid">34002056</pub-id><pub-id pub-id-type="pmcid">PMC8127496</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Cohen P, Cross D, J&#228;nne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021;20(7):551&#8211;69. 10.1038/s41573-021-00195-4.<pub-id pub-id-type="pmid">34002056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-021-00195-4</pub-id><pub-id pub-id-type="pmcid">PMC8127496</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burness</surname><given-names>CB</given-names></name></person-group><article-title>Omarigliptin: first global approval</article-title><source>Drugs</source><year>2015</year><volume>75</volume><issue>16</issue><fpage>1947</fpage><lpage>1952</lpage><pub-id pub-id-type="doi">10.1007/s40265-015-0493-8</pub-id><pub-id pub-id-type="pmid">26507988</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Burness CB. Omarigliptin: first global approval. Drugs. 2015;75(16):1947&#8211;52. 10.1007/s40265-015-0493-8.<pub-id pub-id-type="pmid">26507988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-015-0493-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makhoba</surname><given-names>XH</given-names></name><name name-style="western"><surname>Viegas</surname><given-names>C</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Mosa</surname><given-names>RA</given-names></name><name name-style="western"><surname>Viegas</surname><given-names>FPD</given-names></name><name name-style="western"><surname>Pooe</surname><given-names>OJ</given-names></name></person-group><article-title>Potential impact of the multi-target drug approach in the treatment of some complex diseases</article-title><source>Drug Des Devel Ther</source><year>2020</year><volume>14</volume><fpage>3235</fpage><lpage>3249</lpage><pub-id pub-id-type="doi">10.2147/dddt.S257494</pub-id><pub-id pub-id-type="pmid">32884235</pub-id><pub-id pub-id-type="pmcid">PMC7440888</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Makhoba XH, Viegas C Jr, Mosa RA, Viegas FPD, Pooe OJ. Potential impact of the multi-target drug approach in the treatment of some complex diseases. Drug Des Devel Ther. 2020;14:3235&#8211;49. 10.2147/dddt.S257494.<pub-id pub-id-type="pmid">32884235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S257494</pub-id><pub-id pub-id-type="pmcid">PMC7440888</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choudhary</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>PK</given-names></name><name name-style="western"><surname>Verma</surname><given-names>H</given-names></name><name name-style="western"><surname>Singh</surname><given-names>H</given-names></name><name name-style="western"><surname>Silakari</surname><given-names>O</given-names></name></person-group><article-title>Success stories of natural product-based hybrid molecules for multi-factorial diseases</article-title><source>Eur J Med Chem</source><year>2018</year><volume>151</volume><fpage>62</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.03.057</pub-id><pub-id pub-id-type="pmid">29605809</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Choudhary S, Singh PK, Verma H, Singh H, Silakari O. Success stories of natural product-based hybrid molecules for multi-factorial diseases. Eur J Med Chem. 2018;151:62&#8211;97. 10.1016/j.ejmech.2018.03.057.<pub-id pub-id-type="pmid">29605809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2018.03.057</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer</article-title><source>Signal Transduct Target Ther</source><year>2021</year><volume>6</volume><issue>1</issue><fpage>362</fpage><pub-id pub-id-type="doi">10.1038/s41392-021-00670-9</pub-id><pub-id pub-id-type="pmid">34620838</pub-id><pub-id pub-id-type="pmcid">PMC8497485</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Li K, Shi H, Zhang B, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6(1):362. 10.1038/s41392-021-00670-9.<pub-id pub-id-type="pmid">34620838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-021-00670-9</pub-id><pub-id pub-id-type="pmcid">PMC8497485</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>Understanding the genetic mechanisms of cancer drug resistance using genomic approaches</article-title><source>Trends Genet</source><year>2016</year><volume>32</volume><issue>2</issue><fpage>127</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2015.11.003</pub-id><pub-id pub-id-type="pmid">26689126</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Hu X, Zhang Z. Understanding the genetic mechanisms of cancer drug resistance using genomic approaches. Trends Genet. 2016;32(2):127&#8211;37. 10.1016/j.tig.2015.11.003.<pub-id pub-id-type="pmid">26689126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tig.2015.11.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>D</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>DI</given-names></name></person-group><article-title>Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms</article-title><source>Nat Rev Genet</source><year>2015</year><volume>16</volume><issue>8</issue><fpage>459</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1038/nrg3922</pub-id><pub-id pub-id-type="pmid">26149714</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Hughes D, Andersson DI. Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat Rev Genet. 2015;16(8):459&#8211;71. 10.1038/nrg3922.<pub-id pub-id-type="pmid">26149714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrg3922</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ukidve</surname><given-names>A</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Mitragotri</surname><given-names>S</given-names></name></person-group><article-title>Targeting strategies for tissue-specific drug delivery</article-title><source>Cell</source><year>2020</year><volume>181</volume><issue>1</issue><fpage>151</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.001</pub-id><pub-id pub-id-type="pmid">32243788</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Zhao Z, Ukidve A, Kim J, Mitragotri S. Targeting strategies for tissue-specific drug delivery. Cell. 2020;181(1):151&#8211;67. 10.1016/j.cell.2020.02.001.<pub-id pub-id-type="pmid">32243788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.02.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wenzler</surname><given-names>E</given-names></name><name name-style="western"><surname>Fraidenburg</surname><given-names>DR</given-names></name><name name-style="western"><surname>Scardina</surname><given-names>T</given-names></name><name name-style="western"><surname>Danziger</surname><given-names>LH</given-names></name></person-group><article-title>Inhaled antibiotics for gram-negative respiratory infections</article-title><source>Clin Microbiol Rev</source><year>2016</year><volume>29</volume><issue>3</issue><fpage>581</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1128/cmr.00101-15</pub-id><pub-id pub-id-type="pmid">27226088</pub-id><pub-id pub-id-type="pmcid">PMC4978611</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Wenzler E, Fraidenburg DR, Scardina T, Danziger LH. Inhaled antibiotics for gram-negative respiratory infections. Clin Microbiol Rev. 2016;29(3):581&#8211;632. 10.1128/cmr.00101-15.<pub-id pub-id-type="pmid">27226088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.00101-15</pub-id><pub-id pub-id-type="pmcid">PMC4978611</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scannell</surname><given-names>JW</given-names></name><name name-style="western"><surname>Blanckley</surname><given-names>A</given-names></name><name name-style="western"><surname>Boldon</surname><given-names>H</given-names></name><name name-style="western"><surname>Warrington</surname><given-names>B</given-names></name></person-group><article-title>Diagnosing the decline in pharmaceutical R&amp;D efficiency</article-title><source>Nat Rev Drug Discov</source><year>2012</year><volume>11</volume><issue>3</issue><fpage>191</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/nrd3681</pub-id><pub-id pub-id-type="pmid">22378269</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&amp;D efficiency. Nat Rev Drug Discov. 2012;11(3):191&#8211;200. 10.1038/nrd3681.<pub-id pub-id-type="pmid">22378269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd3681</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><name name-style="western"><surname>Ross</surname><given-names>A</given-names></name><name name-style="western"><surname>You</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name></person-group><article-title>Revealing chronic disease progression patterns using Gaussian process for stage inference</article-title><source>J Am Med Inform Assoc</source><year>2024</year><volume>31</volume><issue>2</issue><fpage>396</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1093/jamia/ocad230</pub-id><pub-id pub-id-type="pmid">38055638</pub-id><pub-id pub-id-type="pmcid">PMC10797260</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Wang Y, Zhao W, Ross A, You L, Wang H, Zhou X. Revealing chronic disease progression patterns using Gaussian process for stage inference. J Am Med Inform Assoc. 2024;31(2):396&#8211;405. 10.1093/jamia/ocad230.<pub-id pub-id-type="pmid">38055638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jamia/ocad230</pub-id><pub-id pub-id-type="pmcid">PMC10797260</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">The top 10 causes of death. World Health Organization Web. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death">https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death</ext-link></mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Menche</surname><given-names>J</given-names></name><name name-style="western"><surname>Barab&#225;si</surname><given-names>AL</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name></person-group><article-title>Human symptoms-disease network</article-title><source>Nat Commun</source><year>2014</year><volume>5</volume><fpage>4212</fpage><pub-id pub-id-type="doi">10.1038/ncomms5212</pub-id><pub-id pub-id-type="pmid">24967666</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Zhou X, Menche J, Barab&#225;si AL, Sharma A. Human symptoms-disease network. Nat Commun. 2014;5:4212. 10.1038/ncomms5212.<pub-id pub-id-type="pmid">24967666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms5212</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Safiabadi Tali</surname><given-names>SH</given-names></name><name name-style="western"><surname>LeBlanc</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Sadiq</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection</article-title><source>Clin Microbiol Rev</source><year>2021</year><pub-id pub-id-type="doi">10.1128/cmr.00228-20</pub-id><pub-id pub-id-type="pmid">33980687</pub-id><pub-id pub-id-type="pmcid">PMC8142517</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, et al. Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection. Clin Microbiol Rev. 2021. 10.1128/cmr.00228-20.<pub-id pub-id-type="pmid">33980687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.00228-20</pub-id><pub-id pub-id-type="pmcid">PMC8142517</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>K</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Gu</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>New insights for infection mechanism and potential targets of COVID-19: three Chinese patent medicines and three Chinese medicine formulas as promising therapeutic approaches</article-title><source>Chin Herbal Med</source><year>2023</year><volume>15</volume><issue>2</issue><fpage>157</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.chmed.2022.06.014</pub-id><pub-id pub-id-type="pmcid">PMC9993661</pub-id><pub-id pub-id-type="pmid">37220535</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Jia K, Li Y, Liu T, Gu X, Li X. New insights for infection mechanism and potential targets of COVID-19: three Chinese patent medicines and three Chinese medicine formulas as promising therapeutic approaches. Chin Herbal Med. 2023;15(2):157&#8211;68. 10.1016/j.chmed.2022.06.014.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chmed.2022.06.014</pub-id><pub-id pub-id-type="pmcid">PMC9993661</pub-id><pub-id pub-id-type="pmid">37220535</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Renzi</surname><given-names>C</given-names></name><name name-style="western"><surname>Kaushal</surname><given-names>A</given-names></name><name name-style="western"><surname>Emery</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comorbid chronic diseases and cancer diagnosis: disease-specific effects and underlying mechanisms</article-title><source>Nat Rev Clin Oncol</source><year>2019</year><volume>16</volume><issue>12</issue><fpage>746</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1038/s41571-019-0249-6</pub-id><pub-id pub-id-type="pmid">31350467</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Renzi C, Kaushal A, Emery J, et al. Comorbid chronic diseases and cancer diagnosis: disease-specific effects and underlying mechanisms. Nat Rev Clin Oncol. 2019;16(12):746&#8211;61. 10.1038/s41571-019-0249-6.<pub-id pub-id-type="pmid">31350467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-019-0249-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diederichs</surname><given-names>C</given-names></name><name name-style="western"><surname>Berger</surname><given-names>K</given-names></name><name name-style="western"><surname>Bartels</surname><given-names>DB</given-names></name></person-group><article-title>The measurement of multiple chronic diseases&#8211;a systematic review on existing multimorbidity indices</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2011</year><volume>66</volume><issue>3</issue><fpage>301</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1093/gerona/glq208</pub-id><pub-id pub-id-type="pmid">21112963</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Diederichs C, Berger K, Bartels DB. The measurement of multiple chronic diseases&#8211;a systematic review on existing multimorbidity indices. J Gerontol A Biol Sci Med Sci. 2011;66(3):301&#8211;11. 10.1093/gerona/glq208.<pub-id pub-id-type="pmid">21112963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glq208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Yifan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xuechun</surname><given-names>S</given-names></name></person-group><article-title>Prevalence trends of multimorbidity among residents in mainland China: a meta-analysis</article-title><source>Chin Gen Pract</source><year>2023</year><volume>26</volume><issue>29</issue><fpage>3599</fpage><lpage>3607</lpage></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Li H, Yifan Z, Xuechun S. Prevalence trends of multimorbidity among residents in mainland China: a meta-analysis. Chin Gen Pract. 2023;26(29):3599&#8211;607.</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morphy</surname><given-names>R</given-names></name><name name-style="western"><surname>Kay</surname><given-names>C</given-names></name><name name-style="western"><surname>Rankovic</surname><given-names>Z</given-names></name></person-group><article-title>From magic bullets to designed multiple ligands</article-title><source>Drug Discov Today</source><year>2004</year><volume>9</volume><issue>15</issue><fpage>641</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1016/s1359-6446(04)03163-0</pub-id><pub-id pub-id-type="pmid">15279847</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today. 2004;9(15):641&#8211;51. 10.1016/s1359-6446(04)03163-0.<pub-id pub-id-type="pmid">15279847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1359-6446(04)03163-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Besnard</surname><given-names>J</given-names></name><name name-style="western"><surname>Ruda</surname><given-names>GF</given-names></name><name name-style="western"><surname>Setola</surname><given-names>V</given-names></name><etal/></person-group><article-title>Automated design of ligands to polypharmacological profiles</article-title><source>Nature</source><year>2012</year><volume>492</volume><issue>7428</issue><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/nature11691</pub-id><pub-id pub-id-type="pmid">23235874</pub-id><pub-id pub-id-type="pmcid">PMC3653568</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Besnard J, Ruda GF, Setola V, et al. Automated design of ligands to polypharmacological profiles. Nature. 2012;492(7428):215&#8211;20. 10.1038/nature11691.<pub-id pub-id-type="pmid">23235874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11691</pub-id><pub-id pub-id-type="pmcid">PMC3653568</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>F</given-names></name><name name-style="western"><surname>Kov&#225;cs</surname><given-names>IA</given-names></name><name name-style="western"><surname>Barab&#225;si</surname><given-names>AL</given-names></name></person-group><article-title>Network-based prediction of drug combinations</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>1197</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-09186-x</pub-id><pub-id pub-id-type="pmid">30867426</pub-id><pub-id pub-id-type="pmcid">PMC6416394</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Cheng F, Kov&#225;cs IA, Barab&#225;si AL. Network-based prediction of drug combinations. Nat Commun. 2019;10(1):1197. 10.1038/s41467-019-09186-x.<pub-id pub-id-type="pmid">30867426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-09186-x</pub-id><pub-id pub-id-type="pmcid">PMC6416394</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>P</given-names></name><name name-style="western"><surname>Delost</surname><given-names>MD</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>MH</given-names></name><name name-style="western"><surname>Smith</surname><given-names>DT</given-names></name><name name-style="western"><surname>Njardarson</surname><given-names>JT</given-names></name></person-group><article-title>A survey of the structures of US FDA approved combination drugs</article-title><source>J Med Chem</source><year>2019</year><volume>62</volume><issue>9</issue><fpage>4265</fpage><lpage>4311</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b01610</pub-id><pub-id pub-id-type="pmid">30444362</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Das P, Delost MD, Qureshi MH, Smith DT, Njardarson JT. A survey of the structures of US FDA approved combination drugs. J Med Chem. 2019;62(9):4265&#8211;311. 10.1021/acs.jmedchem.8b01610.<pub-id pub-id-type="pmid">30444362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.8b01610</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atanasov</surname><given-names>AG</given-names></name><name name-style="western"><surname>Zotchev</surname><given-names>SB</given-names></name><name name-style="western"><surname>Dirsch</surname><given-names>VM</given-names></name><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group><article-title>Natural products in drug discovery: advances and opportunities</article-title><source>Nat Rev Drug Discov</source><year>2021</year><volume>20</volume><issue>3</issue><fpage>200</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/s41573-020-00114-z</pub-id><pub-id pub-id-type="pmid">33510482</pub-id><pub-id pub-id-type="pmcid">PMC7841765</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20(3):200&#8211;16. 10.1038/s41573-020-00114-z.<pub-id pub-id-type="pmid">33510482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-020-00114-z</pub-id><pub-id pub-id-type="pmcid">PMC7841765</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boone</surname><given-names>SA</given-names></name><name name-style="western"><surname>Ijaz</surname><given-names>MK</given-names></name><name name-style="western"><surname>Bright</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Antiviral natural products, their mechanisms of action and potential applications as sanitizers and disinfectants</article-title><source>Food Environ Virol</source><year>2023</year><volume>15</volume><issue>4</issue><fpage>265</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1007/s12560-023-09568-x</pub-id><pub-id pub-id-type="pmid">37906416</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Boone SA, Ijaz MK, Bright KR, et al. Antiviral natural products, their mechanisms of action and potential applications as sanitizers and disinfectants. Food Environ Virol. 2023;15(4):265&#8211;80. 10.1007/s12560-023-09568-x.<pub-id pub-id-type="pmid">37906416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12560-023-09568-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Xu H, Li S, Liu J, et al. Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19. Proceedings of the National Academy of Sciences of the United States of America. 2023;120(18):e2301775120. 10.1073/pnas.2301775120<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2301775120</pub-id><pub-id pub-id-type="pmcid">PMC10160982</pub-id><pub-id pub-id-type="pmid">37094153</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name></person-group><article-title>Functional metabolomics innovates therapeutic discovery of traditional Chinese medicine derived functional compounds</article-title><source>Pharmacol Ther</source><year>2021</year><volume>224</volume><fpage>107824</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2021.107824</pub-id><pub-id pub-id-type="pmid">33667524</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Wang T, Liu J, Luo X, Hu L, Lu H. Functional metabolomics innovates therapeutic discovery of traditional Chinese medicine derived functional compounds. Pharmacol Ther. 2021;224: 107824. 10.1016/j.pharmthera.2021.107824.<pub-id pub-id-type="pmid">33667524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2021.107824</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mei</surname><given-names>M</given-names></name><name name-style="western"><surname>Tan</surname><given-names>X</given-names></name></person-group><article-title>Current strategies of antiviral drug discovery for COVID-19</article-title><source>Front Mol Biosci</source><year>2021</year><volume>8</volume><fpage>671263</fpage><pub-id pub-id-type="doi">10.3389/fmolb.2021.671263</pub-id><pub-id pub-id-type="pmid">34055887</pub-id><pub-id pub-id-type="pmcid">PMC8155633</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Mei M, Tan X. Current strategies of antiviral drug discovery for COVID-19. Front Mol Biosci. 2021;8: 671263. 10.3389/fmolb.2021.671263.<pub-id pub-id-type="pmid">34055887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2021.671263</pub-id><pub-id pub-id-type="pmcid">PMC8155633</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yiqing</surname><given-names>Z</given-names></name><name name-style="western"><surname>Youli</surname><given-names>X</given-names></name></person-group><article-title>Target identification of bioactive natural products</article-title><source>Acta Chim Sinica</source><year>2018</year><volume>76</volume><issue>3</issue><fpage>177</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.6023/A17110484</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Yiqing Z, Youli X. Target identification of bioactive natural products. Acta Chim Sinica. 2018;76(3):177&#8211;89. 10.6023/A17110484.</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maurer</surname><given-names>TS</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D</given-names></name><name name-style="western"><surname>Beaumont</surname><given-names>K</given-names></name><name name-style="western"><surname>Di</surname><given-names>L</given-names></name></person-group><article-title>Dose predictions for drug design</article-title><source>J Med Chem</source><year>2020</year><volume>63</volume><issue>12</issue><fpage>6423</fpage><lpage>6435</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01365</pub-id><pub-id pub-id-type="pmid">31913040</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Maurer TS, Smith D, Beaumont K, Di L. Dose predictions for drug design. J Med Chem. 2020;63(12):6423&#8211;35. 10.1021/acs.jmedchem.9b01365.<pub-id pub-id-type="pmid">31913040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.9b01365</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>K</given-names></name><name name-style="western"><surname>Chandak</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>A foundation model for clinician-centered drug repurposing</article-title><source>Nat Med</source><year>2024</year><volume>30</volume><issue>12</issue><fpage>3601</fpage><lpage>3613</lpage><pub-id pub-id-type="doi">10.1038/s41591-024-03233-x</pub-id><pub-id pub-id-type="pmid">39322717</pub-id><pub-id pub-id-type="pmcid">PMC11645266</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Huang K, Chandak P, Wang Q, et al. A foundation model for clinician-centered drug repurposing. Nat Med. 2024;30(12):3601&#8211;13. 10.1038/s41591-024-03233-x.<pub-id pub-id-type="pmid">39322717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03233-x</pub-id><pub-id pub-id-type="pmcid">PMC11645266</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davidson</surname><given-names>KW</given-names></name><name name-style="western"><surname>Barry</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Mangione</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Aspirin use to prevent cardiovascular disease: US preventive services task force recommendation statement</article-title><source>JAMA</source><year>2022</year><volume>327</volume><issue>16</issue><fpage>1577</fpage><lpage>1584</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.4983</pub-id><pub-id pub-id-type="pmid">35471505</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Davidson KW, Barry MJ, Mangione CM, et al. Aspirin use to prevent cardiovascular disease: US preventive services task force recommendation statement. JAMA. 2022;327(16):1577&#8211;84. 10.1001/jama.2022.4983.<pub-id pub-id-type="pmid">35471505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2022.4983</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fatima</surname><given-names>ST</given-names></name></person-group><article-title>From erectile dysfunction to dementia: a new role for sildenafil</article-title><source>Eur Neuropsychopharmacol</source><year>2024</year><volume>88</volume><fpage>30</fpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2024.07.008</pub-id><pub-id pub-id-type="pmid">39121712</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Fatima ST. From erectile dysfunction to dementia: a new role for sildenafil. Eur Neuropsychopharmacol. 2024;88:30. 10.1016/j.euroneuro.2024.07.008.<pub-id pub-id-type="pmid">39121712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.euroneuro.2024.07.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Chotivanich</surname><given-names>K</given-names></name></person-group><article-title>Artemisinin-resistant malaria. <italic toggle="yes">Clinical</italic></article-title><source>Microbiol Rev</source><year>2024</year><volume>37</volume><issue>4</issue><fpage>e0010924</fpage><pub-id pub-id-type="doi">10.1128/cmr.00109-24</pub-id><pub-id pub-id-type="pmcid">PMC11629630</pub-id><pub-id pub-id-type="pmid">39404268</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">White NJ, Chotivanich K. Artemisinin-resistant malaria. <italic toggle="yes">Clinical</italic>. Microbiol Rev. 2024;37(4):e0010924. 10.1128/cmr.00109-24.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/cmr.00109-24</pub-id><pub-id pub-id-type="pmcid">PMC11629630</pub-id><pub-id pub-id-type="pmid">39404268</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Issa</surname><given-names>GC</given-names></name><name name-style="western"><surname>Stein</surname><given-names>EM</given-names></name><name name-style="western"><surname>DiNardo</surname><given-names>CDD</given-names></name></person-group><article-title>How i treat: differentiation therapy in acute myeloid leukemia</article-title><source>Blood</source><year>2024</year><pub-id pub-id-type="doi">10.1182/blood.2024024008</pub-id><pub-id pub-id-type="pmid">38976876</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Issa GC, Stein EM, DiNardo CDD. How i treat: differentiation therapy in acute myeloid leukemia. Blood. 2024. 10.1182/blood.2024024008.<pub-id pub-id-type="pmid">38976876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.2024024008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>T</given-names></name><name name-style="western"><surname>Mao</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Therapeutic potential of bicyclol in liver diseases: Lessons from a synthetic drug based on herbal derivative in traditional Chinese medicine</article-title><source>Int Immunopharmacol</source><year>2021</year><volume>91</volume><fpage>107308</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2020.107308</pub-id><pub-id pub-id-type="pmid">33383448</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Zhao T, Mao L, Yu Z, et al. Therapeutic potential of bicyclol in liver diseases: Lessons from a synthetic drug based on herbal derivative in traditional Chinese medicine. Int Immunopharmacol. 2021;91: 107308. 10.1016/j.intimp.2020.107308.<pub-id pub-id-type="pmid">33383448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2020.107308</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>H</given-names></name><name name-style="western"><surname>Ahrens</surname><given-names>E</given-names></name><name name-style="western"><surname>Wachtendorf</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Intraoperative use of phenylephrine versus ephedrine and postoperative Delirium: a multicenter retrospective cohort study</article-title><source>Anesthesiology</source><year>2024</year><volume>140</volume><issue>4</issue><fpage>657</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1097/aln.0000000000004774</pub-id><pub-id pub-id-type="pmid">37725759</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Ma H, Ahrens E, Wachtendorf LJ, et al. Intraoperative use of phenylephrine versus ephedrine and postoperative Delirium: a multicenter retrospective cohort study. Anesthesiology. 2024;140(4):657&#8211;67. 10.1097/aln.0000000000004774.<pub-id pub-id-type="pmid">37725759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0000000000004774</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">NHC Full text: Diagnosis and treatment protocol for COVID-19 patients (tentative 8th edition) 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://en.nhc.gov.cn/2020-09/07/c_81565.htm">http://en.nhc.gov.cn/2020-09/07/c_81565.htm</ext-link>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.ID9.0000733564.21786.b0</pub-id><pub-id pub-id-type="pmcid">PMC8057316</pub-id><pub-id pub-id-type="pmid">38630124</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brimacombe</surname><given-names>KR</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>T</given-names></name><name name-style="western"><surname>Eastman</surname><given-names>RT</given-names></name><etal/></person-group><article-title>An OpenData portal to share COVID-19 drug repurposing data in real time</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.06.04.135046</pub-id><pub-id pub-id-type="pmid">32511420</pub-id><pub-id pub-id-type="pmcid">PMC7276055</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Brimacombe KR, Zhao T, Eastman RT, et al. An OpenData portal to share COVID-19 drug repurposing data in real time. bioRxiv. 2020. 10.1101/2020.06.04.135046.<pub-id pub-id-type="pmid">32511420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/2020.06.04.135046</pub-id><pub-id pub-id-type="pmcid">PMC7276055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabal</surname><given-names>O</given-names></name><name name-style="western"><surname>Link</surname><given-names>W</given-names></name><name name-style="western"><surname>Serelde</surname><given-names>BG</given-names></name><name name-style="western"><surname>Bischoff</surname><given-names>JR</given-names></name><name name-style="western"><surname>Oyarzabal</surname><given-names>J</given-names></name></person-group><article-title>An integrated one-step system to extract, analyze and annotate all relevant information from image-based cell screening of chemical libraries</article-title><source>Mol Biosyst</source><year>2010</year><volume>6</volume><issue>4</issue><fpage>711</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1039/b919830j</pub-id><pub-id pub-id-type="pmid">20237649</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Rabal O, Link W, Serelde BG, Bischoff JR, Oyarzabal J. An integrated one-step system to extract, analyze and annotate all relevant information from image-based cell screening of chemical libraries. Mol Biosyst. 2010;6(4):711&#8211;20. 10.1039/b919830j.<pub-id pub-id-type="pmid">20237649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/b919830j</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name><name name-style="western"><surname>Schorpp</surname><given-names>K</given-names></name><name name-style="western"><surname>Rothenaigner</surname><given-names>I</given-names></name><name name-style="western"><surname>Hadian</surname><given-names>K</given-names></name></person-group><article-title>Image-based high-content screening in drug discovery</article-title><source>Drug Discov Today</source><year>2020</year><volume>25</volume><issue>8</issue><fpage>1348</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2020.06.001</pub-id><pub-id pub-id-type="pmid">32561299</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Lin S, Schorpp K, Rothenaigner I, Hadian K. Image-based high-content screening in drug discovery. Drug Discov Today. 2020;25(8):1348&#8211;61. 10.1016/j.drudis.2020.06.001.<pub-id pub-id-type="pmid">32561299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2020.06.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>C</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Guidelines for application of high-content screening in traditional Chinese medicine: concept, equipment, and troubleshooting. Guidelines &amp; standards</article-title><source>Acupunct Herbal Med</source><year>2024</year><pub-id pub-id-type="doi">10.1097/HM9.0000000000000105</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Chen X, Li L, Zhang M, Yang J, Lyu C, Xu Y, Yang Y, Wang Y. Guidelines for application of high-content screening in traditional Chinese medicine: concept, equipment, and troubleshooting. Guidelines &amp; standards. Acupunct Herbal Med. 2024. 10.1097/HM9.0000000000000105.</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellomo</surname><given-names>F</given-names></name><name name-style="western"><surname>Medina</surname><given-names>DL</given-names></name><name name-style="western"><surname>De Leo</surname><given-names>E</given-names></name><name name-style="western"><surname>Panarella</surname><given-names>A</given-names></name><name name-style="western"><surname>Emma</surname><given-names>F</given-names></name></person-group><article-title>High-content drug screening for rare diseases</article-title><source>J Inherit Metab Dis</source><year>2017</year><volume>40</volume><issue>4</issue><fpage>601</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1007/s10545-017-0055-1</pub-id><pub-id pub-id-type="pmid">28593466</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Bellomo F, Medina DL, De Leo E, Panarella A, Emma F. High-content drug screening for rare diseases. J Inherit Metab Dis. 2017;40(4):601&#8211;7. 10.1007/s10545-017-0055-1.<pub-id pub-id-type="pmid">28593466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10545-017-0055-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kropivsek</surname><given-names>K</given-names></name><name name-style="western"><surname>Kachel</surname><given-names>P</given-names></name><name name-style="western"><surname>Goetze</surname><given-names>S</given-names></name><etal/></person-group><article-title>Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma</article-title><source>Nat Cancer</source><year>2023</year><volume>4</volume><issue>5</issue><fpage>734</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1038/s43018-023-00544-9</pub-id><pub-id pub-id-type="pmid">37081258</pub-id><pub-id pub-id-type="pmcid">PMC10212768</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Kropivsek K, Kachel P, Goetze S, et al. Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma. Nat Cancer. 2023;4(5):734&#8211;53. 10.1038/s43018-023-00544-9.<pub-id pub-id-type="pmid">37081258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43018-023-00544-9</pub-id><pub-id pub-id-type="pmcid">PMC10212768</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Xia</surname><given-names>M</given-names></name></person-group><article-title>Review of high-content screening applications in toxicology</article-title><source>Arch Toxicol</source><year>2019</year><volume>93</volume><issue>12</issue><fpage>3387</fpage><lpage>3396</lpage><pub-id pub-id-type="doi">10.1007/s00204-019-02593-5</pub-id><pub-id pub-id-type="pmid">31664499</pub-id><pub-id pub-id-type="pmcid">PMC7011178</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Li S, Xia M. Review of high-content screening applications in toxicology. Arch Toxicol. 2019;93(12):3387&#8211;96. 10.1007/s00204-019-02593-5.<pub-id pub-id-type="pmid">31664499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00204-019-02593-5</pub-id><pub-id pub-id-type="pmcid">PMC7011178</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L</given-names></name><etal/></person-group><article-title>The strategies and techniques of drug discovery from natural products</article-title><source>Pharmacol Ther</source><year>2020</year><volume>216</volume><fpage>107686</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107686</pub-id><pub-id pub-id-type="pmid">32961262</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Zhang L, Song J, Kong L, et al. The strategies and techniques of drug discovery from natural products. Pharmacol Ther. 2020;216: 107686. 10.1016/j.pharmthera.2020.107686.<pub-id pub-id-type="pmid">32961262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2020.107686</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadybekov</surname><given-names>AV</given-names></name><name name-style="western"><surname>Katritch</surname><given-names>V</given-names></name></person-group><article-title>Computational approaches streamlining drug discovery</article-title><source>Nature</source><year>2023</year><volume>616</volume><issue>7958</issue><fpage>673</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-05905-z</pub-id><pub-id pub-id-type="pmid">37100941</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Sadybekov AV, Katritch V. Computational approaches streamlining drug discovery. Nature. 2023;616(7958):673&#8211;85. 10.1038/s41586-023-05905-z.<pub-id pub-id-type="pmid">37100941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-05905-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forli</surname><given-names>S</given-names></name><name name-style="western"><surname>Huey</surname><given-names>R</given-names></name><name name-style="western"><surname>Pique</surname><given-names>ME</given-names></name><name name-style="western"><surname>Sanner</surname><given-names>MF</given-names></name><name name-style="western"><surname>Goodsell</surname><given-names>DS</given-names></name><name name-style="western"><surname>Olson</surname><given-names>AJ</given-names></name></person-group><article-title>Computational protein-ligand docking and virtual drug screening with the AutoDock suite</article-title><source>Nat Protoc</source><year>2016</year><volume>11</volume><issue>5</issue><fpage>905</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1038/nprot.2016.051</pub-id><pub-id pub-id-type="pmid">27077332</pub-id><pub-id pub-id-type="pmcid">PMC4868550</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc. 2016;11(5):905&#8211;19. 10.1038/nprot.2016.051.<pub-id pub-id-type="pmid">27077332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nprot.2016.051</pub-id><pub-id pub-id-type="pmcid">PMC4868550</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>W</given-names></name><name name-style="western"><surname>Lei</surname><given-names>W</given-names></name><name name-style="western"><surname>Katritsis</surname><given-names>NM</given-names></name><name name-style="western"><surname>MacMahon</surname><given-names>M</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>K</given-names></name><name name-style="western"><surname>Han</surname><given-names>N</given-names></name></person-group><article-title>Current and prospective computational approaches and challenges for developing COVID-19 vaccines</article-title><source>Adv Drug Deliv Rev</source><year>2021</year><volume>172</volume><fpage>249</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.02.004</pub-id><pub-id pub-id-type="pmid">33561453</pub-id><pub-id pub-id-type="pmcid">PMC7871111</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Hwang W, Lei W, Katritsis NM, MacMahon M, Chapman K, Han N. Current and prospective computational approaches and challenges for developing COVID-19 vaccines. Adv Drug Deliv Rev. 2021;172:249&#8211;74. 10.1016/j.addr.2021.02.004.<pub-id pub-id-type="pmid">33561453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2021.02.004</pub-id><pub-id pub-id-type="pmcid">PMC7871111</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadybekov</surname><given-names>AA</given-names></name><name name-style="western"><surname>Sadybekov</surname><given-names>AV</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Synthon-based ligand discovery in virtual libraries of over 11 billion compounds</article-title><source>Nature</source><year>2022</year><volume>601</volume><issue>7893</issue><fpage>452</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04220-9</pub-id><pub-id pub-id-type="pmid">34912117</pub-id><pub-id pub-id-type="pmcid">PMC9763054</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Sadybekov AA, Sadybekov AV, Liu Y, et al. Synthon-based ligand discovery in virtual libraries of over 11 billion compounds. Nature. 2022;601(7893):452&#8211;9. 10.1038/s41586-021-04220-9.<pub-id pub-id-type="pmid">34912117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-04220-9</pub-id><pub-id pub-id-type="pmcid">PMC9763054</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SM</given-names></name><name name-style="western"><surname>Yen</surname><given-names>HL</given-names></name></person-group><article-title>Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection</article-title><source>Antiviral Res</source><year>2012</year><volume>96</volume><issue>3</issue><fpage>391</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2012.09.013</pub-id><pub-id pub-id-type="pmid">23022351</pub-id><pub-id pub-id-type="pmcid">PMC7132421</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Lee SM, Yen HL. Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection. Antiviral Res. 2012;96(3):391&#8211;404. 10.1016/j.antiviral.2012.09.013.<pub-id pub-id-type="pmid">23022351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2012.09.013</pub-id><pub-id pub-id-type="pmcid">PMC7132421</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maia</surname><given-names>EHB</given-names></name><name name-style="western"><surname>Assis</surname><given-names>LC</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>TA</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>AM</given-names></name><name name-style="western"><surname>Taranto</surname><given-names>AG</given-names></name></person-group><article-title>Structure-based virtual screening: from classical to artificial intelligence</article-title><source>Front Chem</source><year>2020</year><volume>8</volume><fpage>343</fpage><pub-id pub-id-type="doi">10.3389/fchem.2020.00343</pub-id><pub-id pub-id-type="pmid">32411671</pub-id><pub-id pub-id-type="pmcid">PMC7200080</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Maia EHB, Assis LC, de Oliveira TA, da Silva AM, Taranto AG. Structure-based virtual screening: from classical to artificial intelligence. Front Chem. 2020;8:343. 10.3389/fchem.2020.00343.<pub-id pub-id-type="pmid">32411671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fchem.2020.00343</pub-id><pub-id pub-id-type="pmcid">PMC7200080</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alonso</surname><given-names>H</given-names></name><name name-style="western"><surname>Bliznyuk</surname><given-names>AA</given-names></name><name name-style="western"><surname>Gready</surname><given-names>JE</given-names></name></person-group><article-title>Combining docking and molecular dynamic simulations in drug design</article-title><source>Med Res Rev</source><year>2006</year><volume>26</volume><issue>5</issue><fpage>531</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1002/med.20067</pub-id><pub-id pub-id-type="pmid">16758486</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Alonso H, Bliznyuk AA, Gready JE. Combining docking and molecular dynamic simulations in drug design. Med Res Rev. 2006;26(5):531&#8211;68. 10.1002/med.20067.<pub-id pub-id-type="pmid">16758486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/med.20067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Ligand-based approach for predicting drug targets and for virtual screening against COVID-19</article-title><source>Brief Bioinform</source><year>2021</year><volume>22</volume><issue>2</issue><fpage>1053</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1093/bib/bbaa422</pub-id><pub-id pub-id-type="pmid">33461215</pub-id><pub-id pub-id-type="pmcid">PMC7929377</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Yang Y, Zhu Z, Wang X, et al. Ligand-based approach for predicting drug targets and for virtual screening against COVID-19. Brief Bioinform. 2021;22(2):1053&#8211;64. 10.1093/bib/bbaa422.<pub-id pub-id-type="pmid">33461215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbaa422</pub-id><pub-id pub-id-type="pmcid">PMC7929377</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thangavel</surname><given-names>N</given-names></name><name name-style="western"><surname>Albratty</surname><given-names>M</given-names></name></person-group><article-title>Pharmacophore model-aided virtual screening combined with comparative molecular docking and molecular dynamics for identification of marine natural products as SARS-CoV-2 papain-like protease inhibitors</article-title><source>Arab J Chem</source><year>2022</year><volume>15</volume><issue>12</issue><fpage>104334</fpage><pub-id pub-id-type="doi">10.1016/j.arabjc.2022.104334</pub-id><pub-id pub-id-type="pmid">36246784</pub-id><pub-id pub-id-type="pmcid">PMC9554199</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Thangavel N, Albratty M. Pharmacophore model-aided virtual screening combined with comparative molecular docking and molecular dynamics for identification of marine natural products as SARS-CoV-2 papain-like protease inhibitors. Arab J Chem. 2022;15(12): 104334. 10.1016/j.arabjc.2022.104334.<pub-id pub-id-type="pmid">36246784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arabjc.2022.104334</pub-id><pub-id pub-id-type="pmcid">PMC9554199</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Qiao LS, Zhang YL. [Application of CADD on multi-target drug R&amp;D in natural products]. <italic toggle="yes">Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica</italic>. 2014;39(11):1951&#8211;5.<pub-id pub-id-type="pmid">25272821</pub-id></mixed-citation></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanoli</surname><given-names>Z</given-names></name><name name-style="western"><surname>V&#228;h&#228;-Koskela</surname><given-names>M</given-names></name><name name-style="western"><surname>Aittokallio</surname><given-names>T</given-names></name></person-group><article-title>Artificial intelligence, machine learning, and drug repurposing in cancer</article-title><source>Expert Opin Drug Discov</source><year>2021</year><volume>16</volume><issue>9</issue><fpage>977</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1080/17460441.2021.1883585</pub-id><pub-id pub-id-type="pmid">33543671</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Tanoli Z, V&#228;h&#228;-Koskela M, Aittokallio T. Artificial intelligence, machine learning, and drug repurposing in cancer. Expert Opin Drug Discov. 2021;16(9):977&#8211;89. 10.1080/17460441.2021.1883585.<pub-id pub-id-type="pmid">33543671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17460441.2021.1883585</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Author correction: endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease</article-title><source>Nat Aging</source><year>2023</year><volume>3</volume><issue>7</issue><fpage>908</fpage><pub-id pub-id-type="doi">10.1038/s43587-023-00396-z</pub-id><pub-id pub-id-type="pmid">37118557</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Fang J, Zhang P, Zhou Y, et al. Author correction: endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer&#8217;s disease. Nat Aging. 2023;3(7):908. 10.1038/s43587-023-00396-z.<pub-id pub-id-type="pmid">37118557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-023-00396-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gohel</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Sildenafil as a candidate drug for Alzheimer's disease: real-world patient data observation and mechanistic observations from patient-induced pluripotent stem cell-derived neurons</article-title><source>J Alzheimers Dis</source><year>2024</year><volume>98</volume><issue>2</issue><fpage>643</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.3233/jad-231391</pub-id><pub-id pub-id-type="pmid">38427489</pub-id><pub-id pub-id-type="pmcid">PMC10977448</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Gohel D, Zhang P, Gupta AK, et al. Sildenafil as a candidate drug for Alzheimer&#8217;s disease: real-world patient data observation and mechanistic observations from patient-induced pluripotent stem cell-derived neurons. J Alzheimers Dis. 2024;98(2):643&#8211;57. 10.3233/jad-231391.<pub-id pub-id-type="pmid">38427489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-231391</pub-id><pub-id pub-id-type="pmcid">PMC10977448</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rafi</surname><given-names>MO</given-names></name><name name-style="western"><surname>Bhattacharje</surname><given-names>G</given-names></name><name name-style="western"><surname>Al-Khafaji</surname><given-names>K</given-names></name><etal/></person-group><article-title>Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19</article-title><source>J Biomol Struct Dyn</source><year>2022</year><volume>40</volume><issue>8</issue><fpage>3711</fpage><lpage>3730</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1850355</pub-id><pub-id pub-id-type="pmid">33251975</pub-id><pub-id pub-id-type="pmcid">PMC7754938</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Rafi MO, Bhattacharje G, Al-Khafaji K, et al. Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19. J Biomol Struct Dyn. 2022;40(8):3711&#8211;30. 10.1080/07391102.2020.1850355.<pub-id pub-id-type="pmid">33251975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2020.1850355</pub-id><pub-id pub-id-type="pmcid">PMC7754938</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>W</given-names></name><name name-style="western"><surname>Stokes</surname><given-names>JM</given-names></name><name name-style="western"><surname>Eastman</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Deep learning identifies synergistic drug combinations for treating COVID-19</article-title><source>Proc Natl Acad Sci USA</source><year>2021</year><pub-id pub-id-type="doi">10.1073/pnas.2105070118</pub-id><pub-id pub-id-type="pmid">34526388</pub-id><pub-id pub-id-type="pmcid">PMC8488647</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Jin W, Stokes JM, Eastman RT, et al. Deep learning identifies synergistic drug combinations for treating COVID-19. Proc Natl Acad Sci USA. 2021. 10.1073/pnas.2105070118.<pub-id pub-id-type="pmid">34526388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2105070118</pub-id><pub-id pub-id-type="pmcid">PMC8488647</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandraghatgi</surname><given-names>R</given-names></name><name name-style="western"><surname>Ji</surname><given-names>HF</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>GL</given-names></name><name name-style="western"><surname>Sokhansanj</surname><given-names>BA</given-names></name></person-group><article-title>Streamlining computational fragment-based drug discovery through evolutionary optimization informed by ligand-based virtual prescreening</article-title><source>J Chem Inf Model</source><year>2024</year><volume>64</volume><issue>9</issue><fpage>3826</fpage><lpage>3840</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.4c00234</pub-id><pub-id pub-id-type="pmid">38696451</pub-id><pub-id pub-id-type="pmcid">PMC11197033</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Chandraghatgi R, Ji HF, Rosen GL, Sokhansanj BA. Streamlining computational fragment-based drug discovery through evolutionary optimization informed by ligand-based virtual prescreening. J Chem Inf Model. 2024;64(9):3826&#8211;40. 10.1021/acs.jcim.4c00234.<pub-id pub-id-type="pmid">38696451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.4c00234</pub-id><pub-id pub-id-type="pmcid">PMC11197033</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galindez</surname><given-names>G</given-names></name><name name-style="western"><surname>Matschinske</surname><given-names>J</given-names></name><name name-style="western"><surname>Rose</surname><given-names>TD</given-names></name><etal/></person-group><article-title>Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies</article-title><source>Nat Comput Sci</source><year>2021</year><volume>1</volume><issue>1</issue><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1038/s43588-020-00007-6</pub-id><pub-id pub-id-type="pmid">38217166</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Galindez G, Matschinske J, Rose TD, et al. Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. Nat Comput Sci. 2021;1(1):33&#8211;41. 10.1038/s43588-020-00007-6.<pub-id pub-id-type="pmid">38217166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43588-020-00007-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Omarini</surname><given-names>AB</given-names></name><name name-style="western"><surname>Gand</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Discovery of TCMs and derivatives against the main protease of SARS-CoV-2 via high throughput screening, ADMET analysis, and inhibition assay in vitro</article-title><source>J Mol Struct</source><year>2022</year><volume>1268</volume><fpage>133709</fpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2022.133709</pub-id><pub-id pub-id-type="pmid">35846732</pub-id><pub-id pub-id-type="pmcid">PMC9273959</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Qi X, Li B, Omarini AB, Gand M, Zhang X, Wang J. Discovery of TCMs and derivatives against the main protease of SARS-CoV-2 via high throughput screening, ADMET analysis, and inhibition assay in vitro. J Mol Struct. 2022;1268:133709. 10.1016/j.molstruc.2022.133709.<pub-id pub-id-type="pmid">35846732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molstruc.2022.133709</pub-id><pub-id pub-id-type="pmcid">PMC9273959</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azad</surname><given-names>MA</given-names></name><name name-style="western"><surname>Wright</surname><given-names>GD</given-names></name></person-group><article-title>Determining the mode of action of bioactive compounds</article-title><source>Bioorg Med Chem</source><year>2012</year><volume>20</volume><issue>6</issue><fpage>1929</fpage><lpage>1939</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2011.10.088</pub-id><pub-id pub-id-type="pmid">22300885</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Azad MA, Wright GD. Determining the mode of action of bioactive compounds. Bioorg Med Chem. 2012;20(6):1929&#8211;39. 10.1016/j.bmc.2011.10.088.<pub-id pub-id-type="pmid">22300885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmc.2011.10.088</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashyap</surname><given-names>AS</given-names></name><name name-style="western"><surname>Schmittnaegel</surname><given-names>M</given-names></name><name name-style="western"><surname>Rigamonti</surname><given-names>N</given-names></name><etal/></person-group><article-title>Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy</article-title><source>Proc Natl Acad Sci USA</source><year>2020</year><volume>117</volume><issue>1</issue><fpage>541</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1073/pnas.1902145116</pub-id><pub-id pub-id-type="pmid">31889004</pub-id><pub-id pub-id-type="pmcid">PMC6955310</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Kashyap AS, Schmittnaegel M, Rigamonti N, et al. Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. Proc Natl Acad Sci USA. 2020;117(1):541&#8211;51. 10.1073/pnas.1902145116.<pub-id pub-id-type="pmid">31889004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1902145116</pub-id><pub-id pub-id-type="pmcid">PMC6955310</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Margolis</surname><given-names>JM</given-names></name><name name-style="western"><surname>Chu</surname><given-names>BC</given-names></name><name name-style="western"><surname>Wang</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>Copher</surname><given-names>R</given-names></name><name name-style="western"><surname>Cavazos</surname><given-names>JE</given-names></name></person-group><article-title>Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action</article-title><source>JAMA Neurol</source><year>2014</year><volume>71</volume><issue>8</issue><fpage>985</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2014.808</pub-id><pub-id pub-id-type="pmid">24911669</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Margolis JM, Chu BC, Wang ZJ, Copher R, Cavazos JE. Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action. JAMA Neurol. 2014;71(8):985&#8211;93. 10.1001/jamaneurol.2014.808.<pub-id pub-id-type="pmid">24911669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2014.808</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tulloch</surname><given-names>LB</given-names></name><name name-style="western"><surname>Menzies</surname><given-names>SK</given-names></name><name name-style="western"><surname>Coron</surname><given-names>RP</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>MD</given-names></name><name name-style="western"><surname>Florence</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Smith</surname><given-names>TK</given-names></name></person-group><article-title>Direct and indirect approaches to identify drug modes of action</article-title><source>IUBMB Life</source><year>2018</year><volume>70</volume><issue>1</issue><fpage>9</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1002/iub.1697</pub-id><pub-id pub-id-type="pmid">29210173</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Tulloch LB, Menzies SK, Coron RP, Roberts MD, Florence GJ, Smith TK. Direct and indirect approaches to identify drug modes of action. IUBMB Life. 2018;70(1):9&#8211;22. 10.1002/iub.1697.<pub-id pub-id-type="pmid">29210173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/iub.1697</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>R</given-names></name><name name-style="western"><surname>Ursu</surname><given-names>O</given-names></name><name name-style="western"><surname>Gaulton</surname><given-names>A</given-names></name><etal/></person-group><article-title>A comprehensive map of molecular drug targets</article-title><source>Nat Rev Drug Dis</source><year>2017</year><volume>16</volume><issue>1</issue><fpage>19</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1038/nrd.2016.230</pub-id><pub-id pub-id-type="pmcid">PMC6314433</pub-id><pub-id pub-id-type="pmid">27910877</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Santos R, Ursu O, Gaulton A, et al. A comprehensive map of molecular drug targets. Nat Rev Drug Dis. 2017;16(1):19&#8211;34. 10.1038/nrd.2016.230.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd.2016.230</pub-id><pub-id pub-id-type="pmcid">PMC6314433</pub-id><pub-id pub-id-type="pmid">27910877</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>GQ</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Shi</surname><given-names>XG</given-names></name><etal/></person-group><article-title>In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins</article-title><source>Blood</source><year>1996</year><volume>88</volume><issue>3</issue><fpage>1052</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1182/blood.V88.3.1052.1052</pub-id><pub-id pub-id-type="pmid">8704214</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88(3):1052&#8211;61.<pub-id pub-id-type="pmid">8704214</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>N</given-names></name><etal/></person-group><article-title>Target identification of natural medicine with chemical proteomics approach: probe synthesis, target fishing and protein identification</article-title><source>Signal Transduct Target Ther</source><year>2020</year><volume>5</volume><issue>1</issue><fpage>72</fpage><pub-id pub-id-type="doi">10.1038/s41392-020-0186-y</pub-id><pub-id pub-id-type="pmid">32435053</pub-id><pub-id pub-id-type="pmcid">PMC7239890</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Chen X, Wang Y, Ma N, et al. Target identification of natural medicine with chemical proteomics approach: probe synthesis, target fishing and protein identification. Signal Transduct Target Ther. 2020;5(1):72. 10.1038/s41392-020-0186-y.<pub-id pub-id-type="pmid">32435053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-0186-y</pub-id><pub-id pub-id-type="pmcid">PMC7239890</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JB</given-names></name></person-group><article-title>Commentary: indirect action pattern: a remote and cross-organ pharmacological mechanism for drug innovation</article-title><source>Acta pharmaceutica Sinica B</source><year>2022</year><volume>12</volume><issue>8</issue><fpage>3448</fpage><lpage>3450</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.05.025</pub-id><pub-id pub-id-type="pmid">35967286</pub-id><pub-id pub-id-type="pmcid">PMC9366289</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Gao Y, Wang JB. Commentary: indirect action pattern: a remote and cross-organ pharmacological mechanism for drug innovation. Acta pharmaceutica Sinica B. 2022;12(8):3448&#8211;50. 10.1016/j.apsb.2022.05.025.<pub-id pub-id-type="pmid">35967286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2022.05.025</pub-id><pub-id pub-id-type="pmcid">PMC9366289</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zha</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Bu Shen Yi Sui capsule promotes myelin repair by modulating the transformation of A1/A2 reactive astrocytes In Vivo and In Vitro</article-title><source>Oxid Med Cell Longev</source><year>2022</year><volume>2022</volume><fpage>3800004</fpage><pub-id pub-id-type="doi">10.1155/2022/3800004</pub-id><pub-id pub-id-type="pmid">36092158</pub-id><pub-id pub-id-type="pmcid">PMC9458373</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Zha Z, Liu YJ, Liu SS, et al. Bu Shen Yi Sui capsule promotes myelin repair by modulating the transformation of A1/A2 reactive astrocytes In Vivo and In Vitro. Oxid Med Cell Longev. 2022;2022:3800004. 10.1155/2022/3800004.<pub-id pub-id-type="pmid">36092158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/3800004</pub-id><pub-id pub-id-type="pmcid">PMC9458373</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wypych</surname><given-names>TP</given-names></name><name name-style="western"><surname>Wickramasinghe</surname><given-names>LC</given-names></name><name name-style="western"><surname>Marsland</surname><given-names>BJ</given-names></name></person-group><article-title>The influence of the microbiome on respiratory health</article-title><source>Nat Immunol</source><year>2019</year><volume>20</volume><issue>10</issue><fpage>1279</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0451-9</pub-id><pub-id pub-id-type="pmid">31501577</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Wypych TP, Wickramasinghe LC, Marsland BJ. The influence of the microbiome on respiratory health. Nat Immunol. 2019;20(10):1279&#8211;90. 10.1038/s41590-019-0451-9.<pub-id pub-id-type="pmid">31501577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-019-0451-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorboni</surname><given-names>SG</given-names></name><name name-style="western"><surname>Moghaddam</surname><given-names>HS</given-names></name><name name-style="western"><surname>Jafarzadeh-Esfehani</surname><given-names>R</given-names></name><name name-style="western"><surname>Soleimanpour</surname><given-names>S</given-names></name></person-group><article-title>A comprehensive review on the role of the gut microbiome in human neurological disorders</article-title><source>Clin Microbiol Rev</source><year>2022</year><volume>35</volume><issue>1</issue><fpage>e0033820</fpage><pub-id pub-id-type="doi">10.1128/cmr.00338-20</pub-id><pub-id pub-id-type="pmid">34985325</pub-id><pub-id pub-id-type="pmcid">PMC8729913</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Sorboni SG, Moghaddam HS, Jafarzadeh-Esfehani R, Soleimanpour S. A comprehensive review on the role of the gut microbiome in human neurological disorders. Clin Microbiol Rev. 2022;35(1):e0033820. 10.1128/cmr.00338-20.<pub-id pub-id-type="pmid">34985325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.00338-20</pub-id><pub-id pub-id-type="pmcid">PMC8729913</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>JB</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>XH</given-names></name></person-group><article-title>The indirect regulatory effect of traditional Chinese medicine and the innovative development of indirect acting traditional Chinese medicine</article-title><source>Chin J Trad Chin Med</source><year>2021</year><volume>46</volume><issue>21</issue><fpage>5443</fpage><lpage>5449</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.19540/j.cnki.cjcmm.20210978.601</pub-id><pub-id pub-id-type="pmid">34951194</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Wang JB, Xiao XH. The indirect regulatory effect of traditional Chinese medicine and the innovative development of indirect acting traditional Chinese medicine. Chin J Trad Chin Med. 2021;46(21):5443&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.19540/j.cnki.cjcmm.20210978.601</pub-id><pub-id pub-id-type="pmid">34951194</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Recent advances in targeting the &#8220;undruggable&#8221; proteins: from drug discovery to clinical trials</article-title><source>Sig Transduct Target Ther</source><year>2023</year><volume>8</volume><issue>1</issue><fpage>335</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01589-z</pub-id><pub-id pub-id-type="pmcid">PMC10480221</pub-id><pub-id pub-id-type="pmid">37669923</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Xie X, Yu T, Li X, et al. Recent advances in targeting the &#8220;undruggable&#8221; proteins: from drug discovery to clinical trials. Sig Transduct Target Ther. 2023;8(1):335. 10.1038/s41392-023-01589-z.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01589-z</pub-id><pub-id pub-id-type="pmcid">PMC10480221</pub-id><pub-id pub-id-type="pmid">37669923</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>J</given-names></name></person-group><article-title>Systems biology of metabolism</article-title><source>Annu Rev Biochem</source><year>2017</year><volume>86</volume><fpage>245</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-061516-044757</pub-id><pub-id pub-id-type="pmid">28301739</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Nielsen J. Systems biology of metabolism. Annu Rev Biochem. 2017;86:245&#8211;75. 10.1146/annurev-biochem-061516-044757.<pub-id pub-id-type="pmid">28301739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-biochem-061516-044757</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindsay</surname><given-names>MA</given-names></name></person-group><article-title>Target discovery</article-title><source>Nat Rev Drug Dis</source><year>2003</year><volume>2</volume><issue>10</issue><fpage>831</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1038/nrd1202</pub-id><pub-id pub-id-type="pmid">14526386</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Lindsay MA. Target discovery. Nat Rev Drug Dis. 2003;2(10):831&#8211;8. 10.1038/nrd1202.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd1202</pub-id><pub-id pub-id-type="pmid">14526386</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulley</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rhoads</surname><given-names>JP</given-names></name><name name-style="western"><surname>Jerome</surname><given-names>RN</given-names></name><etal/></person-group><article-title>Using what we already have: uncovering new drug repurposing strategies in existing omics data</article-title><source>Annu Rev Pharmacol Toxicol</source><year>2020</year><volume>60</volume><fpage>333</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010919-023537</pub-id><pub-id pub-id-type="pmid">31337270</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Pulley JM, Rhoads JP, Jerome RN, et al. Using what we already have: uncovering new drug repurposing strategies in existing omics data. Annu Rev Pharmacol Toxicol. 2020;60:333&#8211;52. 10.1146/annurev-pharmtox-010919-023537.<pub-id pub-id-type="pmid">31337270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-pharmtox-010919-023537</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penrod</surname><given-names>NM</given-names></name><name name-style="western"><surname>Cowper-Sal-lari</surname><given-names>R</given-names></name><name name-style="western"><surname>Moore</surname><given-names>JH</given-names></name></person-group><article-title>Systems genetics for drug target discovery</article-title><source>Trends Pharmacol Sci</source><year>2011</year><volume>32</volume><issue>10</issue><fpage>623</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2011.07.002</pub-id><pub-id pub-id-type="pmid">21862141</pub-id><pub-id pub-id-type="pmcid">PMC3185183</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Penrod NM, Cowper-Sal-lari R, Moore JH. Systems genetics for drug target discovery. Trends Pharmacol Sci. 2011;32(10):623&#8211;30. 10.1016/j.tips.2011.07.002.<pub-id pub-id-type="pmid">21862141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2011.07.002</pub-id><pub-id pub-id-type="pmcid">PMC3185183</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><name name-style="western"><surname>Bai</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name></person-group><article-title>Genome sequencing provides potential strategies for drug discovery and synthesis. Review articles</article-title><source>Acupunct Herbal Med</source><year>2023</year><pub-id pub-id-type="doi">10.1097/HM9.0000000000000076</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Zhao C, Zhang Z, Sun L, Bai R, Wang L, Chen S. Genome sequencing provides potential strategies for drug discovery and synthesis. Review articles. Acupunct Herbal Med. 2023. 10.1097/HM9.0000000000000076.</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trajanoska</surname><given-names>K</given-names></name><name name-style="western"><surname>Bh&#233;rer</surname><given-names>C</given-names></name><name name-style="western"><surname>Taliun</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><name name-style="western"><surname>Richards</surname><given-names>JB</given-names></name><name name-style="western"><surname>Mooser</surname><given-names>V</given-names></name></person-group><article-title>From target discovery to clinical drug development with human genetics</article-title><source>Nature</source><year>2023</year><volume>620</volume><issue>7975</issue><fpage>737</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06388-8</pub-id><pub-id pub-id-type="pmid">37612393</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Trajanoska K, Bh&#233;rer C, Taliun D, Zhou S, Richards JB, Mooser V. From target discovery to clinical drug development with human genetics. Nature. 2023;620(7975):737&#8211;45. 10.1038/s41586-023-06388-8.<pub-id pub-id-type="pmid">37612393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06388-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lauck</surname><given-names>KC</given-names></name><name name-style="western"><surname>Limmer</surname><given-names>A</given-names></name><name name-style="western"><surname>Harris</surname><given-names>P</given-names></name><name name-style="western"><surname>Kivelevitch</surname><given-names>D</given-names></name></person-group><article-title>Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: a global propensity score matched retrospective cohort study</article-title><source>J Am Acad Dermatol</source><year>2024</year><volume>91</volume><issue>1</issue><fpage>163</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2024.03.019</pub-id><pub-id pub-id-type="pmid">38552905</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Lauck KC, Limmer A, Harris P, Kivelevitch D. Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: a global propensity score matched retrospective cohort study. J Am Acad Dermatol. 2024;91(1):163&#8211;6. 10.1016/j.jaad.2024.03.019.<pub-id pub-id-type="pmid">38552905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2024.03.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>AF</given-names></name><name name-style="western"><surname>Hingorani</surname><given-names>AD</given-names></name><name name-style="western"><surname>Finan</surname><given-names>C</given-names></name></person-group><article-title>Human genomics and drug development</article-title><source>Cold Spring Harb Perspect Med</source><year>2022</year><pub-id pub-id-type="doi">10.1101/cshperspect.a039230</pub-id><pub-id pub-id-type="pmid">34649961</pub-id><pub-id pub-id-type="pmcid">PMC8805642</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Schmidt AF, Hingorani AD, Finan C. Human genomics and drug development. Cold Spring Harb Perspect Med. 2022. 10.1101/cshperspect.a039230.<pub-id pub-id-type="pmid">34649961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a039230</pub-id><pub-id pub-id-type="pmcid">PMC8805642</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsui</surname><given-names>M</given-names></name><name name-style="western"><surname>Corey</surname><given-names>DR</given-names></name></person-group><article-title>Non-coding RNAs as drug targets</article-title><source>Nat Rev Drug Discov</source><year>2017</year><volume>16</volume><issue>3</issue><fpage>167</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1038/nrd.2016.117</pub-id><pub-id pub-id-type="pmid">27444227</pub-id><pub-id pub-id-type="pmcid">PMC5831170</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2017;16(3):167&#8211;79. 10.1038/nrd.2016.117.<pub-id pub-id-type="pmid">27444227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd.2016.117</pub-id><pub-id pub-id-type="pmcid">PMC5831170</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><mixed-citation publication-type="other">Anderson DE, Cui J, Ye Q, et al. Orthogonal genome-wide screens of bat cells identify MTHFD1 as a target of broad antiviral therapy. Proceedings of the National Academy of Sciences of the United States of America. 2021; 118(39)10.1073/pnas.2104759118<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2104759118</pub-id><pub-id pub-id-type="pmcid">PMC8488669</pub-id><pub-id pub-id-type="pmid">34544865</pub-id></mixed-citation></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arakelyan</surname><given-names>A</given-names></name><name name-style="western"><surname>Nersisyan</surname><given-names>L</given-names></name><name name-style="western"><surname>Nikoghosyan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Transcriptome-guided drug repositioning</article-title><source>Pharmaceutics</source><year>2019</year><pub-id pub-id-type="doi">10.3390/pharmaceutics11120677</pub-id><pub-id pub-id-type="pmid">31842375</pub-id><pub-id pub-id-type="pmcid">PMC6969900</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Arakelyan A, Nersisyan L, Nikoghosyan M, et al. Transcriptome-guided drug repositioning. Pharmaceutics. 2019. 10.3390/pharmaceutics11120677.<pub-id pub-id-type="pmid">31842375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics11120677</pub-id><pub-id pub-id-type="pmcid">PMC6969900</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>Z</given-names></name><name name-style="western"><surname>Song</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>He</surname><given-names>K</given-names></name></person-group><article-title>Transcriptome-based drug repositioning for coronavirus disease 2019 (COVID-19)</article-title><source>Pathog Dis</source><year>2020</year><pub-id pub-id-type="doi">10.1093/femspd/ftaa036</pub-id><pub-id pub-id-type="pmid">32667665</pub-id><pub-id pub-id-type="pmcid">PMC7454646</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Jia Z, Song X, Shi J, Wang W, He K. Transcriptome-based drug repositioning for coronavirus disease 2019 (COVID-19). Pathog Dis. 2020. 10.1093/femspd/ftaa036.<pub-id pub-id-type="pmid">32667665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/femspd/ftaa036</pub-id><pub-id pub-id-type="pmcid">PMC7454646</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasap</surname><given-names>C</given-names></name><name name-style="western"><surname>Elemento</surname><given-names>O</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>TM</given-names></name></person-group><article-title>DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets</article-title><source>Nat Chem Biol</source><year>2014</year><volume>10</volume><issue>8</issue><fpage>626</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1551</pub-id><pub-id pub-id-type="pmid">24929528</pub-id><pub-id pub-id-type="pmcid">PMC4123312</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Kasap C, Elemento O, Kapoor TM. DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets. Nat Chem Biol. 2014;10(8):626&#8211;8. 10.1038/nchembio.1551.<pub-id pub-id-type="pmid">24929528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nchembio.1551</pub-id><pub-id pub-id-type="pmcid">PMC4123312</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savino</surname><given-names>R</given-names></name><name name-style="western"><surname>Paduano</surname><given-names>S</given-names></name><name name-style="western"><surname>Preian&#242;</surname><given-names>M</given-names></name><name name-style="western"><surname>Terracciano</surname><given-names>R</given-names></name></person-group><article-title>The proteomics big challenge for biomarkers and new drug-targets discovery</article-title><source>Int J Mol Sci</source><year>2012</year><volume>13</volume><issue>11</issue><fpage>13926</fpage><lpage>13948</lpage><pub-id pub-id-type="doi">10.3390/ijms131113926</pub-id><pub-id pub-id-type="pmid">23203042</pub-id><pub-id pub-id-type="pmcid">PMC3509558</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Savino R, Paduano S, Preian&#242; M, Terracciano R. The proteomics big challenge for biomarkers and new drug-targets discovery. Int J Mol Sci. 2012;13(11):13926&#8211;48. 10.3390/ijms131113926.<pub-id pub-id-type="pmid">23203042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms131113926</pub-id><pub-id pub-id-type="pmcid">PMC3509558</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bojkova</surname><given-names>D</given-names></name><name name-style="western"><surname>Klann</surname><given-names>K</given-names></name><name name-style="western"><surname>Koch</surname><given-names>B</given-names></name><etal/></person-group><article-title>Proteomics of SARS-CoV-2-infected host cells reveals therapy targets</article-title><source>Nature</source><year>2020</year><volume>583</volume><issue>7816</issue><fpage>469</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2332-7</pub-id><pub-id pub-id-type="pmid">32408336</pub-id><pub-id pub-id-type="pmcid">PMC7616921</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Bojkova D, Klann K, Koch B, et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature. 2020;583(7816):469&#8211;72. 10.1038/s41586-020-2332-7.<pub-id pub-id-type="pmid">32408336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2332-7</pub-id><pub-id pub-id-type="pmcid">PMC7616921</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>SE</given-names></name><name name-style="western"><surname>Mann</surname><given-names>M</given-names></name></person-group><article-title>Mass spectrometry-based proteomics turns quantitative</article-title><source>Nat Chem Biol</source><year>2005</year><volume>1</volume><issue>5</issue><fpage>252</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1038/nchembio736</pub-id><pub-id pub-id-type="pmid">16408053</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Ong SE, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol. 2005;1(5):252&#8211;62. 10.1038/nchembio736.<pub-id pub-id-type="pmid">16408053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nchembio736</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yates</surname><given-names>JR</given-names><suffix>3rd</suffix></name></person-group><article-title>The revolution and evolution of shotgun proteomics for large-scale proteome analysis</article-title><source>J Am Chem Soc</source><year>2013</year><volume>135</volume><issue>5</issue><fpage>1629</fpage><lpage>1640</lpage><pub-id pub-id-type="doi">10.1021/ja3094313</pub-id><pub-id pub-id-type="pmid">23294060</pub-id><pub-id pub-id-type="pmcid">PMC3751590</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Yates JR 3rd. The revolution and evolution of shotgun proteomics for large-scale proteome analysis. J Am Chem Soc. 2013;135(5):1629&#8211;40. 10.1021/ja3094313.<pub-id pub-id-type="pmid">23294060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ja3094313</pub-id><pub-id pub-id-type="pmcid">PMC3751590</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Quantitative proteomics reveals molecular mechanism of gamabufotalin and its potential inhibition on Hsp90 in lung cancer</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><issue>47</issue><fpage>76551</fpage><lpage>76564</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.10388</pub-id><pub-id pub-id-type="pmid">27384878</pub-id><pub-id pub-id-type="pmcid">PMC5363529</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Zhang L, Yu Z, Wang Y, et al. Quantitative proteomics reveals molecular mechanism of gamabufotalin and its potential inhibition on Hsp90 in lung cancer. Oncotarget. 2016;7(47):76551&#8211;64. 10.18632/oncotarget.10388.<pub-id pub-id-type="pmid">27384878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.10388</pub-id><pub-id pub-id-type="pmcid">PMC5363529</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Geng</surname><given-names>M</given-names></name><etal/></person-group><article-title>Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies</article-title><source>Sig Transduct Target Ther</source><year>2023</year><volume>8</volume><issue>1</issue><fpage>220</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01439-y</pub-id><pub-id pub-id-type="pmcid">PMC10224996</pub-id><pub-id pub-id-type="pmid">37244925</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Wu X, Xu M, Geng M, et al. Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies. Sig Transduct Target Ther. 2023;8(1):220. 10.1038/s41392-023-01439-y.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01439-y</pub-id><pub-id pub-id-type="pmcid">PMC10224996</pub-id><pub-id pub-id-type="pmid">37244925</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beger</surname><given-names>RD</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>W</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Metabolomics enables precision medicine: "a white paper, community perspective"</article-title><source>Metabolomics</source><year>2016</year><volume>12</volume><issue>10</issue><fpage>149</fpage><pub-id pub-id-type="doi">10.1007/s11306-016-1094-6</pub-id><pub-id pub-id-type="pmid">27642271</pub-id><pub-id pub-id-type="pmcid">PMC5009152</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Beger RD, Dunn W, Schmidt MA, et al. Metabolomics enables precision medicine: &#8220;a white paper, community perspective.&#8221; Metabolomics. 2016;12(10):149. 10.1007/s11306-016-1094-6.<pub-id pub-id-type="pmid">27642271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11306-016-1094-6</pub-id><pub-id pub-id-type="pmcid">PMC5009152</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wishart</surname><given-names>DS</given-names></name></person-group><article-title>Metabolomics for investigating physiological and pathophysiological processes</article-title><source>Physiol Rev</source><year>2019</year><volume>99</volume><issue>4</issue><fpage>1819</fpage><lpage>1875</lpage><pub-id pub-id-type="doi">10.1152/physrev.00035.2018</pub-id><pub-id pub-id-type="pmid">31434538</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Wishart DS. Metabolomics for investigating physiological and pathophysiological processes. Physiol Rev. 2019;99(4):1819&#8211;75. 10.1152/physrev.00035.2018.<pub-id pub-id-type="pmid">31434538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00035.2018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>HW</given-names></name><name name-style="western"><surname>Lv</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Application of omics- and multi-omics-based techniques for natural product target discovery</article-title><source>Biomed Pharmacother</source><year>2021</year><volume>141</volume><fpage>111833</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2021.111833</pub-id><pub-id pub-id-type="pmid">34175822</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Zhang HW, Lv C, Zhang LJ, et al. Application of omics- and multi-omics-based techniques for natural product target discovery. Biomed Pharmacother. 2021;141:111833. 10.1016/j.biopha.2021.111833.<pub-id pub-id-type="pmid">34175822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2021.111833</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>N</given-names></name><name name-style="western"><surname>Nie</surname><given-names>M</given-names></name><name name-style="western"><surname>Pang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>1618</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-21907-9</pub-id><pub-id pub-id-type="pmid">33712622</pub-id><pub-id pub-id-type="pmcid">PMC7955129</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Xiao N, Nie M, Pang H, et al. Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications. Nat Commun. 2021;12(1):1618. 10.1038/s41467-021-21907-9.<pub-id pub-id-type="pmid">33712622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-21907-9</pub-id><pub-id pub-id-type="pmcid">PMC7955129</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>L</given-names></name><name name-style="western"><surname>Sun</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name></person-group><article-title>Metabolomics, metabolic flux analysis and cancer pharmacology</article-title><source>Pharmacol Ther</source><year>2021</year><volume>224</volume><fpage>107827</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2021.107827</pub-id><pub-id pub-id-type="pmid">33662451</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Liang L, Sun F, Wang H, Hu Z. Metabolomics, metabolic flux analysis and cancer pharmacology. Pharmacol Ther. 2021;224: 107827. 10.1016/j.pharmthera.2021.107827.<pub-id pub-id-type="pmid">33662451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2021.107827</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Metformin attenuates hepatoma cell proliferation by decreasing glycolytic flux through the HIF-1&#945;/PFKFB3/PFK1 pathway</article-title><source>Life Sci</source><year>2019</year><volume>239</volume><fpage>116966</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2019.116966</pub-id><pub-id pub-id-type="pmid">31626790</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Hu L, Zeng Z, Xia Q, et al. Metformin attenuates hepatoma cell proliferation by decreasing glycolytic flux through the HIF-1&#945;/PFKFB3/PFK1 pathway. Life Sci. 2019;239:116966. 10.1016/j.lfs.2019.116966.<pub-id pub-id-type="pmid">31626790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2019.116966</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nogales</surname><given-names>C</given-names></name><name name-style="western"><surname>Mamdouh</surname><given-names>ZM</given-names></name><name name-style="western"><surname>List</surname><given-names>M</given-names></name><name name-style="western"><surname>Kiel</surname><given-names>C</given-names></name><name name-style="western"><surname>Casas</surname><given-names>AI</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>H</given-names></name></person-group><article-title>Network pharmacology: curing causal mechanisms instead of treating symptoms</article-title><source>Trends Pharmacol Sci</source><year>2022</year><volume>43</volume><issue>2</issue><fpage>136</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2021.11.004</pub-id><pub-id pub-id-type="pmid">34895945</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Nogales C, Mamdouh ZM, List M, Kiel C, Casas AI, Schmidt H. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci. 2022;43(2):136&#8211;50. 10.1016/j.tips.2021.11.004.<pub-id pub-id-type="pmid">34895945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2021.11.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><collab>World Federation of Chinese Medicine Societies</collab></person-group><article-title>Network pharmacology evaluation method guidance</article-title><source>WJTCM</source><year>2021</year><volume>16</volume><issue>04</issue><fpage>527</fpage><lpage>532</lpage></element-citation><mixed-citation id="mc-CR105" publication-type="journal">World Federation of Chinese Medicine Societies. Network pharmacology evaluation method guidance. WJTCM. 2021;16(04):527&#8211;32.</mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liao</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name><name name-style="western"><surname>Fan</surname><given-names>X</given-names></name></person-group><article-title>Network pharmacology approaches for research of traditional chinese medicines</article-title><source>Chin J Nat Med</source><year>2023</year><volume>21</volume><issue>5</issue><fpage>323</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1016/s1875-5364(23)60429-7</pub-id><pub-id pub-id-type="pmid">37245871</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Li X, Liu Z, Liao J, Chen Q, Lu X, Fan X. Network pharmacology approaches for research of traditional chinese medicines. Chin J Nat Med. 2023;21(5):323&#8211;32. 10.1016/s1875-5364(23)60429-7.<pub-id pub-id-type="pmid">37245871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1875-5364(23)60429-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Tourneau</surname><given-names>C</given-names></name><name name-style="western"><surname>Stathis</surname><given-names>A</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>L</given-names></name><name name-style="western"><surname>Moore</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Siu</surname><given-names>LL</given-names></name></person-group><article-title>Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><issue>8</issue><fpage>1401</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1200/jco.2009.25.9606</pub-id><pub-id pub-id-type="pmid">20124167</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Le Tourneau C, Stathis A, Vidal L, Moore MJ, Siu LL. Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials. J Clin Oncol. 2010;28(8):1401&#8211;7. 10.1200/jco.2009.25.9606.<pub-id pub-id-type="pmid">20124167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2009.25.9606</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><mixed-citation publication-type="other">European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on Strategies to ldentify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medical Products [EB/OL]. 2007.</mixed-citation></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>W</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L</given-names></name><etal/></person-group><article-title>Structure-tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety</article-title><source>Acta Pharm Sinica B</source><year>2022</year><volume>12</volume><issue>5</issue><fpage>2462</fpage><lpage>2478</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.02.015</pub-id><pub-id pub-id-type="pmcid">PMC9136610</pub-id><pub-id pub-id-type="pmid">35646532</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Gao W, Hu H, Dai L, et al. Structure-tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety. Acta Pharm Sinica B. 2022;12(5):2462&#8211;78. 10.1016/j.apsb.2022.02.015.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2022.02.015</pub-id><pub-id pub-id-type="pmcid">PMC9136610</pub-id><pub-id pub-id-type="pmid">35646532</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>JP</given-names></name><name name-style="western"><surname>Rees</surname><given-names>S</given-names></name><name name-style="western"><surname>Kalindjian</surname><given-names>SB</given-names></name><name name-style="western"><surname>Philpott</surname><given-names>KL</given-names></name></person-group><article-title>Principles of early drug discovery</article-title><source>Br J Pharmacol</source><year>2011</year><volume>162</volume><issue>6</issue><fpage>1239</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.01127.x</pub-id><pub-id pub-id-type="pmid">21091654</pub-id><pub-id pub-id-type="pmcid">PMC3058157</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011;162(6):1239&#8211;49. 10.1111/j.1476-5381.2010.01127.x.<pub-id pub-id-type="pmid">21091654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1476-5381.2010.01127.x</pub-id><pub-id pub-id-type="pmcid">PMC3058157</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>P</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>N</given-names></name><etal/></person-group><article-title>Applications of human pharmacokinetic prediction in first-in-human dose estimation</article-title><source>Aaps J</source><year>2012</year><volume>14</volume><issue>2</issue><fpage>262</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1208/s12248-012-9332-y</pub-id><pub-id pub-id-type="pmid">22407287</pub-id><pub-id pub-id-type="pmcid">PMC3326168</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Zou P, Yu Y, Zheng N, et al. Applications of human pharmacokinetic prediction in first-in-human dose estimation. Aaps J. 2012;14(2):262&#8211;81. 10.1208/s12248-012-9332-y.<pub-id pub-id-type="pmid">22407287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12248-012-9332-y</pub-id><pub-id pub-id-type="pmcid">PMC3326168</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><mixed-citation publication-type="other">Food and Drug Administration.US Food and Drug Administratian. Guidance for industry: estimating the Maximum Safe Starting Dos ein initial Clinical Trials for Therapeutics in Adult Healthy Volunteers [EB/OL]. 2005.</mixed-citation></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>CWY</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Role of pharmacokinetics in the starting dose calculation of first-in-human clinical trial of investigational new drugs</article-title><source>Chin J Clin Pharmacol</source><year>2016</year><volume>32</volume><issue>24</issue><fpage>2341</fpage><lpage>2344</lpage></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Wei CWY, Yang J. Role of pharmacokinetics in the starting dose calculation of first-in-human clinical trial of investigational new drugs. Chin J Clin Pharmacol. 2016;32(24):2341&#8211;4.</mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stebbings</surname><given-names>R</given-names></name><name name-style="western"><surname>Poole</surname><given-names>S</given-names></name><name name-style="western"><surname>Thorpe</surname><given-names>R</given-names></name></person-group><article-title>Safety of biologics, lessons learnt from TGN1412</article-title><source>Curr Opin Biotechnol</source><year>2009</year><volume>20</volume><issue>6</issue><fpage>673</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2009.10.002</pub-id><pub-id pub-id-type="pmid">19892543</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Stebbings R, Poole S, Thorpe R. Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol. 2009;20(6):673&#8211;7. 10.1016/j.copbio.2009.10.002.<pub-id pub-id-type="pmid">19892543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.copbio.2009.10.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>CWY</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Role of pharmacokinetics in the starting dose calculation of first-in-human clinical trial of investigational new drugs</article-title><source>Chin J Clin Pharmacol</source><year>2016</year><volume>32</volume><issue>24</issue><fpage>2341</fpage><lpage>2344</lpage></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Wei CWY, Yang J. Role of pharmacokinetics in the starting dose calculation of first-in-human clinical trial of investigational new drugs. Chin J Clin Pharmacol. 2016;32(24):2341&#8211;4.</mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Riviere</surname><given-names>JE</given-names></name></person-group><article-title>The application of allometric scaling principles to predict pharmacokinetic parameters across species</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2014</year><volume>10</volume><issue>9</issue><fpage>1241</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1517/17425255.2014.934671</pub-id><pub-id pub-id-type="pmid">24984569</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Huang Q, Riviere JE. The application of allometric scaling principles to predict pharmacokinetic parameters across species. Expert Opin Drug Metab Toxicol. 2014;10(9):1241&#8211;53. 10.1517/17425255.2014.934671.<pub-id pub-id-type="pmid">24984569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.2014.934671</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C</given-names></name></person-group><article-title>The Yin and Yang of traditional Chinese and Western medicine</article-title><source>Med Res Rev</source><year>2021</year><volume>41</volume><issue>6</issue><fpage>3182</fpage><lpage>3200</lpage><pub-id pub-id-type="doi">10.1002/med.21793</pub-id><pub-id pub-id-type="pmid">33599314</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Fu R, Li J, Yu H, Zhang Y, Xu Z, Martin C. The Yin and Yang of traditional Chinese and Western medicine. Med Res Rev. 2021;41(6):3182&#8211;200. 10.1002/med.21793.<pub-id pub-id-type="pmid">33599314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/med.21793</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilkins</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>EM</given-names></name><name name-style="western"><surname>Ernest</surname><given-names>JP</given-names></name><name name-style="western"><surname>Savic</surname><given-names>RM</given-names></name><name name-style="western"><surname>Simonsson</surname><given-names>USH</given-names></name><name name-style="western"><surname>McIlleron</surname><given-names>H</given-names></name></person-group><article-title>Pharmacometrics in tuberculosis: progress and opportunities</article-title><source>Int J Antimicrob Agents</source><year>2022</year><volume>60</volume><issue>3</issue><fpage>106620</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2022.106620</pub-id><pub-id pub-id-type="pmid">35724859</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Wilkins JJ, Svensson EM, Ernest JP, Savic RM, Simonsson USH, McIlleron H. Pharmacometrics in tuberculosis: progress and opportunities. Int J Antimicrob Agents. 2022;60(3): 106620. 10.1016/j.ijantimicag.2022.106620.<pub-id pub-id-type="pmid">35724859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2022.106620</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>EI</given-names></name><name name-style="western"><surname>Friberg</surname><given-names>LE</given-names></name></person-group><article-title>Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs</article-title><source>Pharmacol Rev</source><year>2013</year><volume>65</volume><issue>3</issue><fpage>1053</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1124/pr.111.005769</pub-id><pub-id pub-id-type="pmid">23803529</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Nielsen EI, Friberg LE. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev. 2013;65(3):1053&#8211;90. 10.1124/pr.111.005769.<pub-id pub-id-type="pmid">23803529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/pr.111.005769</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>HM</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>C</given-names></name><etal/></person-group><article-title>Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective</article-title><source>Clin Pharmacol Ther</source><year>2015</year><volume>97</volume><issue>3</issue><fpage>247</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1002/cpt.37</pub-id><pub-id pub-id-type="pmid">25670209</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Jones HM, Chen Y, Gibson C, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97(3):247&#8211;62. 10.1002/cpt.37.<pub-id pub-id-type="pmid">25670209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.37</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>F</given-names></name><name name-style="western"><surname>Shah</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><etal/></person-group><article-title>Biopharmaceutics applications of physiologically based pharmacokinetic absorption modeling and simulation in regulatory submissions to the U.S. food and drug administration for new drugs</article-title><source>AAPS J</source><year>2021</year><volume>23</volume><issue>2</issue><fpage>31</fpage><pub-id pub-id-type="doi">10.1208/s12248-021-00564-2</pub-id><pub-id pub-id-type="pmid">33619657</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Wu F, Shah H, Li M, et al. Biopharmaceutics applications of physiologically based pharmacokinetic absorption modeling and simulation in regulatory submissions to the U.S. food and drug administration for new drugs. AAPS J. 2021;23(2):31. 10.1208/s12248-021-00564-2.<pub-id pub-id-type="pmid">33619657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12248-021-00564-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneckener</surname><given-names>S</given-names></name><name name-style="western"><surname>Preuss</surname><given-names>TG</given-names></name><name name-style="western"><surname>Kuepfer</surname><given-names>L</given-names></name><name name-style="western"><surname>Witt</surname><given-names>J</given-names></name></person-group><article-title>A workflow to build PBTK models for novel species</article-title><source>Arch Toxicol</source><year>2020</year><volume>94</volume><issue>11</issue><fpage>3847</fpage><lpage>3860</lpage><pub-id pub-id-type="doi">10.1007/s00204-020-02922-z</pub-id><pub-id pub-id-type="pmid">33033842</pub-id><pub-id pub-id-type="pmcid">PMC7603467</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Schneckener S, Preuss TG, Kuepfer L, Witt J. A workflow to build PBTK models for novel species. Arch Toxicol. 2020;94(11):3847&#8211;60. 10.1007/s00204-020-02922-z.<pub-id pub-id-type="pmid">33033842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00204-020-02922-z</pub-id><pub-id pub-id-type="pmcid">PMC7603467</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>V</given-names></name><name name-style="western"><surname>McNeill</surname><given-names>JH</given-names></name></person-group><article-title>To scale or not to scale: the principles of dose extrapolation</article-title><source>Br J Pharmacol</source><year>2009</year><volume>157</volume><issue>6</issue><fpage>907</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00267.x</pub-id><pub-id pub-id-type="pmid">19508398</pub-id><pub-id pub-id-type="pmcid">PMC2737649</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol. 2009;157(6):907&#8211;21. 10.1111/j.1476-5381.2009.00267.x.<pub-id pub-id-type="pmid">19508398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1476-5381.2009.00267.x</pub-id><pub-id pub-id-type="pmcid">PMC2737649</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saeheng</surname><given-names>T</given-names></name><name name-style="western"><surname>Na-Bangchang</surname><given-names>K</given-names></name><name name-style="western"><surname>Siccardi</surname><given-names>M</given-names></name><name name-style="western"><surname>Rajoli</surname><given-names>RKR</given-names></name><name name-style="western"><surname>Karbwang</surname><given-names>J</given-names></name></person-group><article-title>Physiologically-based pharmacokinetic modeling for optimal dosage prediction of quinine coadministered with ritonavir-boosted Lopinavir</article-title><source>Clin Pharmacol Ther</source><year>2020</year><volume>107</volume><issue>5</issue><fpage>1209</fpage><lpage>1220</lpage><pub-id pub-id-type="doi">10.1002/cpt.1721</pub-id><pub-id pub-id-type="pmid">31721171</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Saeheng T, Na-Bangchang K, Siccardi M, Rajoli RKR, Karbwang J. Physiologically-based pharmacokinetic modeling for optimal dosage prediction of quinine coadministered with ritonavir-boosted Lopinavir. Clin Pharmacol Ther. 2020;107(5):1209&#8211;20. 10.1002/cpt.1721.<pub-id pub-id-type="pmid">31721171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1721</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name></person-group><article-title>In vitro-in silico-based probabilistic risk assessment of combined exposure to bisphenol A and its analogues by integrating ToxCast high-throughput in vitro assays with in vitro to in vivo extrapolation (IVIVE) via physiologically based pharmacokinetic (PBPK) modeling</article-title><source>J Hazard Mater</source><year>2020</year><volume>399</volume><fpage>122856</fpage><pub-id pub-id-type="doi">10.1016/j.jhazmat.2020.122856</pub-id><pub-id pub-id-type="pmid">32937695</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Lin YJ, Lin Z. In vitro-in silico-based probabilistic risk assessment of combined exposure to bisphenol A and its analogues by integrating ToxCast high-throughput in vitro assays with in vitro to in vivo extrapolation (IVIVE) via physiologically based pharmacokinetic (PBPK) modeling. J Hazard Mater. 2020;399:122856. 10.1016/j.jhazmat.2020.122856.<pub-id pub-id-type="pmid">32937695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhazmat.2020.122856</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>X</given-names></name><name name-style="western"><surname>Ye</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><etal/></person-group><article-title>In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</article-title><source>Clin Infect Dis</source><year>2020</year><volume>71</volume><issue>15</issue><fpage>732</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id><pub-id pub-id-type="pmid">32150618</pub-id><pub-id pub-id-type="pmcid">PMC7108130</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732&#8211;9. 10.1093/cid/ciaa237.<pub-id pub-id-type="pmid">32150618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa237</pub-id><pub-id pub-id-type="pmcid">PMC7108130</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name></person-group><article-title>PBPK modeling and simulation in drug research and development</article-title><source>Acta Pharm Sinica B</source><year>2016</year><volume>6</volume><issue>5</issue><fpage>430</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2016.04.004</pub-id><pub-id pub-id-type="pmcid">PMC5125732</pub-id><pub-id pub-id-type="pmid">27909650</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Zhuang X, Lu C. PBPK modeling and simulation in drug research and development. Acta Pharm Sinica B. 2016;6(5):430&#8211;40. 10.1016/j.apsb.2016.04.004.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2016.04.004</pub-id><pub-id pub-id-type="pmcid">PMC5125732</pub-id><pub-id pub-id-type="pmid">27909650</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeWoskin</surname><given-names>RS</given-names></name></person-group><article-title>PBPK models in risk assessment&#8211;A focus on chloroprene</article-title><source>Chem Biol Interact</source><year>2007</year><volume>166</volume><issue>1&#8211;3</issue><fpage>352</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2007.01.016</pub-id><pub-id pub-id-type="pmid">17324392</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">DeWoskin RS. PBPK models in risk assessment&#8211;A focus on chloroprene. Chem Biol Interact. 2007;166(1&#8211;3):352&#8211;9. 10.1016/j.cbi.2007.01.016.<pub-id pub-id-type="pmid">17324392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cbi.2007.01.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>W</given-names></name><name name-style="western"><surname>Ng</surname><given-names>CA</given-names></name></person-group><article-title>A permeability-limited physiologically based pharmacokinetic (PBPK) model for perfluorooctanoic acid (PFOA) in male rats</article-title><source>Environ Sci Technol</source><year>2017</year><volume>51</volume><issue>17</issue><fpage>9930</fpage><lpage>9939</lpage><pub-id pub-id-type="doi">10.1021/acs.est.7b02602</pub-id><pub-id pub-id-type="pmid">28759222</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Cheng W, Ng CA. A permeability-limited physiologically based pharmacokinetic (PBPK) model for perfluorooctanoic acid (PFOA) in male rats. Environ Sci Technol. 2017;51(17):9930&#8211;9. 10.1021/acs.est.7b02602.<pub-id pub-id-type="pmid">28759222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.est.7b02602</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanacher</surname><given-names>T</given-names></name><name name-style="western"><surname>Lindauer</surname><given-names>A</given-names></name><name name-style="western"><surname>Mezzalana</surname><given-names>E</given-names></name><etal/></person-group><article-title>A physiologically-based pharmacokinetic (PBPK) model network for the prediction of CYP1A2 and CYP2C19 drug-drug-gene interactions with fluvoxamine, omeprazole, S-mephenytoin, moclobemide, tizanidine, mexiletine, ethinylestradiol, and caffeine</article-title><source>Pharmaceutics</source><year>2020</year><pub-id pub-id-type="doi">10.3390/pharmaceutics12121191</pub-id><pub-id pub-id-type="pmid">33302490</pub-id><pub-id pub-id-type="pmcid">PMC7764797</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Kanacher T, Lindauer A, Mezzalana E, et al. A physiologically-based pharmacokinetic (PBPK) model network for the prediction of CYP1A2 and CYP2C19 drug-drug-gene interactions with fluvoxamine, omeprazole, S-mephenytoin, moclobemide, tizanidine, mexiletine, ethinylestradiol, and caffeine. Pharmaceutics. 2020. 10.3390/pharmaceutics12121191.<pub-id pub-id-type="pmid">33302490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics12121191</pub-id><pub-id pub-id-type="pmcid">PMC7764797</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krstevska</surname><given-names>A</given-names></name><name name-style="western"><surname>&#272;uri&#353;</surname><given-names>J</given-names></name><name name-style="western"><surname>Ibri&#263;</surname><given-names>S</given-names></name><name name-style="western"><surname>Cviji&#263;</surname><given-names>S</given-names></name></person-group><article-title>In-depth analysis of physiologically based pharmacokinetic (pbpk) modeling utilization in different application fields using text mining tools</article-title><source>Pharmaceutics</source><year>2022</year><pub-id pub-id-type="doi">10.3390/pharmaceutics15010107</pub-id><pub-id pub-id-type="pmid">36678737</pub-id><pub-id pub-id-type="pmcid">PMC9860979</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Krstevska A, &#272;uri&#353; J, Ibri&#263; S, Cviji&#263; S. In-depth analysis of physiologically based pharmacokinetic (pbpk) modeling utilization in different application fields using text mining tools. Pharmaceutics. 2022. 10.3390/pharmaceutics15010107.<pub-id pub-id-type="pmid">36678737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15010107</pub-id><pub-id pub-id-type="pmcid">PMC9860979</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dornbos</surname><given-names>P</given-names></name><name name-style="western"><surname>LaPres</surname><given-names>JJ</given-names></name></person-group><article-title>Incorporating population-level genetic variability within laboratory models in toxicology: from the individual to the population</article-title><source>Toxicology</source><year>2018</year><volume>395</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.tox.2017.12.007</pub-id><pub-id pub-id-type="pmid">29275117</pub-id><pub-id pub-id-type="pmcid">PMC5801153</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Dornbos P, LaPres JJ. Incorporating population-level genetic variability within laboratory models in toxicology: from the individual to the population. Toxicology. 2018;395:1&#8211;8. 10.1016/j.tox.2017.12.007.<pub-id pub-id-type="pmid">29275117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tox.2017.12.007</pub-id><pub-id pub-id-type="pmcid">PMC5801153</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><mixed-citation publication-type="other">J W, C R, Z T. Combining PBPK and PopPK models to assist in dosage selection in pediatric drug development: a case study of rivaroxaban. J Pharm. 2022;57(10):3157&#8211;3162. 10.16438/j.0513-4870.2022-0880</mixed-citation></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bigos</surname><given-names>KL</given-names></name><name name-style="western"><surname>Bies</surname><given-names>RR</given-names></name><name name-style="western"><surname>Pollock</surname><given-names>BG</given-names></name></person-group><article-title>Population pharmacokinetics in geriatric psychiatry</article-title><source>Am J Geriat Psychiatry</source><year>2006</year><volume>14</volume><issue>12</issue><fpage>993</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1097/01.JGP.0000224330.73063.6c</pub-id><pub-id pub-id-type="pmid">17138806</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Bigos KL, Bies RR, Pollock BG. Population pharmacokinetics in geriatric psychiatry. Am J Geriat Psychiatry. 2006;14(12):993&#8211;1003. 10.1097/01.JGP.0000224330.73063.6c.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.JGP.0000224330.73063.6c</pub-id><pub-id pub-id-type="pmid">17138806</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolff</surname><given-names>K</given-names></name><name name-style="western"><surname>Rostami-Hodjegan</surname><given-names>A</given-names></name><name name-style="western"><surname>Hay</surname><given-names>AW</given-names></name><name name-style="western"><surname>Raistrick</surname><given-names>D</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>G</given-names></name></person-group><article-title>Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility</article-title><source>Addiction</source><year>2000</year><volume>95</volume><issue>12</issue><fpage>1771</fpage><lpage>1783</lpage><pub-id pub-id-type="doi">10.1046/j.1360-0443.2000.951217717.x</pub-id><pub-id pub-id-type="pmid">11177493</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Wolff K, Rostami-Hodjegan A, Hay AW, Raistrick D, Tucker G. Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction. 2000;95(12):1771&#8211;83. 10.1046/j.1360-0443.2000.951217717.x.<pub-id pub-id-type="pmid">11177493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1360-0443.2000.951217717.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Offman</surname><given-names>E</given-names></name><name name-style="western"><surname>Phipps</surname><given-names>C</given-names></name><name name-style="western"><surname>Edginton</surname><given-names>AN</given-names></name></person-group><article-title>Population physiologically-based pharmacokinetic model incorporating lymphatic uptake for a subcutaneously administered pegylated peptide</article-title><source>In silico Pharmacol</source><year>2016</year><volume>4</volume><issue>1</issue><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/s40203-016-0018-5</pub-id><pub-id pub-id-type="pmid">26932471</pub-id><pub-id pub-id-type="pmcid">PMC4773320</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Offman E, Phipps C, Edginton AN. Population physiologically-based pharmacokinetic model incorporating lymphatic uptake for a subcutaneously administered pegylated peptide. In silico Pharmacol. 2016;4(1):3. 10.1186/s40203-016-0018-5.<pub-id pub-id-type="pmid">26932471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40203-016-0018-5</pub-id><pub-id pub-id-type="pmcid">PMC4773320</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model</article-title><source>Acta pharmaceutica Sinica B</source><year>2020</year><volume>10</volume><issue>7</issue><fpage>1216</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2020.04.007</pub-id><pub-id pub-id-type="pmid">32834950</pub-id><pub-id pub-id-type="pmcid">PMC7252145</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Cui C, Zhang M, Yao X, et al. Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model. Acta pharmaceutica Sinica B. 2020;10(7):1216&#8211;27. 10.1016/j.apsb.2020.04.007.<pub-id pub-id-type="pmid">32834950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2020.04.007</pub-id><pub-id pub-id-type="pmcid">PMC7252145</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jorga</surname><given-names>K</given-names></name><name name-style="western"><surname>Chavanne</surname><given-names>C</given-names></name><name name-style="western"><surname>Frey</surname><given-names>N</given-names></name><etal/></person-group><article-title>Bottom-up meets top-down: complementary physiologically based pharmacokinetic and population pharmacokinetic modeling for regulatory approval of a dosing algorithm of valganciclovir in very young children</article-title><source>Clin Pharmacol Ther</source><year>2016</year><volume>100</volume><issue>6</issue><fpage>761</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1002/cpt.449</pub-id><pub-id pub-id-type="pmid">27530217</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Jorga K, Chavanne C, Frey N, et al. Bottom-up meets top-down: complementary physiologically based pharmacokinetic and population pharmacokinetic modeling for regulatory approval of a dosing algorithm of valganciclovir in very young children. Clin Pharmacol Ther. 2016;100(6):761&#8211;9. 10.1002/cpt.449.<pub-id pub-id-type="pmid">27530217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.449</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pillai</surname><given-names>VC</given-names></name><name name-style="western"><surname>Han</surname><given-names>K</given-names></name><name name-style="western"><surname>Beigi</surname><given-names>RH</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women</article-title><source>Br J Clin Pharmacol</source><year>2015</year><volume>80</volume><issue>5</issue><fpage>1042</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1111/bcp.12691</pub-id><pub-id pub-id-type="pmid">26040405</pub-id><pub-id pub-id-type="pmcid">PMC4631177</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Pillai VC, Han K, Beigi RH, et al. Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women. Br J Clin Pharmacol. 2015;80(5):1042&#8211;50. 10.1111/bcp.12691.<pub-id pub-id-type="pmid">26040405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.12691</pub-id><pub-id pub-id-type="pmcid">PMC4631177</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>S</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><name name-style="western"><surname>Parrott</surname><given-names>N</given-names></name><etal/></person-group><article-title>Combining 'bottom-up' and 'top-down' methods to assess ethnic difference in clearance: bitopertin as an example</article-title><source>Clin Pharmacokinet</source><year>2016</year><volume>55</volume><issue>7</issue><fpage>823</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1007/s40262-015-0356-1</pub-id><pub-id pub-id-type="pmid">26715215</pub-id><pub-id pub-id-type="pmcid">PMC4916198</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Feng S, Shi J, Parrott N, et al. Combining &#8220;bottom-up&#8221; and &#8220;top-down&#8221; methods to assess ethnic difference in clearance: bitopertin as an example. Clin Pharmacokinet. 2016;55(7):823&#8211;32. 10.1007/s40262-015-0356-1.<pub-id pub-id-type="pmid">26715215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-015-0356-1</pub-id><pub-id pub-id-type="pmcid">PMC4916198</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>MCJX</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>LS</given-names></name></person-group><article-title>PBPK model and its application in TCM studies</article-title><source>Mod Tradit Chin Med Mater Med World Sci Technol</source><year>2007</year><volume>22</volume><issue>12</issue><fpage>4147</fpage><lpage>4153</lpage></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Jiang MCJX, Qiao LS. PBPK model and its application in TCM studies. Mod Tradit Chin Med Mater Med World Sci Technol. 2007;22(12):4147&#8211;53.</mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Law</surname><given-names>FCP</given-names></name><name name-style="western"><surname>Yao</surname><given-names>M</given-names></name><name name-style="western"><surname>Bi</surname><given-names>HC</given-names></name><name name-style="western"><surname>Lam</surname><given-names>S</given-names></name></person-group><article-title>Physiologically based pharmacokinetic modeling of tea catechin mixture in rats and humans</article-title><source>Pharmacol Res Perspect</source><year>2017</year><volume>5</volume><issue>3</issue><fpage>e00305</fpage><pub-id pub-id-type="doi">10.1002/prp2.305</pub-id><pub-id pub-id-type="pmid">28603626</pub-id><pub-id pub-id-type="pmcid">PMC5464336</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Law FCP, Yao M, Bi HC, Lam S. Physiologically based pharmacokinetic modeling of tea catechin mixture in rats and humans. Pharmacol Res Perspect. 2017;5(3): e00305. 10.1002/prp2.305.<pub-id pub-id-type="pmid">28603626</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/prp2.305</pub-id><pub-id pub-id-type="pmcid">PMC5464336</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gufford</surname><given-names>BT</given-names></name><name name-style="western"><surname>Barr</surname><given-names>JT</given-names></name><name name-style="western"><surname>Gonz&#225;lez-P&#233;rez</surname><given-names>V</given-names></name><etal/></person-group><article-title>Quantitative prediction and clinical evaluation of an unexplored herb-drug interaction mechanism in healthy volunteers</article-title><source>CPT Pharmacomet Syst Pharmacol</source><year>2015</year><volume>4</volume><issue>12</issue><fpage>701</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1002/psp4.12047</pub-id><pub-id pub-id-type="pmcid">PMC4759704</pub-id><pub-id pub-id-type="pmid">26904384</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Gufford BT, Barr JT, Gonz&#225;lez-P&#233;rez V, et al. Quantitative prediction and clinical evaluation of an unexplored herb-drug interaction mechanism in healthy volunteers. CPT Pharmacomet Syst Pharmacol. 2015;4(12):701&#8211;10. 10.1002/psp4.12047.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12047</pub-id><pub-id pub-id-type="pmcid">PMC4759704</pub-id><pub-id pub-id-type="pmid">26904384</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pushpakom</surname><given-names>S</given-names></name><name name-style="western"><surname>Iorio</surname><given-names>F</given-names></name><name name-style="western"><surname>Eyers</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Drug repurposing: progress, challenges and recommendations</article-title><source>Nat Rev Drug Discovery</source><year>2019</year><volume>18</volume><issue>1</issue><fpage>41</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1038/nrd.2018.168</pub-id><pub-id pub-id-type="pmid">30310233</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discovery. 2019;18(1):41&#8211;58. 10.1038/nrd.2018.168.<pub-id pub-id-type="pmid">30310233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd.2018.168</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>SK</given-names></name><name name-style="western"><surname>Liu</surname><given-names>RH</given-names></name><name name-style="western"><surname>Jin</surname><given-names>HZ</given-names></name><etal/></person-group><article-title>&#8220;Omics&#8221; in pharmaceutical research: overview, applications, challenges, and future perspectives</article-title><source>Chin J Nat Med</source><year>2015</year><volume>13</volume><issue>1</issue><fpage>3</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/s1875-5364(15)60002-4</pub-id><pub-id pub-id-type="pmid">25660284</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Yan SK, Liu RH, Jin HZ, et al. &#8220;Omics&#8221; in pharmaceutical research: overview, applications, challenges, and future perspectives. Chin J Nat Med. 2015;13(1):3&#8211;21. 10.1016/s1875-5364(15)60002-4.<pub-id pub-id-type="pmid">25660284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1875-5364(15)60002-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><mixed-citation publication-type="other">US Food and Drug Administration. Guidance for industry: enhancing the diversity of clinical trial populations&#8212;eligibility criteria, enrollment practices, and trial designs guidance for industry&lt;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs">https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs</ext-link>. Accessed March 5, 2024. 2024</mixed-citation></ref><ref-list id="BSec1"><title>;</title><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowland Yeo</surname><given-names>K</given-names></name><name name-style="western"><surname>Gil Bergland</surname><given-names>E</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>Dose optimization informed by PBPK modeling: state-of-the art and future</article-title><source>Clin Pharmacol Ther</source><year>2024</year><pub-id pub-id-type="doi">10.1002/cpt.3289</pub-id><pub-id pub-id-type="pmid">38686708</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Rowland Yeo K, Gil Bergland E, Chen Y. Dose optimization informed by PBPK modeling: state-of-the art and future. Clin Pharmacol Ther. 2024. 10.1002/cpt.3289.<pub-id pub-id-type="pmid">38686708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.3289</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marsousi</surname><given-names>N</given-names></name><name name-style="western"><surname>Desmeules</surname><given-names>JA</given-names></name><name name-style="western"><surname>Rudaz</surname><given-names>S</given-names></name><name name-style="western"><surname>Daali</surname><given-names>Y</given-names></name></person-group><article-title>Usefulness of PBPK modeling in incorporation of clinical conditions in personalized medicine</article-title><source>J Pharm Sci</source><year>2017</year><volume>106</volume><issue>9</issue><fpage>2380</fpage><lpage>2391</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2017.04.035</pub-id><pub-id pub-id-type="pmid">28456730</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Marsousi N, Desmeules JA, Rudaz S, Daali Y. Usefulness of PBPK modeling in incorporation of clinical conditions in personalized medicine. J Pharm Sci. 2017;106(9):2380&#8211;91. 10.1016/j.xphs.2017.04.035.<pub-id pub-id-type="pmid">28456730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xphs.2017.04.035</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Hilgenfeld</surname><given-names>R</given-names></name><name name-style="western"><surname>Whitley</surname><given-names>R</given-names></name><name name-style="western"><surname>De Clercq</surname><given-names>E</given-names></name></person-group><article-title>Therapeutic strategies for COVID-19: progress and lessons learned</article-title><source>Nat Rev Drug Disc</source><year>2023</year><volume>22</volume><issue>6</issue><fpage>449</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1038/s41573-023-00672-y</pub-id><pub-id pub-id-type="pmcid">PMC10113999</pub-id><pub-id pub-id-type="pmid">37076602</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Disc. 2023;22(6):449&#8211;75. 10.1038/s41573-023-00672-y.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-023-00672-y</pub-id><pub-id pub-id-type="pmcid">PMC10113999</pub-id><pub-id pub-id-type="pmid">37076602</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>GB</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia</article-title><source>Proc Natl Acad Sci USA</source><year>2008</year><volume>105</volume><issue>12</issue><fpage>4826</fpage><lpage>4831</lpage><pub-id pub-id-type="doi">10.1073/pnas.0712365105</pub-id><pub-id pub-id-type="pmid">18344322</pub-id><pub-id pub-id-type="pmcid">PMC2290784</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Wang L, Zhou GB, Liu P, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA. 2008;105(12):4826&#8211;31. 10.1073/pnas.0712365105.<pub-id pub-id-type="pmid">18344322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0712365105</pub-id><pub-id pub-id-type="pmcid">PMC2290784</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>KM</given-names></name><name name-style="western"><surname>Ghantous</surname><given-names>H</given-names></name><name name-style="western"><surname>Birnkrant</surname><given-names>DB</given-names></name></person-group><article-title>Current regulatory toxicology perspectives on the development of herbal medicines to prescription drug products in the United States</article-title><source>Food Chem Toxicol</source><year>2008</year><volume>46</volume><issue>8</issue><fpage>2606</fpage><lpage>2610</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2008.05.029</pub-id><pub-id pub-id-type="pmid">18614266</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Wu KM, Ghantous H, Birnkrant DB. Current regulatory toxicology perspectives on the development of herbal medicines to prescription drug products in the United States. Food Chem Toxicol. 2008;46(8):2606&#8211;10. 10.1016/j.fct.2008.05.029.<pub-id pub-id-type="pmid">18614266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fct.2008.05.029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>M</given-names></name><name name-style="western"><surname>Lv</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Strategies on biosynthesis and production of bioactive compounds in medicinal plants</article-title><source>Chin Herbal Med</source><year>2024</year><volume>16</volume><issue>1</issue><fpage>13</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.chmed.2023.01.007</pub-id><pub-id pub-id-type="pmcid">PMC10874775</pub-id><pub-id pub-id-type="pmid">38375043</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Guo M, Lv H, Chen H, et al. Strategies on biosynthesis and production of bioactive compounds in medicinal plants. Chin Herbal Med. 2024;16(1):13&#8211;26. 10.1016/j.chmed.2023.01.007.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chmed.2023.01.007</pub-id><pub-id pub-id-type="pmcid">PMC10874775</pub-id><pub-id pub-id-type="pmid">38375043</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heath</surname><given-names>JR</given-names></name><name name-style="western"><surname>Ribas</surname><given-names>A</given-names></name><name name-style="western"><surname>Mischel</surname><given-names>PS</given-names></name></person-group><article-title>Single-cell analysis tools for drug discovery and development</article-title><source>Nat Rev Drug Discov</source><year>2016</year><volume>15</volume><issue>3</issue><fpage>204</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/nrd.2015.16</pub-id><pub-id pub-id-type="pmid">26669673</pub-id><pub-id pub-id-type="pmcid">PMC4883669</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Heath JR, Ribas A, Mischel PS. Single-cell analysis tools for drug discovery and development. Nat Rev Drug Discov. 2016;15(3):204&#8211;16. 10.1038/nrd.2015.16.<pub-id pub-id-type="pmid">26669673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd.2015.16</pub-id><pub-id pub-id-type="pmcid">PMC4883669</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation</article-title><source>J Immunother Cancer.</source><year>2022</year><pub-id pub-id-type="doi">10.1136/jitc-2022-004874</pub-id><pub-id pub-id-type="pmid">36307151</pub-id><pub-id pub-id-type="pmcid">PMC9621195</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Deng G, Zhou L, Wang B, et al. Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation. J Immunother Cancer. 2022. 10.1136/jitc-2022-004874.<pub-id pub-id-type="pmid">36307151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2022-004874</pub-id><pub-id pub-id-type="pmcid">PMC9621195</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>C</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X</given-names></name><etal/></person-group><article-title>Personalized tumor combination therapy optimization using the single-cell transcriptome</article-title><source>Genome Med</source><year>2023</year><volume>15</volume><issue>1</issue><fpage>105</fpage><pub-id pub-id-type="doi">10.1186/s13073-023-01256-6</pub-id><pub-id pub-id-type="pmid">38041202</pub-id><pub-id pub-id-type="pmcid">PMC10691165</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Tang C, Fu S, Jin X, et al. Personalized tumor combination therapy optimization using the single-cell transcriptome. Genome Med. 2023;15(1):105. 10.1186/s13073-023-01256-6.<pub-id pub-id-type="pmid">38041202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-023-01256-6</pub-id><pub-id pub-id-type="pmcid">PMC10691165</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>PBPK modeling on organs-on-chips: an overview of recent advancements</article-title><source>Front Bioeng Biotechnol</source><year>2022</year><volume>10</volume><fpage>900481</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2022.900481</pub-id><pub-id pub-id-type="pmid">35497341</pub-id><pub-id pub-id-type="pmcid">PMC9046607</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Yang Y, Chen Y, Wang L, et al. PBPK modeling on organs-on-chips: an overview of recent advancements. Front Bioeng Biotechnol. 2022;10: 900481. 10.3389/fbioe.2022.900481.<pub-id pub-id-type="pmid">35497341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fbioe.2022.900481</pub-id><pub-id pub-id-type="pmcid">PMC9046607</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer</surname><given-names>C</given-names></name><name name-style="western"><surname>Garzia</surname><given-names>A</given-names></name><name name-style="western"><surname>Miller</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Small-molecule inhibition of SARS-CoV-2 NSP14 RNA cap methyltransferase</article-title><source>Nature.</source><year>2024</year><pub-id pub-id-type="doi">10.1038/s41586-024-08320-0</pub-id><pub-id pub-id-type="pmid">39663451</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Meyer C, Garzia A, Miller MW, et al. Small-molecule inhibition of SARS-CoV-2 NSP14 RNA cap methyltransferase. Nature. 2024. 10.1038/s41586-024-08320-0.<pub-id pub-id-type="pmid">39663451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-024-08320-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Miao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Modeling craniopharyngioma for drug screening reveals a neuronal mechanism for tumor growth</article-title><source>Sci Transl Med</source><year>2024</year><volume>16</volume><issue>778</issue><fpage>eadn6763</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.adn6763</pub-id><pub-id pub-id-type="pmid">39693408</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Li S, Li W, Miao Y, et al. Modeling craniopharyngioma for drug screening reveals a neuronal mechanism for tumor growth. Sci Transl Med. 2024;16(778):eadn6763. 10.1126/scitranslmed.adn6763.<pub-id pub-id-type="pmid">39693408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.adn6763</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Discovery of novel small molecules targeting hepatitis B virus core protein from marine natural products with HiBiT-based high-throughput screening</article-title><source>Acta Pharm Sinica B</source><year>2024</year><volume>14</volume><issue>11</issue><fpage>4914</fpage><lpage>4933</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2024.07.019</pub-id><pub-id pub-id-type="pmcid">PMC11628845</pub-id><pub-id pub-id-type="pmid">39664428</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Huang C, Jin Y, Fu P, et al. Discovery of novel small molecules targeting hepatitis B virus core protein from marine natural products with HiBiT-based high-throughput screening. Acta Pharm Sinica B. 2024;14(11):4914&#8211;33. 10.1016/j.apsb.2024.07.019.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2024.07.019</pub-id><pub-id pub-id-type="pmcid">PMC11628845</pub-id><pub-id pub-id-type="pmid">39664428</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors</article-title><source>Acta Neuropathol Commun</source><year>2024</year><volume>12</volume><issue>1</issue><fpage>61</fpage><pub-id pub-id-type="doi">10.1186/s40478-024-01775-2</pub-id><pub-id pub-id-type="pmid">38637883</pub-id><pub-id pub-id-type="pmcid">PMC11025224</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Cheng Y, Dai Y, Tang H, et al. Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors. Acta Neuropathol Commun. 2024;12(1):61. 10.1186/s40478-024-01775-2.<pub-id pub-id-type="pmid">38637883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-024-01775-2</pub-id><pub-id pub-id-type="pmcid">PMC11025224</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fallon</surname><given-names>I</given-names></name><name name-style="western"><surname>Hernando</surname><given-names>H</given-names></name><name name-style="western"><surname>Almacellas-Rabaiget</surname><given-names>O</given-names></name><etal/></person-group><article-title>Development of a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3</article-title><source>SLAS Dis</source><year>2024</year><volume>29</volume><issue>2</issue><fpage>100147</fpage><pub-id pub-id-type="doi">10.1016/j.slasd.2024.100147</pub-id><pub-id pub-id-type="pmid">38355016</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Fallon I, Hernando H, Almacellas-Rabaiget O, et al. Development of a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3. SLAS Dis. 2024;29(2): 100147. 10.1016/j.slasd.2024.100147.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.slasd.2024.100147</pub-id><pub-id pub-id-type="pmid">38355016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>K</given-names></name><name name-style="western"><surname>Lienau</surname><given-names>P</given-names></name><name name-style="western"><surname>Bader</surname><given-names>B</given-names></name><etal/></person-group><article-title>Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling</article-title><source>Cell Chem Biol</source><year>2024</year><volume>31</volume><issue>7</issue><fpage>1247</fpage><lpage>1263.e16</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2024.02.013</pub-id><pub-id pub-id-type="pmid">38537632</pub-id></element-citation><mixed-citation id="mc-CR162" publication-type="journal">Graham K, Lienau P, Bader B, et al. Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell Chem Biol. 2024;31(7):1247-1263.e16. 10.1016/j.chembiol.2024.02.013.<pub-id pub-id-type="pmid">38537632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2024.02.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name></person-group><article-title>FDA compound library screening Baicalin upregulates TREM2 for the treatment of cerebral ischemia-reperfusion injury</article-title><source>Eur J Pharmacol</source><year>2024</year><volume>969</volume><fpage>176427</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2024.176427</pub-id><pub-id pub-id-type="pmid">38428662</pub-id></element-citation><mixed-citation id="mc-CR163" publication-type="journal">Wang H, Ma J, Li X, Peng Y, Wang M. FDA compound library screening Baicalin upregulates TREM2 for the treatment of cerebral ischemia-reperfusion injury. Eur J Pharmacol. 2024;969:176427. 10.1016/j.ejphar.2024.176427.<pub-id pub-id-type="pmid">38428662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2024.176427</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smiejkowska</surname><given-names>N</given-names></name><name name-style="western"><surname>Oorts</surname><given-names>L</given-names></name><name name-style="western"><surname>Van Calster</surname><given-names>K</given-names></name><etal/></person-group><article-title>A high-throughput target-based screening approach for the identification and assessment of Mycobacterium tuberculosis mycothione reductase inhibitors</article-title><source>Microbiol Spectr</source><year>2024</year><volume>12</volume><issue>3</issue><fpage>e0372323</fpage><pub-id pub-id-type="doi">10.1128/spectrum.03723-23</pub-id><pub-id pub-id-type="pmid">38315026</pub-id><pub-id pub-id-type="pmcid">PMC10913476</pub-id></element-citation><mixed-citation id="mc-CR164" publication-type="journal">Smiejkowska N, Oorts L, Van Calster K, et al. A high-throughput target-based screening approach for the identification and assessment of Mycobacterium tuberculosis mycothione reductase inhibitors. Microbiol Spectr. 2024;12(3):e0372323. 10.1128/spectrum.03723-23.<pub-id pub-id-type="pmid">38315026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/spectrum.03723-23</pub-id><pub-id pub-id-type="pmcid">PMC10913476</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Novel antiviral discoveries for Japanese encephalitis virus infections through reporter virus-based high-throughput screening</article-title><source>J Med Virol</source><year>2024</year><volume>96</volume><issue>1</issue><fpage>e29382</fpage><pub-id pub-id-type="doi">10.1002/jmv.29382</pub-id><pub-id pub-id-type="pmid">38235833</pub-id></element-citation><mixed-citation id="mc-CR165" publication-type="journal">Yin C, Yang P, Xiao Q, et al. Novel antiviral discoveries for Japanese encephalitis virus infections through reporter virus-based high-throughput screening. J Med Virol. 2024;96(1): e29382. 10.1002/jmv.29382.<pub-id pub-id-type="pmid">38235833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.29382</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fatima</surname><given-names>I</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>R</given-names></name><name name-style="western"><surname>Barman</surname><given-names>S</given-names></name><etal/></person-group><article-title>Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20</article-title><source>Br J Cancer</source><year>2024</year><volume>130</volume><issue>6</issue><fpage>1046</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1038/s41416-023-02570-x</pub-id><pub-id pub-id-type="pmid">38278978</pub-id><pub-id pub-id-type="pmcid">PMC10951408</pub-id></element-citation><mixed-citation id="mc-CR166" publication-type="journal">Fatima I, Ahmad R, Barman S, et al. Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20. Br J Cancer. 2024;130(6):1046&#8211;58. 10.1038/s41416-023-02570-x.<pub-id pub-id-type="pmid">38278978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-023-02570-x</pub-id><pub-id pub-id-type="pmcid">PMC10951408</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>X</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A large-scale transcriptional analysis reveals herb-derived ginsenoside F2 suppressing hepatocellular carcinoma via inhibiting STAT3</article-title><source>Phytomedicine</source><year>2023</year><volume>120</volume><fpage>155031</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2023.155031</pub-id><pub-id pub-id-type="pmid">37666060</pub-id></element-citation><mixed-citation id="mc-CR167" publication-type="journal">Tan X, Ma X, Dai Y, et al. A large-scale transcriptional analysis reveals herb-derived ginsenoside F2 suppressing hepatocellular carcinoma via inhibiting STAT3. Phytomedicine. 2023;120: 155031. 10.1016/j.phymed.2023.155031.<pub-id pub-id-type="pmid">37666060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phymed.2023.155031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nani</surname><given-names>JV</given-names></name><name name-style="western"><surname>Coelho</surname><given-names>C</given-names></name><name name-style="western"><surname>Oyadomari</surname><given-names>WY</given-names></name><etal/></person-group><article-title>Identification of an ex vivo inhibitor of the schizophrenia biomarker Ndel1 by high throughput screening</article-title><source>Biochem Pharmacol</source><year>2023</year><volume>217</volume><fpage>115841</fpage><pub-id pub-id-type="doi">10.1016/j.bcp.2023.115841</pub-id><pub-id pub-id-type="pmid">37820964</pub-id></element-citation><mixed-citation id="mc-CR168" publication-type="journal">Nani JV, Coelho C, Oyadomari WY, et al. Identification of an ex vivo inhibitor of the schizophrenia biomarker Ndel1 by high throughput screening. Biochem Pharmacol. 2023;217: 115841. 10.1016/j.bcp.2023.115841.<pub-id pub-id-type="pmid">37820964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2023.115841</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corsello</surname><given-names>SM</given-names></name><name name-style="western"><surname>Nagari</surname><given-names>RT</given-names></name><name name-style="western"><surname>Spangler</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling</article-title><source>Nat Cancer</source><year>2020</year><volume>1</volume><issue>2</issue><fpage>235</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1038/s43018-019-0018-6</pub-id><pub-id pub-id-type="pmid">32613204</pub-id><pub-id pub-id-type="pmcid">PMC7328899</pub-id></element-citation><mixed-citation id="mc-CR169" publication-type="journal">Corsello SM, Nagari RT, Spangler RD, et al. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer. 2020;1(2):235&#8211;48. 10.1038/s43018-019-0018-6.<pub-id pub-id-type="pmid">32613204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43018-019-0018-6</pub-id><pub-id pub-id-type="pmcid">PMC7328899</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schindler</surname><given-names>M</given-names></name><name name-style="western"><surname>Siegerist</surname><given-names>F</given-names></name><name name-style="western"><surname>Lange</surname><given-names>T</given-names></name><etal/></person-group><article-title>A novel high-content screening assay identified belinostat as protective in a FSGS-like Zebrafish model</article-title><source>J Am Soc Nephrol</source><year>2023</year><volume>34</volume><issue>12</issue><fpage>1977</fpage><lpage>1990</lpage><pub-id pub-id-type="doi">10.1681/asn.0000000000000235</pub-id><pub-id pub-id-type="pmid">37752628</pub-id><pub-id pub-id-type="pmcid">PMC10703078</pub-id></element-citation><mixed-citation id="mc-CR170" publication-type="journal">Schindler M, Siegerist F, Lange T, et al. A novel high-content screening assay identified belinostat as protective in a FSGS-like Zebrafish model. J Am Soc Nephrol. 2023;34(12):1977&#8211;90. 10.1681/asn.0000000000000235.<pub-id pub-id-type="pmid">37752628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.0000000000000235</pub-id><pub-id pub-id-type="pmcid">PMC10703078</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Q</given-names></name><name name-style="western"><surname>Su</surname><given-names>W</given-names></name><etal/></person-group><article-title>High-content screening of active components of traditional Chinese medicine inhibiting TGF-&#946;-induced cell EMT</article-title><source>Heliyon</source><year>2022</year><volume>8</volume><issue>8</issue><fpage>e10238</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e10238</pub-id><pub-id pub-id-type="pmid">36042745</pub-id><pub-id pub-id-type="pmcid">PMC9420491</pub-id></element-citation><mixed-citation id="mc-CR171" publication-type="journal">Xu M, Cui Q, Su W, et al. High-content screening of active components of traditional Chinese medicine inhibiting TGF-&#946;-induced cell EMT. Heliyon. 2022;8(8): e10238. 10.1016/j.heliyon.2022.e10238.<pub-id pub-id-type="pmid">36042745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2022.e10238</pub-id><pub-id pub-id-type="pmcid">PMC9420491</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>QQ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>YL</given-names></name><name name-style="western"><surname>Lei</surname><given-names>JL</given-names></name><name name-style="western"><surname>Kong</surname><given-names>LY</given-names></name><name name-style="western"><surname>Luo</surname><given-names>JG</given-names></name></person-group><article-title>Dimeric guaianes from leaves of Xylopia vielana as snail inhibitors identified by high content screening</article-title><source>Bioorg Chem</source><year>2021</year><volume>108</volume><fpage>104646</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2021.104646</pub-id><pub-id pub-id-type="pmid">33484941</pub-id></element-citation><mixed-citation id="mc-CR172" publication-type="journal">Xu QQ, Zhang C, Zhang YL, Lei JL, Kong LY, Luo JG. Dimeric guaianes from leaves of Xylopia vielana as snail inhibitors identified by high content screening. Bioorg Chem. 2021;108: 104646. 10.1016/j.bioorg.2021.104646.<pub-id pub-id-type="pmid">33484941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioorg.2021.104646</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neves</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Dantas</surname><given-names>RF</given-names></name><name name-style="western"><surname>Senger</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Discovery of new anti-schistosomal hits by integration of QSAR-based virtual screening and high content screening</article-title><source>J Med Chem</source><year>2016</year><volume>59</volume><issue>15</issue><fpage>7075</fpage><lpage>7088</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b02038</pub-id><pub-id pub-id-type="pmid">27396732</pub-id><pub-id pub-id-type="pmcid">PMC5844225</pub-id></element-citation><mixed-citation id="mc-CR173" publication-type="journal">Neves BJ, Dantas RF, Senger MR, et al. Discovery of new anti-schistosomal hits by integration of QSAR-based virtual screening and high content screening. J Med Chem. 2016;59(15):7075&#8211;88. 10.1021/acs.jmedchem.5b02038.<pub-id pub-id-type="pmid">27396732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.5b02038</pub-id><pub-id pub-id-type="pmcid">PMC5844225</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR174"><label>174.</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><etal/></person-group><article-title>A high content screening assay to identify compounds with anti-epithelial-mesenchymal transition effects from the chinese herbal medicine Tong-Mai-Yang-Xin-Wan</article-title><source>Molecules</source><year>2016</year><pub-id pub-id-type="doi">10.3390/molecules21101340</pub-id><pub-id pub-id-type="pmid">27735870</pub-id><pub-id pub-id-type="pmcid">PMC6273035</pub-id></element-citation><mixed-citation id="mc-CR174" publication-type="journal">Liu N, Li L, Zhu X, et al. A high content screening assay to identify compounds with anti-epithelial-mesenchymal transition effects from the chinese herbal medicine Tong-Mai-Yang-Xin-Wan. Molecules. 2016. 10.3390/molecules21101340.<pub-id pub-id-type="pmid">27735870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules21101340</pub-id><pub-id pub-id-type="pmcid">PMC6273035</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brandl</surname><given-names>MB</given-names></name><name name-style="western"><surname>Pasquier</surname><given-names>E</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><etal/></person-group><article-title>Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancer</article-title><source>Mol Oncol</source><year>2014</year><volume>8</volume><issue>8</issue><fpage>1548</fpage><lpage>1560</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2014.06.007</pub-id><pub-id pub-id-type="pmid">24997502</pub-id><pub-id pub-id-type="pmcid">PMC4253311</pub-id></element-citation><mixed-citation id="mc-CR175" publication-type="journal">Brandl MB, Pasquier E, Li F, et al. Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancer. Mol Oncol. 2014;8(8):1548&#8211;60. 10.1016/j.molonc.2014.06.007.<pub-id pub-id-type="pmid">24997502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molonc.2014.06.007</pub-id><pub-id pub-id-type="pmcid">PMC4253311</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176.</label><citation-alternatives><element-citation id="ec-CR176" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>HW</given-names></name><name name-style="western"><surname>O'Reilly</surname><given-names>C</given-names></name><name name-style="western"><surname>Beckett</surname><given-names>AN</given-names></name><name name-style="western"><surname>Currier</surname><given-names>DG</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name><name name-style="western"><surname>DeRenzo</surname><given-names>C</given-names></name></person-group><article-title>A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7&#8211;H3-CAR T cell activity by upregulating B7&#8211;H3 on the target cell surface via PKC&#945; activation</article-title><source>J Exp Clin Cancer Res</source><year>2024</year><volume>43</volume><issue>1</issue><fpage>97</fpage><pub-id pub-id-type="doi">10.1186/s13046-024-03022-x</pub-id><pub-id pub-id-type="pmid">38561833</pub-id><pub-id pub-id-type="pmcid">PMC10985962</pub-id></element-citation><mixed-citation id="mc-CR176" publication-type="journal">Lee HW, O&#8217;Reilly C, Beckett AN, Currier DG, Chen T, DeRenzo C. A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7&#8211;H3-CAR T cell activity by upregulating B7&#8211;H3 on the target cell surface via PKC&#945; activation. J Exp Clin Cancer Res. 2024;43(1):97. 10.1186/s13046-024-03022-x.<pub-id pub-id-type="pmid">38561833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-024-03022-x</pub-id><pub-id pub-id-type="pmcid">PMC10985962</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR177"><label>177.</label><citation-alternatives><element-citation id="ec-CR177" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>PS</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name></person-group><article-title>High-content image screening to identify chemical modulators for peroxisome and ferroptosis</article-title><source>Cell Mol Biol Lett</source><year>2024</year><volume>29</volume><issue>1</issue><fpage>26</fpage><pub-id pub-id-type="doi">10.1186/s11658-024-00544-2</pub-id><pub-id pub-id-type="pmid">38368371</pub-id><pub-id pub-id-type="pmcid">PMC10874541</pub-id></element-citation><mixed-citation id="mc-CR177" publication-type="journal">Zheng D, Li F, Wang S, Liu PS, Xie X. High-content image screening to identify chemical modulators for peroxisome and ferroptosis. Cell Mol Biol Lett. 2024;29(1):26. 10.1186/s11658-024-00544-2.<pub-id pub-id-type="pmid">38368371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s11658-024-00544-2</pub-id><pub-id pub-id-type="pmcid">PMC10874541</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR178"><label>178.</label><citation-alternatives><element-citation id="ec-CR178" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozer</surname><given-names>LY</given-names></name><name name-style="western"><surname>Fayed</surname><given-names>HS</given-names></name><name name-style="western"><surname>Ericsson</surname><given-names>J</given-names></name><name name-style="western"><surname>Zen</surname><given-names>AHA</given-names></name></person-group><article-title>Development of a cancer metastasis-on-chip assay for high throughput drug screening</article-title><source>Front Oncol</source><year>2023</year><volume>13</volume><fpage>1269376</fpage><pub-id pub-id-type="doi">10.3389/fonc.2023.1269376</pub-id><pub-id pub-id-type="pmid">38239643</pub-id><pub-id pub-id-type="pmcid">PMC10794518</pub-id></element-citation><mixed-citation id="mc-CR178" publication-type="journal">Ozer LY, Fayed HS, Ericsson J, Zen AHA. Development of a cancer metastasis-on-chip assay for high throughput drug screening. Front Oncol. 2023;13:1269376. 10.3389/fonc.2023.1269376.<pub-id pub-id-type="pmid">38239643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2023.1269376</pub-id><pub-id pub-id-type="pmcid">PMC10794518</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR179"><label>179.</label><citation-alternatives><element-citation id="ec-CR179" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Use of Deep-Learning Assisted Assessment of Cardiac Parameters in Zebrafish to Discover Cyanidin Chloride as a Novel Keap1 Inhibitor Against Doxorubicin-Induced Cardiotoxicity</article-title><source>Adv Sci</source><year>2023</year><volume>10</volume><issue>30</issue><fpage>e2301136</fpage><pub-id pub-id-type="doi">10.1002/advs.202301136</pub-id><pub-id pub-id-type="pmcid">PMC10602559</pub-id><pub-id pub-id-type="pmid">37679058</pub-id></element-citation><mixed-citation id="mc-CR179" publication-type="journal">Liu C, Wang Y, Zeng Y, et al. Use of Deep-Learning Assisted Assessment of Cardiac Parameters in Zebrafish to Discover Cyanidin Chloride as a Novel Keap1 Inhibitor Against Doxorubicin-Induced Cardiotoxicity. Adv Sci. 2023;10(30):e2301136. 10.1002/advs.202301136.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202301136</pub-id><pub-id pub-id-type="pmcid">PMC10602559</pub-id><pub-id pub-id-type="pmid">37679058</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR180"><label>180.</label><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X</given-names></name><name name-style="western"><surname>Xun</surname><given-names>D</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Discovery of natural small molecules promoting collagen secretion by high-throughput screening in Caenorhabditis elegans</article-title><source>Molecules</source><year>2022</year><pub-id pub-id-type="doi">10.3390/molecules27238361</pub-id><pub-id pub-id-type="pmid">36500453</pub-id><pub-id pub-id-type="pmcid">PMC9736230</pub-id></element-citation><mixed-citation id="mc-CR180" publication-type="journal">Fang J, Wu X, Meng X, Xun D, Xu S, Wang Y. Discovery of natural small molecules promoting collagen secretion by high-throughput screening in Caenorhabditis elegans. Molecules. 2022. 10.3390/molecules27238361.<pub-id pub-id-type="pmid">36500453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules27238361</pub-id><pub-id pub-id-type="pmcid">PMC9736230</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR181"><label>181.</label><citation-alternatives><element-citation id="ec-CR181" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Identification of anti-inflammatory compounds from Zhongjing formulae by knowledge mining and high-content screening in a zebrafish model of inflammatory bowel diseases</article-title><source>Chin Med</source><year>2021</year><volume>16</volume><issue>1</issue><fpage>42</fpage><pub-id pub-id-type="doi">10.1186/s13020-021-00452-z</pub-id><pub-id pub-id-type="pmid">34059101</pub-id><pub-id pub-id-type="pmcid">PMC8166029</pub-id></element-citation><mixed-citation id="mc-CR181" publication-type="journal">Yu Y, Chen J, Zhang X, et al. Identification of anti-inflammatory compounds from Zhongjing formulae by knowledge mining and high-content screening in a zebrafish model of inflammatory bowel diseases. Chin Med. 2021;16(1):42. 10.1186/s13020-021-00452-z.<pub-id pub-id-type="pmid">34059101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13020-021-00452-z</pub-id><pub-id pub-id-type="pmcid">PMC8166029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR182"><label>182.</label><citation-alternatives><element-citation id="ec-CR182" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group><article-title>High content screening identifies licoisoflavone A as a bioactive compound of Tongmaiyangxin Pills to restrain cardiomyocyte hypertrophy via activating Sirt3</article-title><source>Phytomedicine</source><year>2020</year><volume>68</volume><fpage>153171</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2020.153171</pub-id><pub-id pub-id-type="pmid">32018211</pub-id></element-citation><mixed-citation id="mc-CR182" publication-type="journal">Guo R, Liu N, Liu H, et al. High content screening identifies licoisoflavone A as a bioactive compound of Tongmaiyangxin Pills to restrain cardiomyocyte hypertrophy via activating Sirt3. Phytomedicine. 2020;68: 153171. 10.1016/j.phymed.2020.153171.<pub-id pub-id-type="pmid">32018211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phymed.2020.153171</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR183"><label>183.</label><citation-alternatives><element-citation id="ec-CR183" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Multimodal identification by transcriptomics and multiscale bioassays of active components in Xuanfeibaidu formula to suppress macrophage-mediated immune response</article-title><source>Engineering</source><year>2023</year><volume>20</volume><fpage>63</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.eng.2021.09.007</pub-id><pub-id pub-id-type="pmid">34815890</pub-id><pub-id pub-id-type="pmcid">PMC8601788</pub-id></element-citation><mixed-citation id="mc-CR183" publication-type="journal">Zhao L, Liu H, Wang Y, et al. Multimodal identification by transcriptomics and multiscale bioassays of active components in Xuanfeibaidu formula to suppress macrophage-mediated immune response. Engineering. 2023;20:63&#8211;76. 10.1016/j.eng.2021.09.007.<pub-id pub-id-type="pmid">34815890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eng.2021.09.007</pub-id><pub-id pub-id-type="pmcid">PMC8601788</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR184"><label>184.</label><citation-alternatives><element-citation id="ec-CR184" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>XT</given-names></name><name name-style="western"><surname>Sun</surname><given-names>XJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><etal/></person-group><article-title>Establishing a cell-based high-content screening assay for TCM compounds with anti-renal fibrosis effects</article-title><source>Evid Based Complement Alternat Med</source><year>2018</year><volume>2018</volume><fpage>7942614</fpage><pub-id pub-id-type="doi">10.1155/2018/7942614</pub-id><pub-id pub-id-type="pmid">30050593</pub-id><pub-id pub-id-type="pmcid">PMC6046160</pub-id></element-citation><mixed-citation id="mc-CR184" publication-type="journal">Wang XT, Sun XJ, Li C, et al. Establishing a cell-based high-content screening assay for TCM compounds with anti-renal fibrosis effects. Evid Based Complement Alternat Med. 2018;2018:7942614. 10.1155/2018/7942614.<pub-id pub-id-type="pmid">30050593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2018/7942614</pub-id><pub-id pub-id-type="pmcid">PMC6046160</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR185"><label>185.</label><citation-alternatives><element-citation id="ec-CR185" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>YL</given-names></name><name name-style="western"><surname>You</surname><given-names>J</given-names></name><name name-style="western"><surname>Cao</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Screening of the ubiquitin-proteasome system activators for anti-Alzheimer's disease by the high-content fluorescence imaging system</article-title><source>Chin J Nat Med</source><year>2022</year><volume>20</volume><issue>1</issue><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/s1875-5364(22)60152-3</pub-id><pub-id pub-id-type="pmid">35101248</pub-id></element-citation><mixed-citation id="mc-CR185" publication-type="journal">Wang YL, You J, Cao JJ, et al. Screening of the ubiquitin-proteasome system activators for anti-Alzheimer&#8217;s disease by the high-content fluorescence imaging system. Chin J Nat Med. 2022;20(1):33&#8211;42. 10.1016/s1875-5364(22)60152-3.<pub-id pub-id-type="pmid">35101248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1875-5364(22)60152-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR186"><label>186.</label><citation-alternatives><element-citation id="ec-CR186" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norgan</surname><given-names>AP</given-names></name><name name-style="western"><surname>Coffman</surname><given-names>PK</given-names></name><name name-style="western"><surname>Kocher</surname><given-names>JP</given-names></name><name name-style="western"><surname>Katzmann</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Sosa</surname><given-names>CP</given-names></name></person-group><article-title>Multilevel parallelization of AutoDock 42</article-title><source>J Cheminf</source><year>2011</year><volume>3</volume><issue>1</issue><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-3-12</pub-id><pub-id pub-id-type="pmcid">PMC3098179</pub-id><pub-id pub-id-type="pmid">21527034</pub-id></element-citation><mixed-citation id="mc-CR186" publication-type="journal">Norgan AP, Coffman PK, Kocher JP, Katzmann DJ, Sosa CP. Multilevel parallelization of AutoDock 42. J Cheminf. 2011;3(1):12. 10.1186/1758-2946-3-12.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1758-2946-3-12</pub-id><pub-id pub-id-type="pmcid">PMC3098179</pub-id><pub-id pub-id-type="pmid">21527034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR187"><label>187.</label><citation-alternatives><element-citation id="ec-CR187" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Russell</surname><given-names>P</given-names></name><etal/></person-group><article-title>Evaluation of the binding performance of flavonoids to estrogen receptor alpha by Autodock, Autodock Vina and Surflex-Dock</article-title><source>Ecotoxicol Environ Safety.</source><year>2022</year><volume>233</volume><fpage>113323</fpage><pub-id pub-id-type="doi">10.1016/j.ecoenv.2022.113323</pub-id><pub-id pub-id-type="pmid">35183811</pub-id></element-citation><mixed-citation id="mc-CR187" publication-type="journal">Xue Q, Liu X, Russell P, et al. Evaluation of the binding performance of flavonoids to estrogen receptor alpha by Autodock, Autodock Vina and Surflex-Dock. Ecotoxicol Environ Safety. 2022;233:113323. 10.1016/j.ecoenv.2022.113323.<pub-id pub-id-type="pmid">35183811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ecoenv.2022.113323</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR188"><label>188.</label><citation-alternatives><element-citation id="ec-CR188" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>R</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Lan</surname><given-names>R</given-names></name><name name-style="western"><surname>Shen</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name></person-group><article-title>Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>56</volume><issue>2</issue><fpage>106012</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.106012</pub-id><pub-id pub-id-type="pmid">32389723</pub-id><pub-id pub-id-type="pmcid">PMC7205718</pub-id></element-citation><mixed-citation id="mc-CR188" publication-type="journal">Yu R, Chen L, Lan R, Shen R, Li P. Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. Int J Antimicrob Agents. 2020;56(2): 106012. 10.1016/j.ijantimicag.2020.106012.<pub-id pub-id-type="pmid">32389723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2020.106012</pub-id><pub-id pub-id-type="pmcid">PMC7205718</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR189"><label>189.</label><citation-alternatives><element-citation id="ec-CR189" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enmozhi</surname><given-names>SK</given-names></name><name name-style="western"><surname>Raja</surname><given-names>K</given-names></name><name name-style="western"><surname>Sebastine</surname><given-names>I</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>J</given-names></name></person-group><article-title>Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach</article-title><source>J Biomol Struct Dyn</source><year>2021</year><volume>39</volume><issue>9</issue><fpage>3092</fpage><lpage>3098</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1760136</pub-id><pub-id pub-id-type="pmid">32329419</pub-id><pub-id pub-id-type="pmcid">PMC7212536</pub-id></element-citation><mixed-citation id="mc-CR189" publication-type="journal">Enmozhi SK, Raja K, Sebastine I, Joseph J. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach. J Biomol Struct Dyn. 2021;39(9):3092&#8211;8. 10.1080/07391102.2020.1760136.<pub-id pub-id-type="pmid">32329419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2020.1760136</pub-id><pub-id pub-id-type="pmcid">PMC7212536</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR190"><label>190.</label><citation-alternatives><element-citation id="ec-CR190" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lang</surname><given-names>PT</given-names></name><name name-style="western"><surname>Brozell</surname><given-names>SR</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S</given-names></name><etal/></person-group><article-title>DOCK 6: combining techniques to model RNA-small molecule complexes</article-title><source>RNA</source><year>2009</year><volume>15</volume><issue>6</issue><fpage>1219</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1261/rna.1563609</pub-id><pub-id pub-id-type="pmid">19369428</pub-id><pub-id pub-id-type="pmcid">PMC2685511</pub-id></element-citation><mixed-citation id="mc-CR190" publication-type="journal">Lang PT, Brozell SR, Mukherjee S, et al. DOCK 6: combining techniques to model RNA-small molecule complexes. RNA. 2009;15(6):1219&#8211;30. 10.1261/rna.1563609.<pub-id pub-id-type="pmid">19369428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1261/rna.1563609</pub-id><pub-id pub-id-type="pmcid">PMC2685511</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR191"><label>191.</label><citation-alternatives><element-citation id="ec-CR191" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>S</given-names></name><name name-style="western"><surname>Sarmah</surname><given-names>S</given-names></name><name name-style="western"><surname>Lyndem</surname><given-names>S</given-names></name><name name-style="western"><surname>Singha</surname><given-names>RA</given-names></name></person-group><article-title>An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study</article-title><source>J Biomol Struct Dyn</source><year>2021</year><volume>39</volume><issue>9</issue><fpage>3347</fpage><lpage>3357</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1763201</pub-id><pub-id pub-id-type="pmid">32362245</pub-id><pub-id pub-id-type="pmcid">PMC7232884</pub-id></element-citation><mixed-citation id="mc-CR191" publication-type="journal">Das S, Sarmah S, Lyndem S, Singha RA. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study. J Biomol Struct Dyn. 2021;39(9):3347&#8211;57. 10.1080/07391102.2020.1763201.<pub-id pub-id-type="pmid">32362245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2020.1763201</pub-id><pub-id pub-id-type="pmcid">PMC7232884</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR192"><label>192.</label><citation-alternatives><element-citation id="ec-CR192" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grosdidier</surname><given-names>A</given-names></name><name name-style="western"><surname>Zoete</surname><given-names>V</given-names></name><name name-style="western"><surname>Michielin</surname><given-names>O</given-names></name></person-group><article-title>SwissDock, a protein-small molecule docking web service based on EADock DSS</article-title><source>Nucleic acids research</source><year>2011</year><volume>39</volume><issue>Web Server issue</issue><fpage>W270</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/nar/gkr366</pub-id><pub-id pub-id-type="pmid">21624888</pub-id><pub-id pub-id-type="pmcid">PMC3125772</pub-id></element-citation><mixed-citation id="mc-CR192" publication-type="journal">Grosdidier A, Zoete V, Michielin O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic acids research. 2011;39(Web Server issue):W270-7. 10.1093/nar/gkr366.<pub-id pub-id-type="pmid">21624888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkr366</pub-id><pub-id pub-id-type="pmcid">PMC3125772</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR193"><label>193.</label><citation-alternatives><element-citation id="ec-CR193" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Kashyap</surname><given-names>P</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>S</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Panwar</surname><given-names>A</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Identification of phytochemicals as potential therapeutic agents that binds to Nsp15 protein target of coronavirus (SARS-CoV-2) that are capable of inhibiting virus replication</article-title><source>Phytomedicine</source><year>2021</year><volume>85</volume><fpage>153317</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2020.153317</pub-id><pub-id pub-id-type="pmid">32943302</pub-id><pub-id pub-id-type="pmcid">PMC7470885</pub-id></element-citation><mixed-citation id="mc-CR193" publication-type="journal">Kumar S, Kashyap P, Chowdhury S, Kumar S, Panwar A, Kumar A. Identification of phytochemicals as potential therapeutic agents that binds to Nsp15 protein target of coronavirus (SARS-CoV-2) that are capable of inhibiting virus replication. Phytomedicine. 2021;85: 153317. 10.1016/j.phymed.2020.153317.<pub-id pub-id-type="pmid">32943302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phymed.2020.153317</pub-id><pub-id pub-id-type="pmcid">PMC7470885</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR194"><label>194.</label><citation-alternatives><element-citation id="ec-CR194" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGann</surname><given-names>M</given-names></name></person-group><article-title>FRED pose prediction and virtual screening accuracy</article-title><source>J Chem Inf Model</source><year>2011</year><volume>51</volume><issue>3</issue><fpage>578</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1021/ci100436p</pub-id><pub-id pub-id-type="pmid">21323318</pub-id></element-citation><mixed-citation id="mc-CR194" publication-type="journal">McGann M. FRED pose prediction and virtual screening accuracy. J Chem Inf Model. 2011;51(3):578&#8211;96. 10.1021/ci100436p.<pub-id pub-id-type="pmid">21323318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ci100436p</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR195"><label>195.</label><citation-alternatives><element-citation id="ec-CR195" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cardoze</surname><given-names>SM</given-names></name><name name-style="western"><surname>Obineche</surname><given-names>OW</given-names></name><name name-style="western"><surname>Melo</surname><given-names>C</given-names></name><name name-style="western"><surname>Persaud</surname><given-names>A</given-names></name><name name-style="western"><surname>Fern&#225;ndez Romero</surname><given-names>JA</given-names></name></person-group><article-title>Small molecules targeting SARS-CoV-2 spike glycoprotein receptor-binding domain</article-title><source>ACS Omega</source><year>2022</year><volume>7</volume><issue>33</issue><fpage>28779</fpage><lpage>28789</lpage><pub-id pub-id-type="doi">10.1021/acsomega.2c00844</pub-id><pub-id pub-id-type="pmid">35991504</pub-id><pub-id pub-id-type="pmcid">PMC9380817</pub-id></element-citation><mixed-citation id="mc-CR195" publication-type="journal">Rodr&#237;guez Y, Cardoze SM, Obineche OW, Melo C, Persaud A, Fern&#225;ndez Romero JA. Small molecules targeting SARS-CoV-2 spike glycoprotein receptor-binding domain. ACS Omega. 2022;7(33):28779&#8211;89. 10.1021/acsomega.2c00844.<pub-id pub-id-type="pmid">35991504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsomega.2c00844</pub-id><pub-id pub-id-type="pmcid">PMC9380817</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR196"><label>196.</label><citation-alternatives><element-citation id="ec-CR196" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gronemeyer</surname><given-names>H</given-names></name><name name-style="western"><surname>Gustafsson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Laudet</surname><given-names>V</given-names></name></person-group><article-title>Principles for modulation of the nuclear receptor superfamily</article-title><source>Nat Rev Drug Dis</source><year>2004</year><volume>3</volume><issue>11</issue><fpage>950</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1038/nrd1551</pub-id><pub-id pub-id-type="pmid">15520817</pub-id></element-citation><mixed-citation id="mc-CR196" publication-type="journal">Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Dis. 2004;3(11):950&#8211;64. 10.1038/nrd1551.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd1551</pub-id><pub-id pub-id-type="pmid">15520817</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR197"><label>197.</label><citation-alternatives><element-citation id="ec-CR197" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zsoldos</surname><given-names>Z</given-names></name><name name-style="western"><surname>Reid</surname><given-names>D</given-names></name><name name-style="western"><surname>Simon</surname><given-names>A</given-names></name><name name-style="western"><surname>Sadjad</surname><given-names>BS</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>AP</given-names></name></person-group><article-title>eHiTS: an innovative approach to the docking and scoring function problems</article-title><source>Curr Protein Pept Sci</source><year>2006</year><volume>7</volume><issue>5</issue><fpage>421</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.2174/138920306778559412</pub-id><pub-id pub-id-type="pmid">17073694</pub-id></element-citation><mixed-citation id="mc-CR197" publication-type="journal">Zsoldos Z, Reid D, Simon A, Sadjad BS, Johnson AP. eHiTS: an innovative approach to the docking and scoring function problems. Curr Protein Pept Sci. 2006;7(5):421&#8211;35. 10.2174/138920306778559412.<pub-id pub-id-type="pmid">17073694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/138920306778559412</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR198"><label>198.</label><citation-alternatives><element-citation id="ec-CR198" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahanta</surname><given-names>S</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>P</given-names></name><name name-style="western"><surname>Gogoi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach</article-title><source>J Biomol Struct Dyn</source><year>2021</year><volume>39</volume><issue>10</issue><fpage>3802</fpage><lpage>3811</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1768902</pub-id><pub-id pub-id-type="pmid">32406317</pub-id></element-citation><mixed-citation id="mc-CR198" publication-type="journal">Mahanta S, Chowdhury P, Gogoi N, et al. Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach. J Biomol Struct Dyn. 2021;39(10):3802&#8211;11. 10.1080/07391102.2020.1768902.<pub-id pub-id-type="pmid">32406317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2020.1768902</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR199"><label>199.</label><citation-alternatives><element-citation id="ec-CR199" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>G</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>DH</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>CL</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Vieth</surname><given-names>M</given-names></name></person-group><article-title>Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm</article-title><source>J Comput Chem</source><year>2003</year><volume>24</volume><issue>13</issue><fpage>1549</fpage><lpage>1562</lpage><pub-id pub-id-type="doi">10.1002/jcc.10306</pub-id><pub-id pub-id-type="pmid">12925999</pub-id></element-citation><mixed-citation id="mc-CR199" publication-type="journal">Wu G, Robertson DH, Brooks CL 3rd, Vieth M. Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem. 2003;24(13):1549&#8211;62. 10.1002/jcc.10306.<pub-id pub-id-type="pmid">12925999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcc.10306</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR200"><label>200.</label><citation-alternatives><element-citation id="ec-CR200" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Exploration of SARS-CoV-2 3CL(pro) inhibitors by virtual screening methods, FRET detection, and CPE assay</article-title><source>J Chem Inf Model</source><year>2021</year><volume>61</volume><issue>12</issue><fpage>5763</fpage><lpage>5773</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.1c01089</pub-id><pub-id pub-id-type="pmid">34797660</pub-id></element-citation><mixed-citation id="mc-CR200" publication-type="journal">Zhao J, Ma Q, Zhang B, et al. Exploration of SARS-CoV-2 3CL(pro) inhibitors by virtual screening methods, FRET detection, and CPE assay. J Chem Inf Model. 2021;61(12):5763&#8211;73. 10.1021/acs.jcim.1c01089.<pub-id pub-id-type="pmid">34797660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.1c01089</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR201"><label>201.</label><citation-alternatives><element-citation id="ec-CR201" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmaaty</surname><given-names>AA</given-names></name><name name-style="western"><surname>Darwish</surname><given-names>KM</given-names></name><name name-style="western"><surname>Khattab</surname><given-names>M</given-names></name><etal/></person-group><article-title>In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins</article-title><source>J Biomol Struct Dyn</source><year>2022</year><volume>40</volume><issue>19</issue><fpage>8866</fpage><lpage>8893</lpage><pub-id pub-id-type="doi">10.1080/07391102.2021.1918256</pub-id><pub-id pub-id-type="pmid">33928870</pub-id></element-citation><mixed-citation id="mc-CR201" publication-type="journal">Elmaaty AA, Darwish KM, Khattab M, et al. In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins. J Biomol Struct Dyn. 2022;40(19):8866&#8211;93. 10.1080/07391102.2021.1918256.<pub-id pub-id-type="pmid">33928870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2021.1918256</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR202"><label>202.</label><citation-alternatives><element-citation id="ec-CR202" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vilar</surname><given-names>S</given-names></name><name name-style="western"><surname>Cozza</surname><given-names>G</given-names></name><name name-style="western"><surname>Moro</surname><given-names>S</given-names></name></person-group><article-title>Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery</article-title><source>Curr Top Med Chem</source><year>2008</year><volume>8</volume><issue>18</issue><fpage>1555</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.2174/156802608786786624</pub-id><pub-id pub-id-type="pmid">19075767</pub-id></element-citation><mixed-citation id="mc-CR202" publication-type="journal">Vilar S, Cozza G, Moro S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr Top Med Chem. 2008;8(18):1555&#8211;72. 10.2174/156802608786786624.<pub-id pub-id-type="pmid">19075767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/156802608786786624</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR203"><label>203.</label><citation-alternatives><element-citation id="ec-CR203" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2</article-title><source>Phytomedicine</source><year>2021</year><volume>85</volume><fpage>153364</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2020.153364</pub-id><pub-id pub-id-type="pmid">33041173</pub-id><pub-id pub-id-type="pmcid">PMC7531286</pub-id></element-citation><mixed-citation id="mc-CR203" publication-type="journal">Yu S, Zhu Y, Xu J, et al. Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2. Phytomedicine. 2021;85: 153364. 10.1016/j.phymed.2020.153364.<pub-id pub-id-type="pmid">33041173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phymed.2020.153364</pub-id><pub-id pub-id-type="pmcid">PMC7531286</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR204"><label>204.</label><citation-alternatives><element-citation id="ec-CR204" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lokhande</surname><given-names>KB</given-names></name><name name-style="western"><surname>Doiphode</surname><given-names>S</given-names></name><name name-style="western"><surname>Vyas</surname><given-names>R</given-names></name><name name-style="western"><surname>Swamy</surname><given-names>KV</given-names></name></person-group><article-title>Molecular docking and simulation studies on SARS-CoV-2 M(pro) reveals Mitoxantrone, Leucovorin, Birinapant, and Dynasore as potent drugs against COVID-19</article-title><source>J Biomol Struct Dyn</source><year>2021</year><volume>39</volume><issue>18</issue><fpage>7294</fpage><lpage>7305</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1805019</pub-id><pub-id pub-id-type="pmid">32815481</pub-id><pub-id pub-id-type="pmcid">PMC7484567</pub-id></element-citation><mixed-citation id="mc-CR204" publication-type="journal">Lokhande KB, Doiphode S, Vyas R, Swamy KV. Molecular docking and simulation studies on SARS-CoV-2 M(pro) reveals Mitoxantrone, Leucovorin, Birinapant, and Dynasore as potent drugs against COVID-19. J Biomol Struct Dyn. 2021;39(18):7294&#8211;305. 10.1080/07391102.2020.1805019.<pub-id pub-id-type="pmid">32815481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2020.1805019</pub-id><pub-id pub-id-type="pmcid">PMC7484567</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR205"><label>205.</label><citation-alternatives><element-citation id="ec-CR205" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rarey</surname><given-names>M</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>B</given-names></name><name name-style="western"><surname>Lengauer</surname><given-names>T</given-names></name><name name-style="western"><surname>Klebe</surname><given-names>G</given-names></name></person-group><article-title>A fast flexible docking method using an incremental construction algorithm</article-title><source>J Mol Biol</source><year>1996</year><volume>261</volume><issue>3</issue><fpage>470</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1996.0477</pub-id><pub-id pub-id-type="pmid">8780787</pub-id></element-citation><mixed-citation id="mc-CR205" publication-type="journal">Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J Mol Biol. 1996;261(3):470&#8211;89. 10.1006/jmbi.1996.0477.<pub-id pub-id-type="pmid">8780787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/jmbi.1996.0477</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR206"><label>206.</label><citation-alternatives><element-citation id="ec-CR206" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>G</given-names></name><name name-style="western"><surname>Willett</surname><given-names>P</given-names></name><name name-style="western"><surname>Glen</surname><given-names>RC</given-names></name><name name-style="western"><surname>Leach</surname><given-names>AR</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>R</given-names></name></person-group><article-title>Development and validation of a genetic algorithm for flexible docking</article-title><source>J Mol Biol</source><year>1997</year><volume>267</volume><issue>3</issue><fpage>727</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1996.0897</pub-id><pub-id pub-id-type="pmid">9126849</pub-id></element-citation><mixed-citation id="mc-CR206" publication-type="journal">Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997;267(3):727&#8211;48. 10.1006/jmbi.1996.0897.<pub-id pub-id-type="pmid">9126849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/jmbi.1996.0897</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR207"><label>207.</label><citation-alternatives><element-citation id="ec-CR207" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Rocha</surname><given-names>JAP</given-names></name><name name-style="western"><surname>da Costa</surname><given-names>RA</given-names></name><name name-style="western"><surname>da Costa</surname><given-names>A</given-names></name><etal/></person-group><article-title>Harnessing Brazilian biodiversity database: identification of flavonoids as potential inhibitors of SARS-CoV-2 main protease using computational approaches and all-atom molecular dynamics simulation</article-title><source>Front Chem</source><year>2024</year><volume>12</volume><fpage>1336001</fpage><pub-id pub-id-type="doi">10.3389/fchem.2024.1336001</pub-id><pub-id pub-id-type="pmid">38456183</pub-id><pub-id pub-id-type="pmcid">PMC10917896</pub-id></element-citation><mixed-citation id="mc-CR207" publication-type="journal">da Rocha JAP, da Costa RA, da Costa A, et al. Harnessing Brazilian biodiversity database: identification of flavonoids as potential inhibitors of SARS-CoV-2 main protease using computational approaches and all-atom molecular dynamics simulation. Front Chem. 2024;12:1336001. 10.3389/fchem.2024.1336001.<pub-id pub-id-type="pmid">38456183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fchem.2024.1336001</pub-id><pub-id pub-id-type="pmcid">PMC10917896</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR208"><label>208.</label><citation-alternatives><element-citation id="ec-CR208" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheohen</surname><given-names>C</given-names></name><name name-style="western"><surname>Esteves</surname><given-names>MEA</given-names></name><name name-style="western"><surname>da Fonseca</surname><given-names>TS</given-names></name><etal/></person-group><article-title>In silico screening of phenylethanoid glycosides, a class of pharmacologically active compounds as natural inhibitors of SARS-CoV-2 proteases</article-title><source>Comput Struct Biotechnol J</source><year>2023</year><volume>21</volume><fpage>1461</fpage><lpage>1472</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2023.02.020</pub-id><pub-id pub-id-type="pmid">36817956</pub-id><pub-id pub-id-type="pmcid">PMC9920770</pub-id></element-citation><mixed-citation id="mc-CR208" publication-type="journal">Cheohen C, Esteves MEA, da Fonseca TS, et al. In silico screening of phenylethanoid glycosides, a class of pharmacologically active compounds as natural inhibitors of SARS-CoV-2 proteases. Comput Struct Biotechnol J. 2023;21:1461&#8211;72. 10.1016/j.csbj.2023.02.020.<pub-id pub-id-type="pmid">36817956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.csbj.2023.02.020</pub-id><pub-id pub-id-type="pmcid">PMC9920770</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR209"><label>209.</label><citation-alternatives><element-citation id="ec-CR209" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>AN</given-names></name></person-group><article-title>Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine</article-title><source>J Med Chem</source><year>2003</year><volume>46</volume><issue>4</issue><fpage>499</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1021/jm020406h</pub-id><pub-id pub-id-type="pmid">12570372</pub-id></element-citation><mixed-citation id="mc-CR209" publication-type="journal">Jain AN. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem. 2003;46(4):499&#8211;511. 10.1021/jm020406h.<pub-id pub-id-type="pmid">12570372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm020406h</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR210"><label>210.</label><citation-alternatives><element-citation id="ec-CR210" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghaleb</surname><given-names>A</given-names></name><name name-style="western"><surname>Aouidate</surname><given-names>A</given-names></name><name name-style="western"><surname>Ayouchia</surname><given-names>HBE</given-names></name><name name-style="western"><surname>Aarjane</surname><given-names>M</given-names></name><name name-style="western"><surname>Anane</surname><given-names>H</given-names></name><name name-style="western"><surname>Stiriba</surname><given-names>SE</given-names></name></person-group><article-title>In silico molecular investigations of pyridine N-Oxide compounds as potential inhibitors of SARS-CoV-2: 3D QSAR, molecular docking modeling, and ADMET screening</article-title><source>J Biomol Struct Dyn</source><year>2022</year><volume>40</volume><issue>1</issue><fpage>143</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1808530</pub-id><pub-id pub-id-type="pmid">32799761</pub-id></element-citation><mixed-citation id="mc-CR210" publication-type="journal">Ghaleb A, Aouidate A, Ayouchia HBE, Aarjane M, Anane H, Stiriba SE. In silico molecular investigations of pyridine N-Oxide compounds as potential inhibitors of SARS-CoV-2: 3D QSAR, molecular docking modeling, and ADMET screening. J Biomol Struct Dyn. 2022;40(1):143&#8211;53. 10.1080/07391102.2020.1808530.<pub-id pub-id-type="pmid">32799761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2020.1808530</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR211"><label>211.</label><citation-alternatives><element-citation id="ec-CR211" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friesner</surname><given-names>RA</given-names></name><name name-style="western"><surname>Banks</surname><given-names>JL</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</article-title><source>J Med Chem</source><year>2004</year><volume>47</volume><issue>7</issue><fpage>1739</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1021/jm0306430</pub-id><pub-id pub-id-type="pmid">15027865</pub-id></element-citation><mixed-citation id="mc-CR211" publication-type="journal">Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739&#8211;49. 10.1021/jm0306430.<pub-id pub-id-type="pmid">15027865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm0306430</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR212"><label>212.</label><citation-alternatives><element-citation id="ec-CR212" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khachatryan</surname><given-names>H</given-names></name><name name-style="western"><surname>Matevosyan</surname><given-names>M</given-names></name><name name-style="western"><surname>Harutyunyan</surname><given-names>V</given-names></name><etal/></person-group><article-title>Computational evaluation and benchmark study of 342 crystallographic holo-structures of SARS-CoV-2 Mpro enzyme</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>14255</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-65228-5</pub-id><pub-id pub-id-type="pmid">38902397</pub-id><pub-id pub-id-type="pmcid">PMC11189913</pub-id></element-citation><mixed-citation id="mc-CR212" publication-type="journal">Khachatryan H, Matevosyan M, Harutyunyan V, et al. Computational evaluation and benchmark study of 342 crystallographic holo-structures of SARS-CoV-2 Mpro enzyme. Sci Rep. 2024;14(1):14255. 10.1038/s41598-024-65228-5.<pub-id pub-id-type="pmid">38902397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-65228-5</pub-id><pub-id pub-id-type="pmcid">PMC11189913</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR213"><label>213.</label><citation-alternatives><element-citation id="ec-CR213" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majumder</surname><given-names>R</given-names></name><name name-style="western"><surname>Mandal</surname><given-names>M</given-names></name></person-group><article-title>Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an in silico docking and molecular dynamics simulation approach</article-title><source>J Biomol Struct Dyn</source><year>2022</year><volume>40</volume><issue>2</issue><fpage>696</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1817787</pub-id><pub-id pub-id-type="pmid">32897138</pub-id><pub-id pub-id-type="pmcid">PMC7544942</pub-id></element-citation><mixed-citation id="mc-CR213" publication-type="journal">Majumder R, Mandal M. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an in silico docking and molecular dynamics simulation approach. J Biomol Struct Dyn. 2022;40(2):696&#8211;711. 10.1080/07391102.2020.1817787.<pub-id pub-id-type="pmid">32897138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2020.1817787</pub-id><pub-id pub-id-type="pmcid">PMC7544942</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR214"><label>214.</label><citation-alternatives><element-citation id="ec-CR214" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Spoel</surname><given-names>D</given-names></name><name name-style="western"><surname>van Maaren</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Caleman</surname><given-names>C</given-names></name></person-group><article-title>GROMACS molecule &amp; liquid database</article-title><source>Bioinformatics</source><year>2012</year><volume>28</volume><issue>5</issue><fpage>752</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts020</pub-id><pub-id pub-id-type="pmid">22238269</pub-id></element-citation><mixed-citation id="mc-CR214" publication-type="journal">van der Spoel D, van Maaren PJ, Caleman C. GROMACS molecule &amp; liquid database. Bioinformatics. 2012;28(5):752&#8211;3. 10.1093/bioinformatics/bts020.<pub-id pub-id-type="pmid">22238269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bts020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR215"><label>215.</label><citation-alternatives><element-citation id="ec-CR215" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Case</surname><given-names>DA</given-names></name><name name-style="western"><surname>Cheatham</surname><given-names>TE</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Darden</surname><given-names>T</given-names></name><etal/></person-group><article-title>The Amber biomolecular simulation programs</article-title><source>J Comput Chem</source><year>2005</year><volume>26</volume><issue>16</issue><fpage>1668</fpage><lpage>1688</lpage><pub-id pub-id-type="doi">10.1002/jcc.20290</pub-id><pub-id pub-id-type="pmid">16200636</pub-id><pub-id pub-id-type="pmcid">PMC1989667</pub-id></element-citation><mixed-citation id="mc-CR215" publication-type="journal">Case DA, Cheatham TE 3rd, Darden T, et al. The Amber biomolecular simulation programs. J Comput Chem. 2005;26(16):1668&#8211;88. 10.1002/jcc.20290.<pub-id pub-id-type="pmid">16200636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcc.20290</pub-id><pub-id pub-id-type="pmcid">PMC1989667</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR216"><label>216.</label><citation-alternatives><element-citation id="ec-CR216" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashyap</surname><given-names>D</given-names></name><name name-style="western"><surname>Jakhmola</surname><given-names>S</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>D</given-names></name><etal/></person-group><article-title>Plant derived active compounds as potential anti SARS-CoV-2 agents: an in-silico study</article-title><source>J Biomol Struct Dyn</source><year>2022</year><volume>40</volume><issue>21</issue><fpage>10629</fpage><lpage>10650</lpage><pub-id pub-id-type="doi">10.1080/07391102.2021.1947384</pub-id><pub-id pub-id-type="pmid">34225565</pub-id></element-citation><mixed-citation id="mc-CR216" publication-type="journal">Kashyap D, Jakhmola S, Tiwari D, et al. Plant derived active compounds as potential anti SARS-CoV-2 agents: an in-silico study. J Biomol Struct Dyn. 2022;40(21):10629&#8211;50. 10.1080/07391102.2021.1947384.<pub-id pub-id-type="pmid">34225565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2021.1947384</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR217"><label>217.</label><citation-alternatives><element-citation id="ec-CR217" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belhassan</surname><given-names>A</given-names></name><name name-style="western"><surname>Zaki</surname><given-names>H</given-names></name><name name-style="western"><surname>Chtita</surname><given-names>S</given-names></name><etal/></person-group><article-title>Camphor, Artemisinin and Sumac Phytochemicals as inhibitors against COVID-19: computational approach</article-title><source>Comput Biol Med</source><year>2021</year><volume>136</volume><fpage>104758</fpage><pub-id pub-id-type="doi">10.1016/j.compbiomed.2021.104758</pub-id><pub-id pub-id-type="pmid">34411900</pub-id><pub-id pub-id-type="pmcid">PMC8354799</pub-id></element-citation><mixed-citation id="mc-CR217" publication-type="journal">Belhassan A, Zaki H, Chtita S, et al. Camphor, Artemisinin and Sumac Phytochemicals as inhibitors against COVID-19: computational approach. Comput Biol Med. 2021;136: 104758. 10.1016/j.compbiomed.2021.104758.<pub-id pub-id-type="pmid">34411900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiomed.2021.104758</pub-id><pub-id pub-id-type="pmcid">PMC8354799</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR218"><label>218.</label><citation-alternatives><element-citation id="ec-CR218" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>BR</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>CL</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Mackerell</surname><given-names>AD</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>CHARMM: the biomolecular simulation program</article-title><source>J Comput Chem</source><year>2009</year><volume>30</volume><issue>10</issue><fpage>1545</fpage><lpage>1614</lpage><pub-id pub-id-type="doi">10.1002/jcc.21287</pub-id><pub-id pub-id-type="pmid">19444816</pub-id><pub-id pub-id-type="pmcid">PMC2810661</pub-id></element-citation><mixed-citation id="mc-CR218" publication-type="journal">Brooks BR, Brooks CL 3rd, Mackerell AD Jr, et al. CHARMM: the biomolecular simulation program. J Comput Chem. 2009;30(10):1545&#8211;614. 10.1002/jcc.21287.<pub-id pub-id-type="pmid">19444816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcc.21287</pub-id><pub-id pub-id-type="pmcid">PMC2810661</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR219"><label>219.</label><citation-alternatives><element-citation id="ec-CR219" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>N</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A</given-names></name><name name-style="western"><surname>Gulati</surname><given-names>HK</given-names></name><etal/></person-group><article-title>Phytoconstituents from ten natural herbs as potent inhibitors of main protease enzyme of SARS-COV-2: In silico study</article-title><source>Phytomed Plus</source><year>2021</year><volume>1</volume><issue>4</issue><fpage>100083</fpage><pub-id pub-id-type="doi">10.1016/j.phyplu.2021.100083</pub-id><pub-id pub-id-type="pmid">35403086</pub-id><pub-id pub-id-type="pmcid">PMC8180089</pub-id></element-citation><mixed-citation id="mc-CR219" publication-type="journal">Kumar N, Singh A, Gulati HK, et al. Phytoconstituents from ten natural herbs as potent inhibitors of main protease enzyme of SARS-COV-2: In silico study. Phytomed Plus. 2021;1(4): 100083. 10.1016/j.phyplu.2021.100083.<pub-id pub-id-type="pmid">35403086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phyplu.2021.100083</pub-id><pub-id pub-id-type="pmcid">PMC8180089</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR220"><label>220.</label><citation-alternatives><element-citation id="ec-CR220" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>DE</given-names></name><name name-style="western"><surname>Maragakis</surname><given-names>P</given-names></name><name name-style="western"><surname>Lindorff-Larsen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Atomic-level characterization of the structural dynamics of proteins</article-title><source>Science</source><year>2010</year><volume>330</volume><issue>6002</issue><fpage>341</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1126/science.1187409</pub-id><pub-id pub-id-type="pmid">20947758</pub-id></element-citation><mixed-citation id="mc-CR220" publication-type="journal">Shaw DE, Maragakis P, Lindorff-Larsen K, et al. Atomic-level characterization of the structural dynamics of proteins. Science. 2010;330(6002):341&#8211;6. 10.1126/science.1187409.<pub-id pub-id-type="pmid">20947758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1187409</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR221"><label>221.</label><citation-alternatives><element-citation id="ec-CR221" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gissinger</surname><given-names>JR</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>BD</given-names></name><name name-style="western"><surname>Wise</surname><given-names>KE</given-names></name></person-group><article-title>Chemical reactions in classical molecular dynamics</article-title><source>Polymer</source><year>2017</year><volume>128</volume><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.polymer.2017.09.038</pub-id><pub-id pub-id-type="pmid">33149370</pub-id><pub-id pub-id-type="pmcid">PMC7608055</pub-id></element-citation><mixed-citation id="mc-CR221" publication-type="journal">Gissinger JR, Jensen BD, Wise KE. Chemical reactions in classical molecular dynamics. Polymer. 2017;128:211&#8211;7. 10.1016/j.polymer.2017.09.038.<pub-id pub-id-type="pmid">33149370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.polymer.2017.09.038</pub-id><pub-id pub-id-type="pmcid">PMC7608055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR222"><label>222.</label><citation-alternatives><element-citation id="ec-CR222" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>JC</given-names></name><name name-style="western"><surname>Braun</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Scalable molecular dynamics with NAMD</article-title><source>J Comput Chem</source><year>2005</year><volume>26</volume><issue>16</issue><fpage>1781</fpage><lpage>1802</lpage><pub-id pub-id-type="doi">10.1002/jcc.20289</pub-id><pub-id pub-id-type="pmid">16222654</pub-id><pub-id pub-id-type="pmcid">PMC2486339</pub-id></element-citation><mixed-citation id="mc-CR222" publication-type="journal">Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26(16):1781&#8211;802. 10.1002/jcc.20289.<pub-id pub-id-type="pmid">16222654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcc.20289</pub-id><pub-id pub-id-type="pmcid">PMC2486339</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR223"><label>223.</label><citation-alternatives><element-citation id="ec-CR223" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mulu</surname><given-names>A</given-names></name><name name-style="western"><surname>Gajaa</surname><given-names>M</given-names></name><name name-style="western"><surname>Woldekidan</surname><given-names>HB</given-names></name></person-group><article-title>The impact of curcumin derived polyphenols on the structure and flexibility COVID-19 main protease binding pocket: a molecular dynamics simulation study</article-title><source>Peer J</source><year>2021</year><volume>9</volume><fpage>11590</fpage><pub-id pub-id-type="doi">10.7717/peerj.11590</pub-id><pub-id pub-id-type="pmcid">PMC8297469</pub-id><pub-id pub-id-type="pmid">34322316</pub-id></element-citation><mixed-citation id="mc-CR223" publication-type="journal">Mulu A, Gajaa M, Woldekidan HB. The impact of curcumin derived polyphenols on the structure and flexibility COVID-19 main protease binding pocket: a molecular dynamics simulation study. Peer J. 2021;9:11590.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7717/peerj.11590</pub-id><pub-id pub-id-type="pmcid">PMC8297469</pub-id><pub-id pub-id-type="pmid">34322316</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR224"><label>224.</label><citation-alternatives><element-citation id="ec-CR224" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Todorov</surname><given-names>IT</given-names></name><name name-style="western"><surname>Smith</surname><given-names>W</given-names></name></person-group><article-title>DL_POLY_3: the CCP5 national UK code for molecular-dynamics simulations</article-title><source>Philos Transact A Math Phys Eng Sci</source><year>1822</year><volume>2004</volume><issue>362</issue><fpage>1835</fpage><lpage>1852</lpage><pub-id pub-id-type="doi">10.1098/rsta.2004.1419</pub-id><pub-id pub-id-type="pmid">15306418</pub-id></element-citation><mixed-citation id="mc-CR224" publication-type="journal">Todorov IT, Smith W. DL_POLY_3: the CCP5 national UK code for molecular-dynamics simulations. Philos Transact A Math Phys Eng Sci. 1822;2004(362):1835&#8211;52. 10.1098/rsta.2004.1419.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1098/rsta.2004.1419</pub-id><pub-id pub-id-type="pmid">15306418</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR225"><label>225.</label><citation-alternatives><element-citation id="ec-CR225" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#252;hne</surname><given-names>TD</given-names></name><name name-style="western"><surname>Iannuzzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Del Ben</surname><given-names>M</given-names></name><etal/></person-group><article-title>CP2K: An electronic structure and molecular dynamics software package&#8212;quickstep: efficient and accurate electronic structure calculations</article-title><source>J Chem Phys</source><year>2020</year><volume>152</volume><issue>19</issue><fpage>194103</fpage><pub-id pub-id-type="doi">10.1063/5.0007045</pub-id><pub-id pub-id-type="pmid">33687235</pub-id></element-citation><mixed-citation id="mc-CR225" publication-type="journal">K&#252;hne TD, Iannuzzi M, Del Ben M, et al. CP2K: An electronic structure and molecular dynamics software package&#8212;quickstep: efficient and accurate electronic structure calculations. J Chem Phys. 2020;152(19):194103. 10.1063/5.0007045.<pub-id pub-id-type="pmid">33687235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1063/5.0007045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR226"><label>226.</label><citation-alternatives><element-citation id="ec-CR226" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dal Peraro</surname><given-names>M</given-names></name><name name-style="western"><surname>Ruggerone</surname><given-names>P</given-names></name><name name-style="western"><surname>Raugei</surname><given-names>S</given-names></name><name name-style="western"><surname>Gervasio</surname><given-names>FL</given-names></name><name name-style="western"><surname>Carloni</surname><given-names>P</given-names></name></person-group><article-title>Investigating biological systems using first principles Car-Parrinello molecular dynamics simulations</article-title><source>Curr Opin Struct Biol</source><year>2007</year><volume>17</volume><issue>2</issue><fpage>149</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.sbi.2007.03.018</pub-id><pub-id pub-id-type="pmid">17419051</pub-id></element-citation><mixed-citation id="mc-CR226" publication-type="journal">Dal Peraro M, Ruggerone P, Raugei S, Gervasio FL, Carloni P. Investigating biological systems using first principles Car-Parrinello molecular dynamics simulations. Curr Opin Struct Biol. 2007;17(2):149&#8211;56. 10.1016/j.sbi.2007.03.018.<pub-id pub-id-type="pmid">17419051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.sbi.2007.03.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR227"><label>227.</label><citation-alternatives><element-citation id="ec-CR227" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rakedzon</surname><given-names>S</given-names></name><name name-style="western"><surname>Neuberger</surname><given-names>A</given-names></name><name name-style="western"><surname>Domb</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Petersiel</surname><given-names>N</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>E</given-names></name></person-group><article-title>From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?</article-title><source>J Travel Med</source><year>2021</year><pub-id pub-id-type="doi">10.1093/jtm/taab005</pub-id><pub-id pub-id-type="pmid">33480414</pub-id><pub-id pub-id-type="pmcid">PMC7928734</pub-id></element-citation><mixed-citation id="mc-CR227" publication-type="journal">Rakedzon S, Neuberger A, Domb AJ, Petersiel N, Schwartz E. From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2? J Travel Med. 2021. 10.1093/jtm/taab005.<pub-id pub-id-type="pmid">33480414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jtm/taab005</pub-id><pub-id pub-id-type="pmcid">PMC7928734</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR228"><label>228.</label><citation-alternatives><element-citation id="ec-CR228" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taunton</surname><given-names>J</given-names></name><name name-style="western"><surname>Hassig</surname><given-names>CA</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>SL</given-names></name></person-group><article-title>A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p</article-title><source>Science</source><year>1996</year><volume>272</volume><issue>5260</issue><fpage>408</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1126/science.272.5260.408</pub-id><pub-id pub-id-type="pmid">8602529</pub-id></element-citation><mixed-citation id="mc-CR228" publication-type="journal">Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science. 1996;272(5260):408&#8211;11. 10.1126/science.272.5260.408.<pub-id pub-id-type="pmid">8602529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.272.5260.408</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR229"><label>229.</label><citation-alternatives><element-citation id="ec-CR229" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>ZR</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>YN</given-names></name><name name-style="western"><surname>Li</surname><given-names>XD</given-names></name><etal/></person-group><article-title>A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2</article-title><source>Signal Transduct Targeted Ther</source><year>2020</year><volume>5</volume><issue>1</issue><fpage>218</fpage><pub-id pub-id-type="doi">10.1038/s41392-020-00343-z</pub-id><pub-id pub-id-type="pmcid">PMC7532339</pub-id><pub-id pub-id-type="pmid">33011739</pub-id></element-citation><mixed-citation id="mc-CR229" publication-type="journal">Zhang ZR, Zhang YN, Li XD, et al. A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2. Signal Transduct Targeted Ther. 2020;5(1):218. 10.1038/s41392-020-00343-z.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-00343-z</pub-id><pub-id pub-id-type="pmcid">PMC7532339</pub-id><pub-id pub-id-type="pmid">33011739</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR230"><label>230.</label><citation-alternatives><element-citation id="ec-CR230" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berdan</surname><given-names>CA</given-names></name><name name-style="western"><surname>Ho</surname><given-names>R</given-names></name><name name-style="western"><surname>Lehtola</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Parthenolide covalently targets and inhibits focal adhesion kinase in breast cancer cells</article-title><source>Cell Chem Biol</source><year>2019</year><volume>26</volume><issue>7</issue><fpage>1027</fpage><lpage>1035.e22</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2019.03.016</pub-id><pub-id pub-id-type="pmid">31080076</pub-id><pub-id pub-id-type="pmcid">PMC6756182</pub-id></element-citation><mixed-citation id="mc-CR230" publication-type="journal">Berdan CA, Ho R, Lehtola HS, et al. Parthenolide covalently targets and inhibits focal adhesion kinase in breast cancer cells. Cell Chem Biol. 2019;26(7):1027-1035.e22. 10.1016/j.chembiol.2019.03.016.<pub-id pub-id-type="pmid">31080076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2019.03.016</pub-id><pub-id pub-id-type="pmcid">PMC6756182</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR231"><label>231.</label><citation-alternatives><element-citation id="ec-CR231" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;n-Acosta</surname><given-names>P</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Klimek</surname><given-names>J</given-names></name><etal/></person-group><article-title>A clickable photoaffinity probe of betulinic acid identifies tropomyosin as a target</article-title><source>Acta pharmaceutica Sinica B</source><year>2022</year><volume>12</volume><issue>5</issue><fpage>2406</fpage><lpage>2416</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2021.12.008</pub-id><pub-id pub-id-type="pmid">35646545</pub-id><pub-id pub-id-type="pmcid">PMC9136574</pub-id></element-citation><mixed-citation id="mc-CR231" publication-type="journal">Mart&#237;n-Acosta P, Meng Q, Klimek J, et al. A clickable photoaffinity probe of betulinic acid identifies tropomyosin as a target. Acta pharmaceutica Sinica B. 2022;12(5):2406&#8211;16. 10.1016/j.apsb.2021.12.008.<pub-id pub-id-type="pmid">35646545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2021.12.008</pub-id><pub-id pub-id-type="pmcid">PMC9136574</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR232"><label>232.</label><citation-alternatives><element-citation id="ec-CR232" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H</given-names></name><etal/></person-group><article-title>A cell-based high-throughput protocol to screen entry inhibitors of highly pathogenic viruses with traditional Chinese medicines</article-title><source>J Med Virol</source><year>2017</year><volume>89</volume><issue>5</issue><fpage>908</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1002/jmv.24705</pub-id><pub-id pub-id-type="pmid">27704591</pub-id><pub-id pub-id-type="pmcid">PMC7167059</pub-id></element-citation><mixed-citation id="mc-CR232" publication-type="journal">Yang Y, Cheng H, Yan H, et al. A cell-based high-throughput protocol to screen entry inhibitors of highly pathogenic viruses with traditional Chinese medicines. J Med Virol. 2017;89(5):908&#8211;16. 10.1002/jmv.24705.<pub-id pub-id-type="pmid">27704591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.24705</pub-id><pub-id pub-id-type="pmcid">PMC7167059</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR233"><label>233.</label><citation-alternatives><element-citation id="ec-CR233" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>HH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LQ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>WL</given-names></name><etal/></person-group><article-title>Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model</article-title><source>Chin Med J</source><year>2020</year><volume>133</volume><issue>9</issue><fpage>1051</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1097/cm9.0000000000000797</pub-id><pub-id pub-id-type="pmid">32149769</pub-id><pub-id pub-id-type="pmcid">PMC7147283</pub-id></element-citation><mixed-citation id="mc-CR233" publication-type="journal">Fan HH, Wang LQ, Liu WL, et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model. Chin Med J. 2020;133(9):1051&#8211;6. 10.1097/cm9.0000000000000797.<pub-id pub-id-type="pmid">32149769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000000797</pub-id><pub-id pub-id-type="pmcid">PMC7147283</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR234"><label>234.</label><citation-alternatives><element-citation id="ec-CR234" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Chia</surname><given-names>WN</given-names></name><etal/></person-group><article-title>Haem-activated promiscuous targeting of artemisinin in <italic toggle="yes">Plasmodium falciparum</italic></article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><fpage>10111</fpage><pub-id pub-id-type="doi">10.1038/ncomms10111</pub-id><pub-id pub-id-type="pmid">26694030</pub-id><pub-id pub-id-type="pmcid">PMC4703832</pub-id></element-citation><mixed-citation id="mc-CR234" publication-type="journal">Wang J, Zhang CJ, Chia WN, et al. Haem-activated promiscuous targeting of artemisinin in <italic toggle="yes">Plasmodium falciparum</italic>. Nat Commun. 2015;6:10111. 10.1038/ncomms10111.<pub-id pub-id-type="pmid">26694030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms10111</pub-id><pub-id pub-id-type="pmcid">PMC4703832</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR235"><label>235.</label><citation-alternatives><element-citation id="ec-CR235" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Guo</surname><given-names>R</given-names></name><etal/></person-group><article-title>Ononin, sec-O-&#946;-d-glucosylhamaudol and astragaloside I: antiviral lead compounds identified via high throughput screening and biological validation from traditional Chinese medicine Zhongjing formulary</article-title><source>Pharmacol Res</source><year>2019</year><volume>145</volume><fpage>104248</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2019.04.032</pub-id><pub-id pub-id-type="pmid">31082475</pub-id></element-citation><mixed-citation id="mc-CR235" publication-type="journal">Yu Y, Li Z, Guo R, et al. Ononin, sec-O-&#946;-d-glucosylhamaudol and astragaloside I: antiviral lead compounds identified via high throughput screening and biological validation from traditional Chinese medicine Zhongjing formulary. Pharmacol Res. 2019;145: 104248. 10.1016/j.phrs.2019.04.032.<pub-id pub-id-type="pmid">31082475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2019.04.032</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR236"><label>236.</label><citation-alternatives><element-citation id="ec-CR236" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drayman</surname><given-names>N</given-names></name><name name-style="western"><surname>DeMarco</surname><given-names>JK</given-names></name><name name-style="western"><surname>Jones</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2</article-title><source>Science</source><year>2021</year><volume>373</volume><issue>6557</issue><fpage>931</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1126/science.abg5827</pub-id><pub-id pub-id-type="pmid">34285133</pub-id><pub-id pub-id-type="pmcid">PMC8809056</pub-id></element-citation><mixed-citation id="mc-CR236" publication-type="journal">Drayman N, DeMarco JK, Jones KA, et al. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021;373(6557):931&#8211;6. 10.1126/science.abg5827.<pub-id pub-id-type="pmid">34285133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abg5827</pub-id><pub-id pub-id-type="pmcid">PMC8809056</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR237"><label>237.</label><citation-alternatives><element-citation id="ec-CR237" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus</article-title><source>Brief Bioinform</source><year>2021</year><volume>22</volume><issue>2</issue><fpage>1378</fpage><lpage>1386</lpage><pub-id pub-id-type="doi">10.1093/bib/bbaa387</pub-id><pub-id pub-id-type="pmid">33423067</pub-id><pub-id pub-id-type="pmcid">PMC7929461</pub-id></element-citation><mixed-citation id="mc-CR237" publication-type="journal">Li S, Liu W, Chen Y, et al. Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus. Brief Bioinform. 2021;22(2):1378&#8211;86. 10.1093/bib/bbaa387.<pub-id pub-id-type="pmid">33423067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbaa387</pub-id><pub-id pub-id-type="pmcid">PMC7929461</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR238"><label>238.</label><citation-alternatives><element-citation id="ec-CR238" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Stepwise rapid tracking strategy to identify active molecules from Ixeris sonchifolia Hance based on &#8220;affinity mass spectrometry-atomic force microscopy imaging&#8221; technology</article-title><source>Talanta</source><year>2020</year><volume>217</volume><fpage>121031</fpage><pub-id pub-id-type="doi">10.1016/j.talanta.2020.121031</pub-id><pub-id pub-id-type="pmid">32498901</pub-id></element-citation><mixed-citation id="mc-CR238" publication-type="journal">Wang X, Li Y, Chen M, et al. Stepwise rapid tracking strategy to identify active molecules from Ixeris sonchifolia Hance based on &#8220;affinity mass spectrometry-atomic force microscopy imaging&#8221; technology. Talanta. 2020;217:121031. 10.1016/j.talanta.2020.121031.<pub-id pub-id-type="pmid">32498901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.talanta.2020.121031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR239"><label>239.</label><citation-alternatives><element-citation id="ec-CR239" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L</given-names></name><etal/></person-group><article-title>Comparison of viral RNA-host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2</article-title><source>Cell Res</source><year>2022</year><volume>32</volume><issue>1</issue><fpage>9</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/s41422-021-00581-y</pub-id><pub-id pub-id-type="pmid">34737357</pub-id><pub-id pub-id-type="pmcid">PMC8566969</pub-id></element-citation><mixed-citation id="mc-CR239" publication-type="journal">Zhang S, Huang W, Ren L, et al. Comparison of viral RNA-host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2. Cell Res. 2022;32(1):9&#8211;23. 10.1038/s41422-021-00581-y.<pub-id pub-id-type="pmid">34737357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-021-00581-y</pub-id><pub-id pub-id-type="pmcid">PMC8566969</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR240"><label>240.</label><mixed-citation publication-type="other">Biospace. PharmadrugAnnounces Successful Completion of Pre-IND meeting with FDA regarding proposed development of its cepharanthine for treatment of mild to moderate COVID-19 infection. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.biospace.com/article/pharmadrug-announces-successful-completion-of-pre-ind-meeting-with-fda-regarding-proposed-development-of-its-cepharanthine-for-treatment-of-mild-to-moderate-covid-19-infection/">https://www.biospace.com/article/pharmadrug-announces-successful-completion-of-pre-ind-meeting-with-fda-regarding-proposed-development-of-its-cepharanthine-for-treatment-of-mild-to-moderate-covid-19-infection/</ext-link></mixed-citation></ref><ref id="CR241"><label>241.</label><citation-alternatives><element-citation id="ec-CR241" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodi</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Janes</surname><given-names>RW</given-names></name><name name-style="western"><surname>Sanganee</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Holton</surname><given-names>RA</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>BA</given-names></name><name name-style="western"><surname>Makowski</surname><given-names>L</given-names></name></person-group><article-title>Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein</article-title><source>J Mol Biol</source><year>1999</year><volume>285</volume><issue>1</issue><fpage>197</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1998.2303</pub-id><pub-id pub-id-type="pmid">9878399</pub-id></element-citation><mixed-citation id="mc-CR241" publication-type="journal">Rodi DJ, Janes RW, Sanganee HJ, Holton RA, Wallace BA, Makowski L. Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. J Mol Biol. 1999;285(1):197&#8211;203. 10.1006/jmbi.1998.2303.<pub-id pub-id-type="pmid">9878399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/jmbi.1998.2303</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR242"><label>242.</label><citation-alternatives><element-citation id="ec-CR242" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ai</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>N</given-names></name><etal/></person-group><article-title>An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants</article-title><source>Emerging Microb Infect</source><year>2022</year><volume>11</volume><issue>1</issue><fpage>1518</fpage><lpage>1523</lpage><pub-id pub-id-type="doi">10.1080/22221751.2022.2078230</pub-id><pub-id pub-id-type="pmcid">PMC9176639</pub-id><pub-id pub-id-type="pmid">35579892</pub-id></element-citation><mixed-citation id="mc-CR242" publication-type="journal">Shen Y, Ai J, Lin N, et al. An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants. Emerging Microb Infect. 2022;11(1):1518&#8211;23. 10.1080/22221751.2022.2078230.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/22221751.2022.2078230</pub-id><pub-id pub-id-type="pmcid">PMC9176639</pub-id><pub-id pub-id-type="pmid">35579892</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR243"><label>243.</label><citation-alternatives><element-citation id="ec-CR243" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name><name name-style="western"><surname>Fan</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><name name-style="western"><surname>Shu</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>A new strategy for the rapid identification and validation of the direct targets of aconitine-induced cardiotoxicity</article-title><source>Drug Des Dev Ther</source><year>2021</year><volume>15</volume><fpage>4649</fpage><lpage>4664</lpage><pub-id pub-id-type="doi">10.2147/dddt.S335461</pub-id><pub-id pub-id-type="pmcid">PMC8599306</pub-id><pub-id pub-id-type="pmid">34803375</pub-id></element-citation><mixed-citation id="mc-CR243" publication-type="journal">Wei J, Fan S, Yu H, Shu L, Li Y. A new strategy for the rapid identification and validation of the direct targets of aconitine-induced cardiotoxicity. Drug Des Dev Ther. 2021;15:4649&#8211;64. 10.2147/dddt.S335461.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S335461</pub-id><pub-id pub-id-type="pmcid">PMC8599306</pub-id><pub-id pub-id-type="pmid">34803375</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR244"><label>244.</label><citation-alternatives><element-citation id="ec-CR244" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Discovery of herbacetin as a novel SGK1 inhibitor to alleviate myocardial hypertrophy</article-title><source>Adv Sci</source><year>2022</year><volume>9</volume><issue>2</issue><fpage>e2101485</fpage><pub-id pub-id-type="doi">10.1002/advs.202101485</pub-id><pub-id pub-id-type="pmcid">PMC8805583</pub-id><pub-id pub-id-type="pmid">34761560</pub-id></element-citation><mixed-citation id="mc-CR244" publication-type="journal">Zhang S, Wang Y, Yu M, et al. Discovery of herbacetin as a novel SGK1 inhibitor to alleviate myocardial hypertrophy. Adv Sci. 2022;9(2):e2101485. 10.1002/advs.202101485.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202101485</pub-id><pub-id pub-id-type="pmcid">PMC8805583</pub-id><pub-id pub-id-type="pmid">34761560</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR245"><label>245.</label><citation-alternatives><element-citation id="ec-CR245" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geer Wallace</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>DY</given-names></name><name name-style="western"><surname>Weitzel</surname><given-names>DH</given-names></name><etal/></person-group><article-title>Discovery of manassantin A protein targets using large-scale protein folding and stability measurements</article-title><source>J Proteome Res</source><year>2016</year><volume>15</volume><issue>8</issue><fpage>2688</fpage><lpage>2696</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.6b00237</pub-id><pub-id pub-id-type="pmid">27322910</pub-id><pub-id pub-id-type="pmcid">PMC5270646</pub-id></element-citation><mixed-citation id="mc-CR245" publication-type="journal">Geer Wallace MA, Kwon DY, Weitzel DH, et al. Discovery of manassantin A protein targets using large-scale protein folding and stability measurements. J Proteome Res. 2016;15(8):2688&#8211;96. 10.1021/acs.jproteome.6b00237.<pub-id pub-id-type="pmid">27322910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jproteome.6b00237</pub-id><pub-id pub-id-type="pmcid">PMC5270646</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR246"><label>246.</label><citation-alternatives><element-citation id="ec-CR246" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>DL</given-names></name><name name-style="western"><surname>Chan</surname><given-names>DS</given-names></name><name name-style="western"><surname>Leung</surname><given-names>CH</given-names></name></person-group><article-title>Drug repositioning by structure-based virtual screening</article-title><source>Chem Soc Rev</source><year>2013</year><volume>42</volume><issue>5</issue><fpage>2130</fpage><lpage>2141</lpage><pub-id pub-id-type="doi">10.1039/c2cs35357a</pub-id><pub-id pub-id-type="pmid">23288298</pub-id></element-citation><mixed-citation id="mc-CR246" publication-type="journal">Ma DL, Chan DS, Leung CH. Drug repositioning by structure-based virtual screening. Chem Soc Rev. 2013;42(5):2130&#8211;41. 10.1039/c2cs35357a.<pub-id pub-id-type="pmid">23288298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c2cs35357a</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR247"><label>247.</label><citation-alternatives><element-citation id="ec-CR247" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirsch</surname><given-names>VC</given-names></name><name name-style="western"><surname>Orgler</surname><given-names>C</given-names></name><name name-style="western"><surname>Braig</surname><given-names>S</given-names></name><etal/></person-group><article-title>The cytotoxic natural product vioprolide A targets nucleolar protein 14, which is essential for ribosome biogenesis</article-title><source>Angew Chem Int Ed Engl</source><year>2020</year><volume>59</volume><issue>4</issue><fpage>1595</fpage><lpage>1600</lpage><pub-id pub-id-type="doi">10.1002/anie.201911158</pub-id><pub-id pub-id-type="pmid">31658409</pub-id><pub-id pub-id-type="pmcid">PMC7004033</pub-id></element-citation><mixed-citation id="mc-CR247" publication-type="journal">Kirsch VC, Orgler C, Braig S, et al. The cytotoxic natural product vioprolide A targets nucleolar protein 14, which is essential for ribosome biogenesis. Angew Chem Int Ed Engl. 2020;59(4):1595&#8211;600. 10.1002/anie.201911158.<pub-id pub-id-type="pmid">31658409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.201911158</pub-id><pub-id pub-id-type="pmcid">PMC7004033</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR248"><label>248.</label><citation-alternatives><element-citation id="ec-CR248" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naik</surname><given-names>B</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>N</given-names></name><name name-style="western"><surname>Ojha</surname><given-names>R</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Prajapati</surname><given-names>VK</given-names></name><name name-style="western"><surname>Prusty</surname><given-names>D</given-names></name></person-group><article-title>High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment</article-title><source>Int J Biol Macromol</source><year>2020</year><volume>160</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.05.184</pub-id><pub-id pub-id-type="pmid">32470577</pub-id><pub-id pub-id-type="pmcid">PMC7250083</pub-id></element-citation><mixed-citation id="mc-CR248" publication-type="journal">Naik B, Gupta N, Ojha R, Singh S, Prajapati VK, Prusty D. High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment. Int J Biol Macromol. 2020;160:1&#8211;17. 10.1016/j.ijbiomac.2020.05.184.<pub-id pub-id-type="pmid">32470577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2020.05.184</pub-id><pub-id pub-id-type="pmcid">PMC7250083</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR249"><label>249.</label><citation-alternatives><element-citation id="ec-CR249" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Farrerol directly activates the deubiqutinase UCHL3 to promote DNA repair and reprogramming when mediated by somatic cell nuclear transfer</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>1838</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-37576-9</pub-id><pub-id pub-id-type="pmid">37012254</pub-id><pub-id pub-id-type="pmcid">PMC10070447</pub-id></element-citation><mixed-citation id="mc-CR249" publication-type="journal">Zhang W, Wang M, Song Z, et al. Farrerol directly activates the deubiqutinase UCHL3 to promote DNA repair and reprogramming when mediated by somatic cell nuclear transfer. Nat Commun. 2023;14(1):1838. 10.1038/s41467-023-37576-9.<pub-id pub-id-type="pmid">37012254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-37576-9</pub-id><pub-id pub-id-type="pmcid">PMC10070447</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR250"><label>250.</label><citation-alternatives><element-citation id="ec-CR250" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pepelnjak</surname><given-names>M</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>N</given-names></name><name name-style="western"><surname>Picotti</surname><given-names>P</given-names></name></person-group><article-title>Detecting protein-small molecule interactions using limited proteolysis-mass spectrometry (LiP-MS)</article-title><source>Trends Biochem Sci</source><year>2020</year><volume>45</volume><issue>10</issue><fpage>919</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2020.05.006</pub-id><pub-id pub-id-type="pmid">32475682</pub-id></element-citation><mixed-citation id="mc-CR250" publication-type="journal">Pepelnjak M, de Souza N, Picotti P. Detecting protein-small molecule interactions using limited proteolysis-mass spectrometry (LiP-MS). Trends Biochem Sci. 2020;45(10):919&#8211;20. 10.1016/j.tibs.2020.05.006.<pub-id pub-id-type="pmid">32475682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibs.2020.05.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR251"><label>251.</label><citation-alternatives><element-citation id="ec-CR251" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Application of PROTACs in target identification and target validation</article-title><source>Acta Mater Med</source><year>2024</year><volume>3</volume><issue>1</issue><fpage>72</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.15212/amm-2024-0010</pub-id><pub-id pub-id-type="pmid">39373008</pub-id><pub-id pub-id-type="pmcid">PMC11452161</pub-id></element-citation><mixed-citation id="mc-CR251" publication-type="journal">Liu Y, Liang J, Zhu R, et al. Application of PROTACs in target identification and target validation. Acta Mater Med. 2024;3(1):72&#8211;87. 10.15212/amm-2024-0010.<pub-id pub-id-type="pmid">39373008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15212/amm-2024-0010</pub-id><pub-id pub-id-type="pmcid">PMC11452161</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR252"><label>252.</label><citation-alternatives><element-citation id="ec-CR252" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>PROTAC technology as a novel tool to identify the target of lathyrane diterpenoids</article-title><source>Acta Pharm Sinica B</source><year>2022</year><volume>12</volume><issue>11</issue><fpage>4262</fpage><lpage>4265</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.07.007</pub-id><pub-id pub-id-type="pmcid">PMC9643283</pub-id><pub-id pub-id-type="pmid">36386476</pub-id></element-citation><mixed-citation id="mc-CR252" publication-type="journal">Wu Y, Yang Y, Wang W, et al. PROTAC technology as a novel tool to identify the target of lathyrane diterpenoids. Acta Pharm Sinica B. 2022;12(11):4262&#8211;5. 10.1016/j.apsb.2022.07.007.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2022.07.007</pub-id><pub-id pub-id-type="pmcid">PMC9643283</pub-id><pub-id pub-id-type="pmid">36386476</pub-id></mixed-citation></citation-alternatives></ref></ref-list></ref-list></back></article></pmc-articleset>